#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Striatal Dopaminergic Reward Response Relates to Age of First Drunkenness and Feedback Response in At-Risk Youth
#Text=Dopamine receptor concentrations, primarily in the striatum, are hypothesized to contribute to a developmental imbalance between subcortical and prefrontal control systems in emerging adulthood potentially biasing motivation and increasing risky behaviors.
1-1	0-8	Striatal	_	
1-2	9-21	Dopaminergic	_	
1-3	22-28	Reward	_	
1-4	29-37	Response	_	
1-5	38-45	Relates	_	
1-6	46-48	to	_	
1-7	49-52	Age	_	
1-8	53-55	of	_	
1-9	56-61	First	_	
1-10	62-73	Drunkenness	_	
1-11	74-77	and	_	
1-12	78-86	Feedback	_	
1-13	87-95	Response	_	
1-14	96-98	in	_	
1-15	99-106	At-Risk	_	
1-16	107-112	Youth	_	
1-17	113-121	Dopamine	_	
1-18	122-130	receptor	_	
1-19	131-145	concentrations	_	
1-20	145-146	,	_	
1-21	147-156	primarily	_	
1-22	157-159	in	_	
1-23	160-163	the	_	
1-24	164-172	striatum	_	
1-25	172-173	,	_	
1-26	174-177	are	_	
1-27	178-190	hypothesized	_	
1-28	191-193	to	_	
1-29	194-204	contribute	_	
1-30	205-207	to	_	
1-31	208-209	a	_	
1-32	210-223	developmental	_	
1-33	224-233	imbalance	_	
1-34	234-241	between	_	
1-35	242-253	subcortical	_	
1-36	254-257	and	_	
1-37	258-268	prefrontal	_	
1-38	269-276	control	_	
1-39	277-284	systems	_	
1-40	285-287	in	_	
1-41	288-296	emerging	_	
1-42	297-306	adulthood	_	
1-43	307-318	potentially	_	
1-44	319-326	biasing	_	
1-45	327-337	motivation	_	
1-46	338-341	and	_	
1-47	342-352	increasing	_	
1-48	353-358	risky	_	
1-49	359-368	behaviors	_	
1-50	368-369	.	_	

#Text=Positron emission tomography (PET) studies have found significant reductions in striatal dopamine D2 receptors, and blunted amphetamine-induced dopamine release, in substance users compared to healthy controls.
2-1	370-378	Positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-2	379-387	emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-3	388-398	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-4	399-400	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-5	400-403	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-6	403-404	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[1]	
2-7	405-412	studies	_	
2-8	413-417	have	_	
2-9	418-423	found	_	
2-10	424-435	significant	_	
2-11	436-446	reductions	_	
2-12	447-449	in	_	
2-13	450-458	striatal	_	
2-14	459-467	dopamine	_	
2-15	468-470	D2	_	
2-16	471-480	receptors	_	
2-17	480-481	,	_	
2-18	482-485	and	_	
2-19	486-493	blunted	_	
2-20	494-513	amphetamine-induced	_	
2-21	514-522	dopamine	_	
2-22	523-530	release	_	
2-23	530-531	,	_	
2-24	532-534	in	_	
2-25	535-544	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
2-26	545-550	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
2-27	551-559	compared	_	
2-28	560-562	to	_	
2-29	563-570	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-30	571-579	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
2-31	579-580	.	_	

#Text=Extant literature is limited and inconsistent concerning vulnerability associated with having a family history of substance abuse (FH+).
3-1	581-587	Extant	_	
3-2	588-598	literature	_	
3-3	599-601	is	_	
3-4	602-609	limited	_	
3-5	610-613	and	_	
3-6	614-626	inconsistent	_	
3-7	627-637	concerning	_	
3-8	638-651	vulnerability	_	
3-9	652-662	associated	_	
3-10	663-667	with	_	
3-11	668-674	having	_	
3-12	675-676	a	_	
3-13	677-683	family	_	
3-14	684-691	history	_	
3-15	692-694	of	_	
3-16	695-704	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
3-17	705-710	abuse	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
3-18	711-712	(	_	
3-19	712-714	FH	_	
3-20	714-715	+	_	
3-21	715-716	)	_	
3-22	716-717	.	_	

#Text=Some studies have reported familial liability associated with higher dopamine receptor levels, reduced dopamine response to stimulant challenges and decreased response to oral alcohol.
4-1	718-722	Some	_	
4-2	723-730	studies	_	
4-3	731-735	have	_	
4-4	736-744	reported	_	
4-5	745-753	familial	_	
4-6	754-763	liability	_	
4-7	764-774	associated	_	
4-8	775-779	with	_	
4-9	780-786	higher	_	
4-10	787-795	dopamine	_	
4-11	796-804	receptor	_	
4-12	805-811	levels	_	
4-13	811-812	,	_	
4-14	813-820	reduced	_	
4-15	821-829	dopamine	_	
4-16	830-838	response	_	
4-17	839-841	to	_	
4-18	842-851	stimulant	_	
4-19	852-862	challenges	_	
4-20	863-866	and	_	
4-21	867-876	decreased	_	
4-22	877-885	response	_	
4-23	886-888	to	_	
4-24	889-893	oral	_	
4-25	894-901	alcohol	_	
4-26	901-902	.	_	

#Text=However other reports have failed to find group differences based on family history.
5-1	903-910	However	_	
5-2	911-916	other	_	
5-3	917-924	reports	_	
5-4	925-929	have	_	
5-5	930-936	failed	_	
5-6	937-939	to	_	
5-7	940-944	find	_	
5-8	945-950	group	_	
5-9	951-962	differences	_	
5-10	963-968	based	_	
5-11	969-971	on	_	
5-12	972-978	family	_	
5-13	979-986	history	_	
5-14	986-987	.	_	

#Text=We explored the interaction of familial liability and behavioral risk with multi-modal molecular and neural imaging of the dopaminergic system.
6-1	988-990	We	_	
6-2	991-999	explored	_	
6-3	1000-1003	the	_	
6-4	1004-1015	interaction	_	
6-5	1016-1018	of	_	
6-6	1019-1027	familial	_	
6-7	1028-1037	liability	_	
6-8	1038-1041	and	_	
6-9	1042-1052	behavioral	_	
6-10	1053-1057	risk	_	
6-11	1058-1062	with	_	
6-12	1063-1074	multi-modal	_	
6-13	1075-1084	molecular	_	
6-14	1085-1088	and	_	
6-15	1089-1095	neural	_	
6-16	1096-1103	imaging	_	
6-17	1104-1106	of	_	
6-18	1107-1110	the	_	
6-19	1111-1123	dopaminergic	_	
6-20	1124-1130	system	_	
6-21	1130-1131	.	_	

#Text=Forty-four young adult male subjects performed monetary incentive delay tasks during both [11C]raclopride PET and functional magnetic resonance imaging (fMRI) scans.
7-1	1132-1142	Forty-four	_	
7-2	1143-1148	young	_	
7-3	1149-1154	adult	_	
7-4	1155-1159	male	_	
7-5	1160-1168	subjects	_	
7-6	1169-1178	performed	_	
7-7	1179-1187	monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
7-8	1188-1197	incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
7-9	1198-1203	delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
7-10	1204-1209	tasks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
7-11	1210-1216	during	_	
7-12	1217-1221	both	_	
7-13	1222-1223	[	_	
7-14	1223-1226	11C	_	
7-15	1226-1227	]	_	
7-16	1227-1237	raclopride	_	
7-17	1238-1241	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
7-18	1242-1245	and	_	
7-19	1246-1256	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-20	1257-1265	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-21	1266-1275	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-22	1276-1283	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-23	1284-1285	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-24	1285-1289	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-25	1289-1290	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-26	1291-1296	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
7-27	1296-1297	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	

#Text=FH+ subjects were identified as Low (n=24) or High Risk (n=9) based on early initiation of drunkenness.
8-1	1298-1300	FH	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
8-2	1300-1301	+	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
8-3	1302-1310	subjects	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[7]	
8-4	1311-1315	were	_	
8-5	1316-1326	identified	_	
8-6	1327-1329	as	_	
8-7	1330-1333	Low	_	
8-8	1334-1335	(	_	
8-9	1335-1336	n	_	
8-10	1336-1337	=	_	
8-11	1337-1339	24	_	
8-12	1339-1340	)	_	
8-13	1341-1343	or	_	
8-14	1344-1348	High	_	
8-15	1349-1353	Risk	_	
8-16	1354-1355	(	_	
8-17	1355-1356	n	_	
8-18	1356-1357	=	_	
8-19	1357-1358	9	_	
8-20	1358-1359	)	_	
8-21	1360-1365	based	_	
8-22	1366-1368	on	_	
8-23	1369-1374	early	_	
8-24	1375-1385	initiation	_	
8-25	1386-1388	of	_	
8-26	1389-1400	drunkenness	_	
8-27	1400-1401	.	_	

#Text=FH+ High Risk subjects exhibited heightened striatal dopamine response to monetary reward but did not differ in neural activations compared with FH+ Low Risk subjects and controls with no familial loading (FH-, n=11).
9-1	1402-1404	FH	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
9-2	1404-1405	+	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
9-3	1406-1410	High	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[9]	
9-4	1411-1415	Risk	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]|http://maven.renci.org/NeuroBridge/neurobridge#HighRisk[9]	
9-5	1416-1424	subjects	_	
9-6	1425-1434	exhibited	_	
9-7	1435-1445	heightened	_	
9-8	1446-1454	striatal	_	
9-9	1455-1463	dopamine	_	
9-10	1464-1472	response	_	
9-11	1473-1475	to	_	
9-12	1476-1484	monetary	_	
9-13	1485-1491	reward	_	
9-14	1492-1495	but	_	
9-15	1496-1499	did	_	
9-16	1500-1503	not	_	
9-17	1504-1510	differ	_	
9-18	1511-1513	in	_	
9-19	1514-1520	neural	_	
9-20	1521-1532	activations	_	
9-21	1533-1541	compared	_	
9-22	1542-1546	with	_	
9-23	1547-1549	FH	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]	
9-24	1549-1550	+	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]	
9-25	1551-1554	Low	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]|http://maven.renci.org/NeuroBridge/neurobridge#LowRisk[11]	
9-26	1555-1559	Risk	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]|http://maven.renci.org/NeuroBridge/neurobridge#LowRisk[11]	
9-27	1560-1568	subjects	_	
9-28	1569-1572	and	_	
9-29	1573-1581	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-30	1582-1586	with	_	
9-31	1587-1589	no	_	
9-32	1590-1598	familial	_	
9-33	1599-1606	loading	_	
9-34	1607-1608	(	_	
9-35	1608-1610	FH	_	
9-36	1610-1611	-	_	
9-37	1611-1612	,	_	
9-38	1613-1614	n	_	
9-39	1614-1615	=	_	
9-40	1615-1617	11	_	
9-41	1617-1618	)	_	
9-42	1618-1619	.	_	

#Text=Across all subjects, a negative relationship was found between dopamine release and age of first drunkenness and a positive relationship with neural response to reward receipt.
10-1	1620-1626	Across	_	
10-2	1627-1630	all	_	
10-3	1631-1639	subjects	_	
10-4	1639-1640	,	_	
10-5	1641-1642	a	_	
10-6	1643-1651	negative	_	
10-7	1652-1664	relationship	_	
10-8	1665-1668	was	_	
10-9	1669-1674	found	_	
10-10	1675-1682	between	_	
10-11	1683-1691	dopamine	_	
10-12	1692-1699	release	_	
10-13	1700-1703	and	_	
10-14	1704-1707	age	_	
10-15	1708-1710	of	_	
10-16	1711-1716	first	_	
10-17	1717-1728	drunkenness	_	
10-18	1729-1732	and	_	
10-19	1733-1734	a	_	
10-20	1735-1743	positive	_	
10-21	1744-1756	relationship	_	
10-22	1757-1761	with	_	
10-23	1762-1768	neural	_	
10-24	1769-1777	response	_	
10-25	1778-1780	to	_	
10-26	1781-1787	reward	_	
10-27	1788-1795	receipt	_	
10-28	1795-1796	.	_	

#Text=These results suggest that in at-risk individuals higher dopamine transmission associated with monetary reward may represent a particularly useful neurobiological phenotype.
11-1	1797-1802	These	_	
11-2	1803-1810	results	_	
11-3	1811-1818	suggest	_	
11-4	1819-1823	that	_	
11-5	1824-1826	in	_	
11-6	1827-1834	at-risk	_	
11-7	1835-1846	individuals	_	
11-8	1847-1853	higher	_	
11-9	1854-1862	dopamine	_	
11-10	1863-1875	transmission	_	
11-11	1876-1886	associated	_	
11-12	1887-1891	with	_	
11-13	1892-1900	monetary	_	
11-14	1901-1907	reward	_	
11-15	1908-1911	may	_	
11-16	1912-1921	represent	_	
11-17	1922-1923	a	_	
11-18	1924-1936	particularly	_	
11-19	1937-1943	useful	_	
11-20	1944-1959	neurobiological	_	
11-21	1960-1969	phenotype	_	
11-22	1969-1970	.	_	

#Text=The transition from adolescence to adulthood is a particularly unique developmental period.
12-1	1971-1974	The	_	
12-2	1975-1985	transition	_	
12-3	1986-1990	from	_	
12-4	1991-2002	adolescence	_	
12-5	2003-2005	to	_	
12-6	2006-2015	adulthood	_	
12-7	2016-2018	is	_	
12-8	2019-2020	a	_	
12-9	2021-2033	particularly	_	
12-10	2034-2040	unique	_	
12-11	2041-2054	developmental	_	
12-12	2055-2061	period	_	
12-13	2061-2062	.	_	

#Text=During these years, heavy substance use, bingeing, and the development of problem substance use generally reaches a peak, and then begins to taper off in most, but not in all, individuals.
13-1	2063-2069	During	_	
13-2	2070-2075	these	_	
13-3	2076-2081	years	_	
13-4	2081-2082	,	_	
13-5	2083-2088	heavy	_	
13-6	2089-2098	substance	_	
13-7	2099-2102	use	_	
13-8	2102-2103	,	_	
13-9	2104-2112	bingeing	_	
13-10	2112-2113	,	_	
13-11	2114-2117	and	_	
13-12	2118-2121	the	_	
13-13	2122-2133	development	_	
13-14	2134-2136	of	_	
13-15	2137-2144	problem	_	
13-16	2145-2154	substance	_	
13-17	2155-2158	use	_	
13-18	2159-2168	generally	_	
13-19	2169-2176	reaches	_	
13-20	2177-2178	a	_	
13-21	2179-2183	peak	_	
13-22	2183-2184	,	_	
13-23	2185-2188	and	_	
13-24	2189-2193	then	_	
13-25	2194-2200	begins	_	
13-26	2201-2203	to	_	
13-27	2204-2209	taper	_	
13-28	2210-2213	off	_	
13-29	2214-2216	in	_	
13-30	2217-2221	most	_	
13-31	2221-2222	,	_	
13-32	2223-2226	but	_	
13-33	2227-2230	not	_	
13-34	2231-2233	in	_	
13-35	2234-2237	all	_	
13-36	2237-2238	,	_	
13-37	2239-2250	individuals	_	
13-38	2250-2251	.	_	

#Text=The significant question remains why the majority of youth transition through this period successfully while a subset remains vulnerable to development of substance use disorders.
14-1	2252-2255	The	_	
14-2	2256-2267	significant	_	
14-3	2268-2276	question	_	
14-4	2277-2284	remains	_	
14-5	2285-2288	why	_	
14-6	2289-2292	the	_	
14-7	2293-2301	majority	_	
14-8	2302-2304	of	_	
14-9	2305-2310	youth	_	
14-10	2311-2321	transition	_	
14-11	2322-2329	through	_	
14-12	2330-2334	this	_	
14-13	2335-2341	period	_	
14-14	2342-2354	successfully	_	
14-15	2355-2360	while	_	
14-16	2361-2362	a	_	
14-17	2363-2369	subset	_	
14-18	2370-2377	remains	_	
14-19	2378-2388	vulnerable	_	
14-20	2389-2391	to	_	
14-21	2392-2403	development	_	
14-22	2404-2406	of	_	
14-23	2407-2416	substance	_	
14-24	2417-2420	use	_	
14-25	2421-2430	disorders	_	
14-26	2430-2431	.	_	

#Text=Concurrent to this period of experimentation, dopamine receptor concentrations, primarily in the striatum (including the nucleus accumbens, NAcc) reach peak levels.
15-1	2432-2442	Concurrent	_	
15-2	2443-2445	to	_	
15-3	2446-2450	this	_	
15-4	2451-2457	period	_	
15-5	2458-2460	of	_	
15-6	2461-2476	experimentation	_	
15-7	2476-2477	,	_	
15-8	2478-2486	dopamine	_	
15-9	2487-2495	receptor	_	
15-10	2496-2510	concentrations	_	
15-11	2510-2511	,	_	
15-12	2512-2521	primarily	_	
15-13	2522-2524	in	_	
15-14	2525-2528	the	_	
15-15	2529-2537	striatum	_	
15-16	2538-2539	(	_	
15-17	2539-2548	including	_	
15-18	2549-2552	the	_	
15-19	2553-2560	nucleus	_	
15-20	2561-2570	accumbens	_	
15-21	2570-2571	,	_	
15-22	2572-2576	NAcc	_	
15-23	2576-2577	)	_	
15-24	2578-2583	reach	_	
15-25	2584-2588	peak	_	
15-26	2589-2595	levels	_	
15-27	2595-2596	.	_	

#Text=Critically, the mesolimbic dopamine system is hypothesized to play a role in addiction disorders, with blunted levels of dopamine D2 receptors and dopamine transmission associated with abuse of alcohol as well as stimulants.
16-1	2597-2607	Critically	_	
16-2	2607-2608	,	_	
16-3	2609-2612	the	_	
16-4	2613-2623	mesolimbic	_	
16-5	2624-2632	dopamine	_	
16-6	2633-2639	system	_	
16-7	2640-2642	is	_	
16-8	2643-2655	hypothesized	_	
16-9	2656-2658	to	_	
16-10	2659-2663	play	_	
16-11	2664-2665	a	_	
16-12	2666-2670	role	_	
16-13	2671-2673	in	_	
16-14	2674-2683	addiction	_	
16-15	2684-2693	disorders	_	
16-16	2693-2694	,	_	
16-17	2695-2699	with	_	
16-18	2700-2707	blunted	_	
16-19	2708-2714	levels	_	
16-20	2715-2717	of	_	
16-21	2718-2726	dopamine	_	
16-22	2727-2729	D2	_	
16-23	2730-2739	receptors	_	
16-24	2740-2743	and	_	
16-25	2744-2752	dopamine	_	
16-26	2753-2765	transmission	_	
16-27	2766-2776	associated	_	
16-28	2777-2781	with	_	
16-29	2782-2787	abuse	_	
16-30	2788-2790	of	_	
16-31	2791-2798	alcohol	_	
16-32	2799-2801	as	_	
16-33	2802-2806	well	_	
16-34	2807-2809	as	_	
16-35	2810-2820	stimulants	_	
16-36	2820-2821	.	_	

#Text=However, it remains unclear whether the dopamine system in some, potentially vulnerable, individuals is different prior to use of substances, or whether this system is altered by use, or both.
17-1	2822-2829	However	_	
17-2	2829-2830	,	_	
17-3	2831-2833	it	_	
17-4	2834-2841	remains	_	
17-5	2842-2849	unclear	_	
17-6	2850-2857	whether	_	
17-7	2858-2861	the	_	
17-8	2862-2870	dopamine	_	
17-9	2871-2877	system	_	
17-10	2878-2880	in	_	
17-11	2881-2885	some	_	
17-12	2885-2886	,	_	
17-13	2887-2898	potentially	_	
17-14	2899-2909	vulnerable	_	
17-15	2909-2910	,	_	
17-16	2911-2922	individuals	_	
17-17	2923-2925	is	_	
17-18	2926-2935	different	_	
17-19	2936-2941	prior	_	
17-20	2942-2944	to	_	
17-21	2945-2948	use	_	
17-22	2949-2951	of	_	
17-23	2952-2962	substances	_	
17-24	2962-2963	,	_	
17-25	2964-2966	or	_	
17-26	2967-2974	whether	_	
17-27	2975-2979	this	_	
17-28	2980-2986	system	_	
17-29	2987-2989	is	_	
17-30	2990-2997	altered	_	
17-31	2998-3000	by	_	
17-32	3001-3004	use	_	
17-33	3004-3005	,	_	
17-34	3006-3008	or	_	
17-35	3009-3013	both	_	
17-36	3013-3014	.	_	

#Text=A family history of alcohol use disorder (AUD) is a known risk factor for AUD and other substance use disorders (SUD) with genetic influence accounting for 40-60% of the variance in substance abuse risk.
18-1	3015-3016	A	_	
18-2	3017-3023	family	_	
18-3	3024-3031	history	_	
18-4	3032-3034	of	_	
18-5	3035-3042	alcohol	_	
18-6	3043-3046	use	_	
18-7	3047-3055	disorder	_	
18-8	3056-3057	(	_	
18-9	3057-3060	AUD	_	
18-10	3060-3061	)	_	
18-11	3062-3064	is	_	
18-12	3065-3066	a	_	
18-13	3067-3072	known	_	
18-14	3073-3077	risk	_	
18-15	3078-3084	factor	_	
18-16	3085-3088	for	_	
18-17	3089-3092	AUD	_	
18-18	3093-3096	and	_	
18-19	3097-3102	other	_	
18-20	3103-3112	substance	_	
18-21	3113-3116	use	_	
18-22	3117-3126	disorders	_	
18-23	3127-3128	(	_	
18-24	3128-3131	SUD	_	
18-25	3131-3132	)	_	
18-26	3133-3137	with	_	
18-27	3138-3145	genetic	_	
18-28	3146-3155	influence	_	
18-29	3156-3166	accounting	_	
18-30	3167-3170	for	_	
18-31	3171-3173	40	_	
18-32	3173-3174	-	_	
18-33	3174-3177	60%	_	
18-34	3178-3180	of	_	
18-35	3181-3184	the	_	
18-36	3185-3193	variance	_	
18-37	3194-3196	in	_	
18-38	3197-3206	substance	_	
18-39	3207-3212	abuse	_	
18-40	3213-3217	risk	_	
18-41	3217-3218	.	_	

#Text=Research has probed the how the dopaminergic system may be involved in familial risk using positron emission tomography (PET).
19-1	3219-3227	Research	_	
19-2	3228-3231	has	_	
19-3	3232-3238	probed	_	
19-4	3239-3242	the	_	
19-5	3243-3246	how	_	
19-6	3247-3250	the	_	
19-7	3251-3263	dopaminergic	_	
19-8	3264-3270	system	_	
19-9	3271-3274	may	_	
19-10	3275-3277	be	_	
19-11	3278-3286	involved	_	
19-12	3287-3289	in	_	
19-13	3290-3298	familial	_	
19-14	3299-3303	risk	_	
19-15	3304-3309	using	_	
19-16	3310-3318	positron	_	
19-17	3319-3327	emission	_	
19-18	3328-3338	tomography	_	
19-19	3339-3340	(	_	
19-20	3340-3343	PET	_	
19-21	3343-3344	)	_	
19-22	3344-3345	.	_	

#Text=For example, Volkow and colleagues found that non-alcoholic adult members of alcoholic families had higher dopamine D2 receptor availability in the caudate and ventral striatum than non-alcoholic controls, suggesting high levels of receptors might be a protective factor against alcohol problems in these individuals.
20-1	3346-3349	For	_	
20-2	3350-3357	example	_	
20-3	3357-3358	,	_	
20-4	3359-3365	Volkow	_	
20-5	3366-3369	and	_	
20-6	3370-3380	colleagues	_	
20-7	3381-3386	found	_	
20-8	3387-3391	that	_	
20-9	3392-3405	non-alcoholic	_	
20-10	3406-3411	adult	_	
20-11	3412-3419	members	_	
20-12	3420-3422	of	_	
20-13	3423-3432	alcoholic	_	
20-14	3433-3441	families	_	
20-15	3442-3445	had	_	
20-16	3446-3452	higher	_	
20-17	3453-3461	dopamine	_	
20-18	3462-3464	D2	_	
20-19	3465-3473	receptor	_	
20-20	3474-3486	availability	_	
20-21	3487-3489	in	_	
20-22	3490-3493	the	_	
20-23	3494-3501	caudate	_	
20-24	3502-3505	and	_	
20-25	3506-3513	ventral	_	
20-26	3514-3522	striatum	_	
20-27	3523-3527	than	_	
20-28	3528-3541	non-alcoholic	_	
20-29	3542-3550	controls	_	
20-30	3550-3551	,	_	
20-31	3552-3562	suggesting	_	
20-32	3563-3567	high	_	
20-33	3568-3574	levels	_	
20-34	3575-3577	of	_	
20-35	3578-3587	receptors	_	
20-36	3588-3593	might	_	
20-37	3594-3596	be	_	
20-38	3597-3598	a	_	
20-39	3599-3609	protective	_	
20-40	3610-3616	factor	_	
20-41	3617-3624	against	_	
20-42	3625-3632	alcohol	_	
20-43	3633-3641	problems	_	
20-44	3642-3644	in	_	
20-45	3645-3650	these	_	
20-46	3651-3662	individuals	_	
20-47	3662-3663	.	_	

#Text=More recently, enrolled young adults with a family history of substance use disorders (FH+) who reported occasional use of psychostimulants.
21-1	3664-3668	More	_	
21-2	3669-3677	recently	_	
21-3	3677-3678	,	_	
21-4	3679-3687	enrolled	_	
21-5	3688-3693	young	_	
21-6	3694-3700	adults	_	
21-7	3701-3705	with	_	
21-8	3706-3707	a	_	
21-9	3708-3714	family	_	
21-10	3715-3722	history	_	
21-11	3723-3725	of	_	
21-12	3726-3735	substance	_	
21-13	3736-3739	use	_	
21-14	3740-3749	disorders	_	
21-15	3750-3751	(	_	
21-16	3751-3753	FH	_	
21-17	3753-3754	+	_	
21-18	3754-3755	)	_	
21-19	3756-3759	who	_	
21-20	3760-3768	reported	_	
21-21	3769-3779	occasional	_	
21-22	3780-3783	use	_	
21-23	3784-3786	of	_	
21-24	3787-3803	psychostimulants	_	
21-25	3803-3804	.	_	

#Text=These subjects had blunted stimulant-induced dopamine release compared to two groups of controls - no familial loading (FH-) subjects that were drug-naïve and FH- subjects who matched the high-risk group on personal drug use though the groups did not differ on baseline receptor availability.
22-1	3805-3810	These	_	
22-2	3811-3819	subjects	_	
22-3	3820-3823	had	_	
22-4	3824-3831	blunted	_	
22-5	3832-3849	stimulant-induced	_	
22-6	3850-3858	dopamine	_	
22-7	3859-3866	release	_	
22-8	3867-3875	compared	_	
22-9	3876-3878	to	_	
22-10	3879-3882	two	_	
22-11	3883-3889	groups	_	
22-12	3890-3892	of	_	
22-13	3893-3901	controls	_	
22-14	3902-3903	-	_	
22-15	3904-3906	no	_	
22-16	3907-3915	familial	_	
22-17	3916-3923	loading	_	
22-18	3924-3925	(	_	
22-19	3925-3927	FH	_	
22-20	3927-3928	-	_	
22-21	3928-3929	)	_	
22-22	3930-3938	subjects	_	
22-23	3939-3943	that	_	
22-24	3944-3948	were	_	
22-25	3949-3959	drug-naïve	_	
22-26	3960-3963	and	_	
22-27	3964-3966	FH	_	
22-28	3966-3967	-	_	
22-29	3968-3976	subjects	_	
22-30	3977-3980	who	_	
22-31	3981-3988	matched	_	
22-32	3989-3992	the	_	
22-33	3993-4002	high-risk	_	
22-34	4003-4008	group	_	
22-35	4009-4011	on	_	
22-36	4012-4020	personal	_	
22-37	4021-4025	drug	_	
22-38	4026-4029	use	_	
22-39	4030-4036	though	_	
22-40	4037-4040	the	_	
22-41	4041-4047	groups	_	
22-42	4048-4051	did	_	
22-43	4052-4055	not	_	
22-44	4056-4062	differ	_	
22-45	4063-4065	on	_	
22-46	4066-4074	baseline	_	
22-47	4075-4083	receptor	_	
22-48	4084-4096	availability	_	
22-49	4096-4097	.	_	

#Text=Taken together, these studies suggest that for individuals with familial risk, high D2 receptor levels may be associated with resilience while reduced striatal dopamine release following a stimulant challenge might be a biomarker of vulnerability for substance use disorders.
23-1	4098-4103	Taken	_	
23-2	4104-4112	together	_	
23-3	4112-4113	,	_	
23-4	4114-4119	these	_	
23-5	4120-4127	studies	_	
23-6	4128-4135	suggest	_	
23-7	4136-4140	that	_	
23-8	4141-4144	for	_	
23-9	4145-4156	individuals	_	
23-10	4157-4161	with	_	
23-11	4162-4170	familial	_	
23-12	4171-4175	risk	_	
23-13	4175-4176	,	_	
23-14	4177-4181	high	_	
23-15	4182-4184	D2	_	
23-16	4185-4193	receptor	_	
23-17	4194-4200	levels	_	
23-18	4201-4204	may	_	
23-19	4205-4207	be	_	
23-20	4208-4218	associated	_	
23-21	4219-4223	with	_	
23-22	4224-4234	resilience	_	
23-23	4235-4240	while	_	
23-24	4241-4248	reduced	_	
23-25	4249-4257	striatal	_	
23-26	4258-4266	dopamine	_	
23-27	4267-4274	release	_	
23-28	4275-4284	following	_	
23-29	4285-4286	a	_	
23-30	4287-4296	stimulant	_	
23-31	4297-4306	challenge	_	
23-32	4307-4312	might	_	
23-33	4313-4315	be	_	
23-34	4316-4317	a	_	
23-35	4318-4327	biomarker	_	
23-36	4328-4330	of	_	
23-37	4331-4344	vulnerability	_	
23-38	4345-4348	for	_	
23-39	4349-4358	substance	_	
23-40	4359-4362	use	_	
23-41	4363-4372	disorders	_	
23-42	4372-4373	.	_	

#Text=However, an earlier stimulant challenge study of nonalcoholic subjects found no effect of family history either on D2 receptor levels or dopamine release.
24-1	4374-4381	However	_	
24-2	4381-4382	,	_	
24-3	4383-4385	an	_	
24-4	4386-4393	earlier	_	
24-5	4394-4403	stimulant	_	
24-6	4404-4413	challenge	_	
24-7	4414-4419	study	_	
24-8	4420-4422	of	_	
24-9	4423-4435	nonalcoholic	_	
24-10	4436-4444	subjects	_	
24-11	4445-4450	found	_	
24-12	4451-4453	no	_	
24-13	4454-4460	effect	_	
24-14	4461-4463	of	_	
24-15	4464-4470	family	_	
24-16	4471-4478	history	_	
24-17	4479-4485	either	_	
24-18	4486-4488	on	_	
24-19	4489-4491	D2	_	
24-20	4492-4500	receptor	_	
24-21	4501-4507	levels	_	
24-22	4508-4510	or	_	
24-23	4511-4519	dopamine	_	
24-24	4520-4527	release	_	
24-25	4527-4528	.	_	

#Text=Furthermore, higher dopamine response in response to oral alcohol was recently found to be associated with higher familial loading.
25-1	4529-4540	Furthermore	_	
25-2	4540-4541	,	_	
25-3	4542-4548	higher	_	
25-4	4549-4557	dopamine	_	
25-5	4558-4566	response	_	
25-6	4567-4569	in	_	
25-7	4570-4578	response	_	
25-8	4579-4581	to	_	
25-9	4582-4586	oral	_	
25-10	4587-4594	alcohol	_	
25-11	4595-4598	was	_	
25-12	4599-4607	recently	_	
25-13	4608-4613	found	_	
25-14	4614-4616	to	_	
25-15	4617-4619	be	_	
25-16	4620-4630	associated	_	
25-17	4631-4635	with	_	
25-18	4636-4642	higher	_	
25-19	4643-4651	familial	_	
25-20	4652-4659	loading	_	
25-21	4659-4660	.	_	

#Text=Given the contradictions in the literature, additional work is required to understand a link between striatal function and vulnerability.
26-1	4661-4666	Given	_	
26-2	4667-4670	the	_	
26-3	4671-4685	contradictions	_	
26-4	4686-4688	in	_	
26-5	4689-4692	the	_	
26-6	4693-4703	literature	_	
26-7	4703-4704	,	_	
26-8	4705-4715	additional	_	
26-9	4716-4720	work	_	
26-10	4721-4723	is	_	
26-11	4724-4732	required	_	
26-12	4733-4735	to	_	
26-13	4736-4746	understand	_	
26-14	4747-4748	a	_	
26-15	4749-4753	link	_	
26-16	4754-4761	between	_	
26-17	4762-4770	striatal	_	
26-18	4771-4779	function	_	
26-19	4780-4783	and	_	
26-20	4784-4797	vulnerability	_	
26-21	4797-4798	.	_	

#Text=We sought to further these investigations of risk with an experimental method that behaviorally probes the reward system and has been well-validated during functional magnetic resonance imaging (fMRI), the Monetary Incentive Delay task, (MID, e.g.).
27-1	4799-4801	We	_	
27-2	4802-4808	sought	_	
27-3	4809-4811	to	_	
27-4	4812-4819	further	_	
27-5	4820-4825	these	_	
27-6	4826-4840	investigations	_	
27-7	4841-4843	of	_	
27-8	4844-4848	risk	_	
27-9	4849-4853	with	_	
27-10	4854-4856	an	_	
27-11	4857-4869	experimental	_	
27-12	4870-4876	method	_	
27-13	4877-4881	that	_	
27-14	4882-4894	behaviorally	_	
27-15	4895-4901	probes	_	
27-16	4902-4905	the	_	
27-17	4906-4912	reward	_	
27-18	4913-4919	system	_	
27-19	4920-4923	and	_	
27-20	4924-4927	has	_	
27-21	4928-4932	been	_	
27-22	4933-4947	well-validated	_	
27-23	4948-4954	during	_	
27-24	4955-4965	functional	_	
27-25	4966-4974	magnetic	_	
27-26	4975-4984	resonance	_	
27-27	4985-4992	imaging	_	
27-28	4993-4994	(	_	
27-29	4994-4998	fMRI	_	
27-30	4998-4999	)	_	
27-31	4999-5000	,	_	
27-32	5001-5004	the	_	
27-33	5005-5013	Monetary	_	
27-34	5014-5023	Incentive	_	
27-35	5024-5029	Delay	_	
27-36	5030-5034	task	_	
27-37	5034-5035	,	_	
27-38	5036-5037	(	_	
27-39	5037-5040	MID	_	
27-40	5040-5041	,	_	
27-41	5042-5045	e.g	_	
27-42	5045-5046	.	_	
27-43	5046-5047	)	_	
27-44	5047-5048	.	_	

#Text=Ventral striatal response to this task, measured by blood oxygen level-dependent (BOLD) signal, has been shown to be associated with substance use as well as risk for substance abuse (see recent review by).
28-1	5049-5056	Ventral	_	
28-2	5057-5065	striatal	_	
28-3	5066-5074	response	_	
28-4	5075-5077	to	_	
28-5	5078-5082	this	_	
28-6	5083-5087	task	_	
28-7	5087-5088	,	_	
28-8	5089-5097	measured	_	
28-9	5098-5100	by	_	
28-10	5101-5106	blood	_	
28-11	5107-5113	oxygen	_	
28-12	5114-5129	level-dependent	_	
28-13	5130-5131	(	_	
28-14	5131-5135	BOLD	_	
28-15	5135-5136	)	_	
28-16	5137-5143	signal	_	
28-17	5143-5144	,	_	
28-18	5145-5148	has	_	
28-19	5149-5153	been	_	
28-20	5154-5159	shown	_	
28-21	5160-5162	to	_	
28-22	5163-5165	be	_	
28-23	5166-5176	associated	_	
28-24	5177-5181	with	_	
28-25	5182-5191	substance	_	
28-26	5192-5195	use	_	
28-27	5196-5198	as	_	
28-28	5199-5203	well	_	
28-29	5204-5206	as	_	
28-30	5207-5211	risk	_	
28-31	5212-5215	for	_	
28-32	5216-5225	substance	_	
28-33	5226-5231	abuse	_	
28-34	5232-5233	(	_	
28-35	5233-5236	see	_	
28-36	5237-5243	recent	_	
28-37	5244-5250	review	_	
28-38	5251-5253	by	_	
28-39	5253-5254	)	_	
28-40	5254-5255	.	_	

#Text=For example, work from our laboratory has shown that NAcc anticipatory response to reward is related to drinking behaviors in transitioning at-risk youth.
29-1	5256-5259	For	_	
29-2	5260-5267	example	_	
29-3	5267-5268	,	_	
29-4	5269-5273	work	_	
29-5	5274-5278	from	_	
29-6	5279-5282	our	_	
29-7	5283-5293	laboratory	_	
29-8	5294-5297	has	_	
29-9	5298-5303	shown	_	
29-10	5304-5308	that	_	
29-11	5309-5313	NAcc	_	
29-12	5314-5326	anticipatory	_	
29-13	5327-5335	response	_	
29-14	5336-5338	to	_	
29-15	5339-5345	reward	_	
29-16	5346-5348	is	_	
29-17	5349-5356	related	_	
29-18	5357-5359	to	_	
29-19	5360-5368	drinking	_	
29-20	5369-5378	behaviors	_	
29-21	5379-5381	in	_	
29-22	5382-5395	transitioning	_	
29-23	5396-5403	at-risk	_	
29-24	5404-5409	youth	_	
29-25	5409-5410	.	_	

#Text=In addition, we recently demonstrated that a version of the MID modified for PET induced the activation of striatal dopamine neurotransmission in healthy individuals.
30-1	5411-5413	In	_	
30-2	5414-5422	addition	_	
30-3	5422-5423	,	_	
30-4	5424-5426	we	_	
30-5	5427-5435	recently	_	
30-6	5436-5448	demonstrated	_	
30-7	5449-5453	that	_	
30-8	5454-5455	a	_	
30-9	5456-5463	version	_	
30-10	5464-5466	of	_	
30-11	5467-5470	the	_	
30-12	5471-5474	MID	_	
30-13	5475-5483	modified	_	
30-14	5484-5487	for	_	
30-15	5488-5491	PET	_	
30-16	5492-5499	induced	_	
30-17	5500-5503	the	_	
30-18	5504-5514	activation	_	
30-19	5515-5517	of	_	
30-20	5518-5526	striatal	_	
30-21	5527-5535	dopamine	_	
30-22	5536-5553	neurotransmission	_	
30-23	5554-5556	in	_	
30-24	5557-5564	healthy	_	
30-25	5565-5576	individuals	_	
30-26	5576-5577	.	_	

#Text=Specifically, we found an average 5% reduction in [11C]raclopride binding potential (BPND) associated with reward .
31-1	5578-5590	Specifically	_	
31-2	5590-5591	,	_	
31-3	5592-5594	we	_	
31-4	5595-5600	found	_	
31-5	5601-5603	an	_	
31-6	5604-5611	average	_	
31-7	5612-5614	5%	_	
31-8	5615-5624	reduction	_	
31-9	5625-5627	in	_	
31-10	5628-5629	[	_	
31-11	5629-5632	11C	_	
31-12	5632-5633	]	_	
31-13	5633-5643	raclopride	_	
31-14	5644-5651	binding	_	
31-15	5652-5661	potential	_	
31-16	5662-5663	(	_	
31-17	5663-5667	BPND	_	
31-18	5667-5668	)	_	
31-19	5669-5679	associated	_	
31-20	5680-5684	with	_	
31-21	5685-5691	reward	_	
31-22	5692-5693	.	_	

#Text=For the current study, we probed neural and molecular substrates of reward processing with the MID during both PET and fMRI scanning of young adults with familial risk and control subjects.
32-1	5694-5697	For	_	
32-2	5698-5701	the	_	
32-3	5702-5709	current	_	
32-4	5710-5715	study	_	
32-5	5715-5716	,	_	
32-6	5717-5719	we	_	
32-7	5720-5726	probed	_	
32-8	5727-5733	neural	_	
32-9	5734-5737	and	_	
32-10	5738-5747	molecular	_	
32-11	5748-5758	substrates	_	
32-12	5759-5761	of	_	
32-13	5762-5768	reward	_	
32-14	5769-5779	processing	_	
32-15	5780-5784	with	_	
32-16	5785-5788	the	_	
32-17	5789-5792	MID	_	
32-18	5793-5799	during	_	
32-19	5800-5804	both	_	
32-20	5805-5808	PET	_	
32-21	5809-5812	and	_	
32-22	5813-5817	fMRI	_	
32-23	5818-5826	scanning	_	
32-24	5827-5829	of	_	
32-25	5830-5835	young	_	
32-26	5836-5842	adults	_	
32-27	5843-5847	with	_	
32-28	5848-5856	familial	_	
32-29	5857-5861	risk	_	
32-30	5862-5865	and	_	
32-31	5866-5873	control	_	
32-32	5874-5882	subjects	_	
32-33	5882-5883	.	_	

#Text=In the FH+ sample, we identified as high-risk (HR) those subjects who had reported drunkenness by age 15, a behavioral predictor of later dependence diagnosis.
33-1	5884-5886	In	_	
33-2	5887-5890	the	_	
33-3	5891-5893	FH	_	
33-4	5893-5894	+	_	
33-5	5895-5901	sample	_	
33-6	5901-5902	,	_	
33-7	5903-5905	we	_	
33-8	5906-5916	identified	_	
33-9	5917-5919	as	_	
33-10	5920-5929	high-risk	_	
33-11	5930-5931	(	_	
33-12	5931-5933	HR	_	
33-13	5933-5934	)	_	
33-14	5935-5940	those	_	
33-15	5941-5949	subjects	_	
33-16	5950-5953	who	_	
33-17	5954-5957	had	_	
33-18	5958-5966	reported	_	
33-19	5967-5978	drunkenness	_	
33-20	5979-5981	by	_	
33-21	5982-5985	age	_	
33-22	5986-5988	15	_	
33-23	5988-5989	,	_	
33-24	5990-5991	a	_	
33-25	5992-6002	behavioral	_	
33-26	6003-6012	predictor	_	
33-27	6013-6015	of	_	
33-28	6016-6021	later	_	
33-29	6022-6032	dependence	_	
33-30	6033-6042	diagnosis	_	
33-31	6042-6043	.	_	

#Text=We sought to explore the interaction between familial and behavioral risk, with multi-modal neuroimaging, hypothesizing that increased NAcc BOLD response and dopamine transmission would be related to both.
34-1	6044-6046	We	_	
34-2	6047-6053	sought	_	
34-3	6054-6056	to	_	
34-4	6057-6064	explore	_	
34-5	6065-6068	the	_	
34-6	6069-6080	interaction	_	
34-7	6081-6088	between	_	
34-8	6089-6097	familial	_	
34-9	6098-6101	and	_	
34-10	6102-6112	behavioral	_	
34-11	6113-6117	risk	_	
34-12	6117-6118	,	_	
34-13	6119-6123	with	_	
34-14	6124-6135	multi-modal	_	
34-15	6136-6148	neuroimaging	_	
34-16	6148-6149	,	_	
34-17	6150-6163	hypothesizing	_	
34-18	6164-6168	that	_	
34-19	6169-6178	increased	_	
34-20	6179-6183	NAcc	_	
34-21	6184-6188	BOLD	_	
34-22	6189-6197	response	_	
34-23	6198-6201	and	_	
34-24	6202-6210	dopamine	_	
34-25	6211-6223	transmission	_	
34-26	6224-6229	would	_	
34-27	6230-6232	be	_	
34-28	6233-6240	related	_	
34-29	6241-6243	to	_	
34-30	6244-6248	both	_	
34-31	6248-6249	.	_	

#Text=Methods
#Text=Subjects
#Text=Forty-four right-handed, young adult male subjects were recruited from the Michigan Longitudinal Study (MLS), an ongoing prospective community study of families with parental AUD (FH+, n = 33) and contrast families (FH-, n = 11).
35-1	6250-6257	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[12]	
35-2	6258-6266	Subjects	http://www.case.edu/ProvCaRe/provcare#StudyMethod[12]	
35-3	6267-6277	Forty-four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-4	6278-6290	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-5	6290-6291	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-6	6292-6297	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-7	6298-6303	adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-8	6304-6308	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-9	6309-6317	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-10	6318-6322	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-11	6323-6332	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-12	6333-6337	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-13	6338-6341	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-14	6342-6350	Michigan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-15	6351-6363	Longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-16	6364-6369	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-17	6370-6371	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-18	6371-6374	MLS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-19	6374-6375	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-20	6375-6376	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-21	6377-6379	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-22	6380-6387	ongoing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
35-23	6388-6399	prospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-24	6400-6409	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-25	6410-6415	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-26	6416-6418	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-27	6419-6427	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-28	6428-6432	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-29	6433-6441	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-30	6442-6445	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]	
35-31	6446-6447	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-32	6447-6449	FH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-33	6449-6450	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-34	6450-6451	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-35	6452-6453	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-36	6454-6455	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-37	6456-6458	33	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-38	6458-6459	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-39	6460-6463	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-40	6464-6472	contrast	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-41	6473-6481	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-42	6482-6483	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-43	6483-6485	FH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-44	6485-6486	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-45	6486-6487	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-46	6488-6489	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-47	6490-6491	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-48	6492-6494	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-49	6494-6495	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-50	6495-6496	.	_	

#Text=Parental AUD was based on at least one parent meeting DSM-IV AUD criteria in their lifetime; detailed descriptions regarding the MLS can be found in.
36-1	6497-6505	Parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-2	6506-6509	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
36-3	6510-6513	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-4	6514-6519	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-5	6520-6522	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-6	6523-6525	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-7	6526-6531	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-8	6532-6535	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-9	6536-6542	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-10	6543-6550	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-11	6551-6557	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-12	6558-6561	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[18]	
36-13	6562-6570	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-14	6571-6573	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-15	6574-6579	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-16	6580-6588	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-17	6588-6589	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-18	6590-6598	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-19	6599-6611	descriptions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-20	6612-6621	regarding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-21	6622-6625	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-22	6626-6629	MLS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-23	6630-6633	can	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-24	6634-6636	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-25	6637-6642	found	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-26	6643-6645	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
36-27	6645-6646	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Families in which the mother reported drinking during pregnancy or in which the target child exhibited signs of fetal alcohol syndrome were excluded.
37-1	6647-6655	Families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-2	6656-6658	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-3	6659-6664	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-4	6665-6668	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-5	6669-6675	mother	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-6	6676-6684	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-7	6685-6693	drinking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-8	6694-6700	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-9	6701-6710	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-10	6711-6713	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-11	6714-6716	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-12	6717-6722	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-13	6723-6726	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-14	6727-6733	target	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-15	6734-6739	child	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-16	6740-6749	exhibited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-17	6750-6755	signs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-18	6756-6758	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-19	6759-6764	fetal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-20	6765-6772	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-21	6773-6781	syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-22	6782-6786	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-23	6787-6795	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-24	6795-6796	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Exclusionary criteria were: any neurological, acute, uncorrected, or chronic illness; any current or recent (within six months) treatment with centrally active medications including sedative hypnotics; and history of psychosis or schizophrenia in first-degree relatives.
38-1	6797-6809	Exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-2	6810-6818	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-3	6819-6823	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-4	6823-6824	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-5	6825-6828	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-6	6829-6841	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-7	6841-6842	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-8	6843-6848	acute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-9	6848-6849	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-10	6850-6861	uncorrected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-11	6861-6862	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-12	6863-6865	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-13	6866-6873	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-14	6874-6881	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-15	6881-6882	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-16	6883-6886	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-17	6887-6894	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-18	6895-6897	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-19	6898-6904	recent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-20	6905-6906	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-21	6906-6912	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-22	6913-6916	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-23	6917-6923	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-24	6923-6924	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-25	6925-6934	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-26	6935-6939	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-27	6940-6949	centrally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-28	6950-6956	active	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-29	6957-6968	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-30	6969-6978	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-31	6979-6987	sedative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-32	6988-6997	hypnotics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-33	6997-6998	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-34	6999-7002	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-35	7003-7010	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-36	7011-7013	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-37	7014-7023	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-38	7024-7026	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-39	7027-7040	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-40	7041-7043	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-41	7044-7056	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-42	7057-7066	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-43	7066-7067	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=The presence of most Axis I psychiatric or developmental disorders was exclusionary.
39-1	7068-7071	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-2	7072-7080	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-3	7081-7083	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-4	7084-7088	most	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-5	7089-7093	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-6	7094-7095	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-7	7096-7107	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-8	7108-7110	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-9	7111-7124	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-10	7125-7134	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-11	7135-7138	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-12	7139-7151	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-13	7151-7152	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=However, externalizing disorders, including conduct disorder, attention deficit/hyperactivity disorder (ADHD), SUD, were not exclusionary as these may lie on a developmental spectrum with AUD risk.
40-1	7153-7160	However	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-2	7160-7161	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-3	7162-7175	externalizing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-4	7176-7185	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-5	7185-7186	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-6	7187-7196	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-7	7197-7204	conduct	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-8	7205-7213	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-9	7213-7214	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-10	7215-7224	attention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-11	7225-7232	deficit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-12	7232-7233	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-13	7233-7246	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-14	7247-7255	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-15	7256-7257	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-16	7257-7261	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-17	7261-7262	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[22]	
40-18	7262-7263	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-19	7264-7267	SUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[23]	
40-20	7267-7268	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-21	7269-7273	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-22	7274-7277	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-23	7278-7290	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-24	7291-7293	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-25	7294-7299	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-26	7300-7303	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-27	7304-7307	lie	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-28	7308-7310	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-29	7311-7312	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-30	7313-7326	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-31	7327-7335	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-32	7336-7340	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-33	7341-7344	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[24]	
40-34	7345-7349	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
40-35	7349-7350	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Diagnoses were determined using DSM-IV criteria.
41-1	7351-7360	Diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-2	7361-7365	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-3	7366-7376	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-4	7377-7382	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-5	7383-7389	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-6	7390-7398	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
41-7	7398-7399	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Participants were told to abstain from alcohol and other drugs (with the exception of nicotine) for 48 hours prior to their appointment and were given a multi-drug 5-panel urine screen before scanning.
42-1	7400-7412	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-2	7413-7417	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-3	7418-7422	told	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-4	7423-7425	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-5	7426-7433	abstain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-6	7434-7438	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-7	7439-7446	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-8	7447-7450	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-9	7451-7456	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-10	7457-7462	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-11	7463-7464	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-12	7464-7468	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-13	7469-7472	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-14	7473-7482	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-15	7483-7485	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-16	7486-7494	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-17	7494-7495	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-18	7496-7499	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-19	7500-7502	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-20	7503-7508	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-21	7509-7514	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-22	7515-7517	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-23	7518-7523	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-24	7524-7535	appointment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-25	7536-7539	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-26	7540-7544	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-27	7545-7550	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-28	7551-7552	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-29	7553-7563	multi-drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-30	7564-7565	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-31	7565-7566	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-32	7566-7571	panel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-33	7572-7577	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-34	7578-7584	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-35	7585-7591	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-36	7592-7600	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-37	7600-7601	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Because THC metabolites are detectible in urine for more than 48 hours, we relied on self-report regarding abstinence in the 2 days prior to the study if a participant tested positive for marijuana.
43-1	7602-7609	Because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-2	7610-7613	THC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-3	7614-7625	metabolites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-4	7626-7629	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-5	7630-7640	detectible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-6	7641-7643	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-7	7644-7649	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-8	7650-7653	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-9	7654-7658	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-10	7659-7663	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-11	7664-7666	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-12	7667-7672	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-13	7672-7673	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-14	7674-7676	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-15	7677-7683	relied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-16	7684-7686	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-17	7687-7698	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-18	7699-7708	regarding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-19	7709-7719	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-20	7720-7722	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-21	7723-7726	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-22	7727-7728	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-23	7729-7733	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-24	7734-7739	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-25	7740-7742	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-26	7743-7746	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-27	7747-7752	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-28	7753-7755	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-29	7756-7757	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-30	7758-7769	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-31	7770-7776	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-32	7777-7785	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-33	7786-7789	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-34	7790-7799	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
43-35	7799-7800	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Report of marijuana use in the prior 48 hours or a positive screen for other drug use was exclusionary.
44-1	7801-7807	Report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-2	7808-7810	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-3	7811-7820	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-4	7821-7824	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-5	7825-7827	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-6	7828-7831	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-7	7832-7837	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-8	7838-7840	48	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-9	7841-7846	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-10	7847-7849	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-11	7850-7851	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-12	7852-7860	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-13	7861-7867	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-14	7868-7871	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-15	7872-7877	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-16	7878-7882	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-17	7883-7886	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-18	7887-7890	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-19	7891-7903	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
44-20	7903-7904	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Subject characteristics are summarized in Table 1.
45-1	7905-7912	Subject	_	
45-2	7913-7928	characteristics	_	
45-3	7929-7932	are	_	
45-4	7933-7943	summarized	_	
45-5	7944-7946	in	_	
45-6	7947-7952	Table	_	
45-7	7953-7954	1	_	
45-8	7954-7955	.	_	

#Text=Protocols were approved by the Investigational Review Board and the Radioactive Drug Research Committee of the University of Michigan and written informed consent was obtained from all subjects.
46-1	7956-7965	Protocols	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-2	7966-7970	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-3	7971-7979	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-4	7980-7982	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-5	7983-7986	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-6	7987-8002	Investigational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-7	8003-8009	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-8	8010-8015	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-9	8016-8019	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-10	8020-8023	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-11	8024-8035	Radioactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-12	8036-8040	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-13	8041-8049	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-14	8050-8059	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-15	8060-8062	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-16	8063-8066	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-17	8067-8077	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-18	8078-8080	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-19	8081-8089	Michigan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-20	8090-8093	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-21	8094-8101	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-22	8102-8110	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-23	8111-8118	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-24	8119-8122	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-25	8123-8131	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-26	8132-8136	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-27	8137-8140	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-28	8141-8149	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-29	8149-8150	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Urine drug screens were performed immediately before both PET and fMRI sessions.
47-1	8151-8156	Urine	_	
47-2	8157-8161	drug	_	
47-3	8162-8169	screens	_	
47-4	8170-8174	were	_	
47-5	8175-8184	performed	_	
47-6	8185-8196	immediately	_	
47-7	8197-8203	before	_	
47-8	8204-8208	both	_	
47-9	8209-8212	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
47-10	8213-8216	and	_	
47-11	8217-8221	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
47-12	8222-8230	sessions	_	
47-13	8230-8231	.	_	

#Text=Substance Use
#Text=Substance use was evaluated with the Drinking and Drug History (DDH) Questionnaire which assesses onset of use, quantity, and frequency of alcohol, marijuana and cigarette consumption; any other drug use; and has questions regarding consequences and problems related to alcohol use.
48-1	8232-8241	Substance	_	
48-2	8242-8245	Use	_	
48-3	8246-8255	Substance	_	
48-4	8256-8259	use	_	
48-5	8260-8263	was	_	
48-6	8264-8273	evaluated	_	
48-7	8274-8278	with	_	
48-8	8279-8282	the	_	
48-9	8283-8291	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-10	8292-8295	and	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-11	8296-8300	Drug	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-12	8301-8308	History	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-13	8309-8310	(	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-14	8310-8313	DDH	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-15	8313-8314	)	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-16	8315-8328	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingandDrugHistoryQuestionnaire[27]	
48-17	8329-8334	which	_	
48-18	8335-8343	assesses	_	
48-19	8344-8349	onset	_	
48-20	8350-8352	of	_	
48-21	8353-8356	use	_	
48-22	8356-8357	,	_	
48-23	8358-8366	quantity	_	
48-24	8366-8367	,	_	
48-25	8368-8371	and	_	
48-26	8372-8381	frequency	_	
48-27	8382-8384	of	_	
48-28	8385-8392	alcohol	_	
48-29	8392-8393	,	_	
48-30	8394-8403	marijuana	_	
48-31	8404-8407	and	_	
48-32	8408-8417	cigarette	_	
48-33	8418-8429	consumption	_	
48-34	8429-8430	;	_	
48-35	8431-8434	any	_	
48-36	8435-8440	other	_	
48-37	8441-8445	drug	_	
48-38	8446-8449	use	_	
48-39	8449-8450	;	_	
48-40	8451-8454	and	_	
48-41	8455-8458	has	_	
48-42	8459-8468	questions	_	
48-43	8469-8478	regarding	_	
48-44	8479-8491	consequences	_	
48-45	8492-8495	and	_	
48-46	8496-8504	problems	_	
48-47	8505-8512	related	_	
48-48	8513-8515	to	_	
48-49	8516-8523	alcohol	_	
48-50	8524-8527	use	_	
48-51	8527-8528	.	_	

#Text=This measure was administered yearly since age 11 and used to derive cumulative substance use by calculating annual use and summing these values through the current age.
49-1	8529-8533	This	_	
49-2	8534-8541	measure	_	
49-3	8542-8545	was	_	
49-4	8546-8558	administered	_	
49-5	8559-8565	yearly	_	
49-6	8566-8571	since	_	
49-7	8572-8575	age	_	
49-8	8576-8578	11	_	
49-9	8579-8582	and	_	
49-10	8583-8587	used	_	
49-11	8588-8590	to	_	
49-12	8591-8597	derive	_	
49-13	8598-8608	cumulative	_	
49-14	8609-8618	substance	_	
49-15	8619-8622	use	_	
49-16	8623-8625	by	_	
49-17	8626-8637	calculating	_	
49-18	8638-8644	annual	_	
49-19	8645-8648	use	_	
49-20	8649-8652	and	_	
49-21	8653-8660	summing	_	
49-22	8661-8666	these	_	
49-23	8667-8673	values	_	
49-24	8674-8681	through	_	
49-25	8682-8685	the	_	
49-26	8686-8693	current	_	
49-27	8694-8697	age	_	
49-28	8697-8698	.	_	

#Text=If data was missing for a year, annual use was calculated as an average of the adjacent years.
50-1	8699-8701	If	_	
50-2	8702-8706	data	_	
50-3	8707-8710	was	_	
50-4	8711-8718	missing	_	
50-5	8719-8722	for	_	
50-6	8723-8724	a	_	
50-7	8725-8729	year	_	
50-8	8729-8730	,	_	
50-9	8731-8737	annual	_	
50-10	8738-8741	use	_	
50-11	8742-8745	was	_	
50-12	8746-8756	calculated	_	
50-13	8757-8759	as	_	
50-14	8760-8762	an	_	
50-15	8763-8770	average	_	
50-16	8771-8773	of	_	
50-17	8774-8777	the	_	
50-18	8778-8786	adjacent	_	
50-19	8787-8792	years	_	
50-20	8792-8793	.	_	

#Text=Abuse or dependence diagnoses were assessed using DSM-IV criteria.
51-1	8794-8799	Abuse	_	
51-2	8800-8802	or	_	
51-3	8803-8813	dependence	_	
51-4	8814-8823	diagnoses	_	
51-5	8824-8828	were	_	
51-6	8829-8837	assessed	_	
51-7	8838-8843	using	_	
51-8	8844-8850	DSM-IV	_	
51-9	8851-8859	criteria	_	
51-10	8859-8860	.	_	

#Text=Recent Substance Use
#Text=The Timeline Follow Back questionnaire (TLFB) was used to query daily alcohol, cigarette, and drug use in the 30 days prior to PET scanning.
52-1	8861-8867	Recent	_	
52-2	8868-8877	Substance	_	
52-3	8878-8881	Use	_	
52-4	8882-8885	The	http://www.case.edu/ProvCaRe/provcare#Questionnaire[28]	
52-5	8886-8894	Timeline	http://www.case.edu/ProvCaRe/provcare#Questionnaire[28]	
52-6	8895-8901	Follow	http://www.case.edu/ProvCaRe/provcare#Questionnaire[28]	
52-7	8902-8906	Back	http://www.case.edu/ProvCaRe/provcare#Questionnaire[28]	
52-8	8907-8920	questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[28]	
52-9	8921-8922	(	_	
52-10	8922-8926	TLFB	_	
52-11	8926-8927	)	_	
52-12	8928-8931	was	_	
52-13	8932-8936	used	_	
52-14	8937-8939	to	_	
52-15	8940-8945	query	_	
52-16	8946-8951	daily	_	
52-17	8952-8959	alcohol	_	
52-18	8959-8960	,	_	
52-19	8961-8970	cigarette	_	
52-20	8970-8971	,	_	
52-21	8972-8975	and	_	
52-22	8976-8980	drug	_	
52-23	8981-8984	use	_	
52-24	8985-8987	in	_	
52-25	8988-8991	the	_	
52-26	8992-8994	30	_	
52-27	8995-8999	days	_	
52-28	9000-9005	prior	_	
52-29	9006-9008	to	_	
52-30	9009-9012	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[29]	
52-31	9013-9021	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[29]	
52-32	9021-9022	.	_	

#Text=Subjects reported the number of days and quantity (i.e., number of standard drink, cigarettes, joints) of use.
53-1	9023-9031	Subjects	_	
53-2	9032-9040	reported	_	
53-3	9041-9044	the	_	
53-4	9045-9051	number	_	
53-5	9052-9054	of	_	
53-6	9055-9059	days	_	
53-7	9060-9063	and	_	
53-8	9064-9072	quantity	_	
53-9	9073-9074	(	_	
53-10	9074-9077	i.e	_	
53-11	9077-9078	.	_	
53-12	9078-9079	,	_	
53-13	9080-9086	number	_	
53-14	9087-9089	of	_	
53-15	9090-9098	standard	_	
53-16	9099-9104	drink	_	
53-17	9104-9105	,	_	
53-18	9106-9116	cigarettes	_	
53-19	9116-9117	,	_	
53-20	9118-9124	joints	_	
53-21	9124-9125	)	_	
53-22	9126-9128	of	_	
53-23	9129-9132	use	_	
53-24	9132-9133	.	_	

#Text=Experimental paradigm - PET
#Text=Each subject underwent a single 90-minute PET scan with [11C]raclopride, a DA radiotracer with affinity for both D2 and D3 receptors during which they performed a modified version of the MID reward task divided into two conditions, reward and control.
54-1	9134-9146	Experimental	_	
54-2	9147-9155	paradigm	_	
54-3	9156-9157	-	_	
54-4	9158-9161	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
54-5	9162-9166	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-6	9167-9174	subject	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-7	9175-9184	underwent	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-8	9185-9186	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-9	9187-9193	single	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-10	9194-9196	90	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-11	9196-9197	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-12	9197-9203	minute	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-13	9204-9207	PET	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[31]	
54-14	9208-9212	scan	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[31]	
54-15	9213-9217	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-16	9218-9219	[	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-17	9219-9222	11C	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-18	9222-9223	]	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-19	9223-9233	raclopride	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-20	9233-9234	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-21	9235-9236	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-22	9237-9239	DA	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-23	9240-9251	radiotracer	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-24	9252-9256	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-25	9257-9265	affinity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-26	9266-9269	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-27	9270-9274	both	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-28	9275-9277	D2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-29	9278-9281	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-30	9282-9284	D3	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-31	9285-9294	receptors	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-32	9295-9301	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-33	9302-9307	which	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-34	9308-9312	they	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-35	9313-9322	performed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-36	9323-9324	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-37	9325-9333	modified	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-38	9334-9341	version	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-39	9342-9344	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-40	9345-9348	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-41	9349-9352	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-42	9353-9359	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-43	9360-9364	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-44	9365-9372	divided	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-45	9373-9377	into	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-46	9378-9381	two	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-47	9382-9392	conditions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-48	9392-9393	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-49	9394-9400	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-50	9401-9404	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-51	9405-9412	control	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	
54-52	9412-9413	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]	

#Text=Trials included an incentive cue, indicating the possibility of reward or the absence of a reward, followed by an anticipation delay.
55-1	9414-9420	Trials	_	
55-2	9421-9429	included	_	
55-3	9430-9432	an	_	
55-4	9433-9442	incentive	_	
55-5	9443-9446	cue	_	
55-6	9446-9447	,	_	
55-7	9448-9458	indicating	_	
55-8	9459-9462	the	_	
55-9	9463-9474	possibility	_	
55-10	9475-9477	of	_	
55-11	9478-9484	reward	_	
55-12	9485-9487	or	_	
55-13	9488-9491	the	_	
55-14	9492-9499	absence	_	
55-15	9500-9502	of	_	
55-16	9503-9504	a	_	
55-17	9505-9511	reward	_	
55-18	9511-9512	,	_	
55-19	9513-9521	followed	_	
55-20	9522-9524	by	_	
55-21	9525-9527	an	_	
55-22	9528-9540	anticipation	_	
55-23	9541-9546	delay	_	
55-24	9546-9547	.	_	

#Text=A target then appeared for a variable length of time during which subject used a mouse press response in an attempt to gain or avoid losing money; a schematic of the task is presented in Figure 1.
56-1	9548-9549	A	_	
56-2	9550-9556	target	_	
56-3	9557-9561	then	_	
56-4	9562-9570	appeared	_	
56-5	9571-9574	for	_	
56-6	9575-9576	a	_	
56-7	9577-9585	variable	_	
56-8	9586-9592	length	_	
56-9	9593-9595	of	_	
56-10	9596-9600	time	_	
56-11	9601-9607	during	_	
56-12	9608-9613	which	_	
56-13	9614-9621	subject	_	
56-14	9622-9626	used	_	
56-15	9627-9628	a	_	
56-16	9629-9634	mouse	_	
56-17	9635-9640	press	_	
56-18	9641-9649	response	_	
56-19	9650-9652	in	_	
56-20	9653-9655	an	_	
56-21	9656-9663	attempt	_	
56-22	9664-9666	to	_	
56-23	9667-9671	gain	_	
56-24	9672-9674	or	_	
56-25	9675-9680	avoid	_	
56-26	9681-9687	losing	_	
56-27	9688-9693	money	_	
56-28	9693-9694	;	_	
56-29	9695-9696	a	_	
56-30	9697-9706	schematic	_	
56-31	9707-9709	of	_	
56-32	9710-9713	the	_	
56-33	9714-9718	task	_	
56-34	9719-9721	is	_	
56-35	9722-9731	presented	_	
56-36	9732-9734	in	_	
56-37	9735-9741	Figure	_	
56-38	9742-9743	1	_	
56-39	9743-9744	.	_	

#Text=In the reward condition, cues varied in amount (from $0.00–5.00) and valence (win or lose) and a feedback message then informed subjects of the trial outcome.
57-1	9745-9747	In	_	
57-2	9748-9751	the	_	
57-3	9752-9758	reward	_	
57-4	9759-9768	condition	_	
57-5	9768-9769	,	_	
57-6	9770-9774	cues	_	
57-7	9775-9781	varied	_	
57-8	9782-9784	in	_	
57-9	9785-9791	amount	_	
57-10	9792-9793	(	_	
57-11	9793-9797	from	_	
57-12	9798-9803	$0.00	_	
57-13	9803-9804	–	_	
57-14	9804-9808	5.00	_	
57-15	9808-9809	)	_	
57-16	9810-9813	and	_	
57-17	9814-9821	valence	_	
57-18	9822-9823	(	_	
57-19	9823-9826	win	_	
57-20	9827-9829	or	_	
57-21	9830-9834	lose	_	
57-22	9834-9835	)	_	
57-23	9836-9839	and	_	
57-24	9840-9841	a	_	
57-25	9842-9850	feedback	_	
57-26	9851-9858	message	_	
57-27	9859-9863	then	_	
57-28	9864-9872	informed	_	
57-29	9873-9881	subjects	_	
57-30	9882-9884	of	_	
57-31	9885-9888	the	_	
57-32	9889-9894	trial	_	
57-33	9895-9902	outcome	_	
57-34	9902-9903	.	_	

#Text=To increase attention and reduce adaptation to the reward in the reward condition over time during the scan, the feedback included increasing positive sounds (i.e. applause, cash register) due to an increasing reward rate over the task.
58-1	9904-9906	To	_	
58-2	9907-9915	increase	_	
58-3	9916-9925	attention	_	
58-4	9926-9929	and	_	
58-5	9930-9936	reduce	_	
58-6	9937-9947	adaptation	_	
58-7	9948-9950	to	_	
58-8	9951-9954	the	_	
58-9	9955-9961	reward	_	
58-10	9962-9964	in	_	
58-11	9965-9968	the	_	
58-12	9969-9975	reward	_	
58-13	9976-9985	condition	_	
58-14	9986-9990	over	_	
58-15	9991-9995	time	_	
58-16	9996-10002	during	_	
58-17	10003-10006	the	_	
58-18	10007-10011	scan	_	
58-19	10011-10012	,	_	
58-20	10013-10016	the	_	
58-21	10017-10025	feedback	_	
58-22	10026-10034	included	_	
58-23	10035-10045	increasing	_	
58-24	10046-10054	positive	_	
58-25	10055-10061	sounds	_	
58-26	10062-10063	(	_	
58-27	10063-10066	i.e	_	
58-28	10066-10067	.	_	
58-29	10068-10076	applause	_	
58-30	10076-10077	,	_	
58-31	10078-10082	cash	_	
58-32	10083-10091	register	_	
58-33	10091-10092	)	_	
58-34	10093-10096	due	_	
58-35	10097-10099	to	_	
58-36	10100-10102	an	_	
58-37	10103-10113	increasing	_	
58-38	10114-10120	reward	_	
58-39	10121-10125	rate	_	
58-40	10126-10130	over	_	
58-41	10131-10134	the	_	
58-42	10135-10139	task	_	
58-43	10139-10140	.	_	

#Text=As a control condition, we utilized a control task involving no incentives, where subjects were instructed to respond to a neutral target and feedback was replaced with a message to continue to the next trial without indication of performance.
59-1	10141-10143	As	_	
59-2	10144-10145	a	_	
59-3	10146-10153	control	_	
59-4	10154-10163	condition	_	
59-5	10163-10164	,	_	
59-6	10165-10167	we	_	
59-7	10168-10176	utilized	_	
59-8	10177-10178	a	_	
59-9	10179-10186	control	_	
59-10	10187-10191	task	_	
59-11	10192-10201	involving	_	
59-12	10202-10204	no	_	
59-13	10205-10215	incentives	_	
59-14	10215-10216	,	_	
59-15	10217-10222	where	_	
59-16	10223-10231	subjects	_	
59-17	10232-10236	were	_	
59-18	10237-10247	instructed	_	
59-19	10248-10250	to	_	
59-20	10251-10258	respond	_	
59-21	10259-10261	to	_	
59-22	10262-10263	a	_	
59-23	10264-10271	neutral	_	
59-24	10272-10278	target	_	
59-25	10279-10282	and	_	
59-26	10283-10291	feedback	_	
59-27	10292-10295	was	_	
59-28	10296-10304	replaced	_	
59-29	10305-10309	with	_	
59-30	10310-10311	a	_	
59-31	10312-10319	message	_	
59-32	10320-10322	to	_	
59-33	10323-10331	continue	_	
59-34	10332-10334	to	_	
59-35	10335-10338	the	_	
59-36	10339-10343	next	_	
59-37	10344-10349	trial	_	
59-38	10350-10357	without	_	
59-39	10358-10368	indication	_	
59-40	10369-10371	of	_	
59-41	10372-10383	performance	_	
59-42	10383-10384	.	_	

#Text=In both conditions, duration of the response target was calculated based on the individual subject's reaction time during a practice session prior to scanning and dynamically adjusted to a mean hit rate of approximately 66%.
60-1	10385-10387	In	_	
60-2	10388-10392	both	_	
60-3	10393-10403	conditions	_	
60-4	10403-10404	,	_	
60-5	10405-10413	duration	_	
60-6	10414-10416	of	_	
60-7	10417-10420	the	_	
60-8	10421-10429	response	_	
60-9	10430-10436	target	_	
60-10	10437-10440	was	_	
60-11	10441-10451	calculated	_	
60-12	10452-10457	based	_	
60-13	10458-10460	on	_	
60-14	10461-10464	the	_	
60-15	10465-10475	individual	_	
60-16	10476-10485	subject's	_	
60-17	10486-10494	reaction	_	
60-18	10495-10499	time	_	
60-19	10500-10506	during	_	
60-20	10507-10508	a	_	
60-21	10509-10517	practice	_	
60-22	10518-10525	session	_	
60-23	10526-10531	prior	_	
60-24	10532-10534	to	_	
60-25	10535-10543	scanning	_	
60-26	10544-10547	and	_	
60-27	10548-10559	dynamically	_	
60-28	10560-10568	adjusted	_	
60-29	10569-10571	to	_	
60-30	10572-10573	a	_	
60-31	10574-10578	mean	_	
60-32	10579-10582	hit	_	
60-33	10583-10587	rate	_	
60-34	10588-10590	of	_	
60-35	10591-10604	approximately	_	
60-36	10605-10608	66%	_	
60-37	10608-10609	.	_	

#Text=Each presentation lasted for approximately 30 minutes without interruption with the control condition presented first, beginning at 5 minutes after tracer injection, followed by the reward condition, beginning at 45 minutes post-injection.
61-1	10610-10614	Each	_	
61-2	10615-10627	presentation	_	
61-3	10628-10634	lasted	_	
61-4	10635-10638	for	_	
61-5	10639-10652	approximately	_	
61-6	10653-10655	30	_	
61-7	10656-10663	minutes	_	
61-8	10664-10671	without	_	
61-9	10672-10684	interruption	_	
61-10	10685-10689	with	_	
61-11	10690-10693	the	_	
61-12	10694-10701	control	_	
61-13	10702-10711	condition	_	
61-14	10712-10721	presented	_	
61-15	10722-10727	first	_	
61-16	10727-10728	,	_	
61-17	10729-10738	beginning	_	
61-18	10739-10741	at	_	
61-19	10742-10743	5	_	
61-20	10744-10751	minutes	_	
61-21	10752-10757	after	_	
61-22	10758-10764	tracer	_	
61-23	10765-10774	injection	_	
61-24	10774-10775	,	_	
61-25	10776-10784	followed	_	
61-26	10785-10787	by	_	
61-27	10788-10791	the	_	
61-28	10792-10798	reward	_	
61-29	10799-10808	condition	_	
61-30	10808-10809	,	_	
61-31	10810-10819	beginning	_	
61-32	10820-10822	at	_	
61-33	10823-10825	45	_	
61-34	10826-10833	minutes	_	
61-35	10834-10848	post-injection	_	
61-36	10848-10849	.	_	

#Text=Participants were paid a fixed rate to participate in the study and additionally received any money they won during the reward condition.
62-1	10850-10862	Participants	_	
62-2	10863-10867	were	_	
62-3	10868-10872	paid	_	
62-4	10873-10874	a	_	
62-5	10875-10880	fixed	_	
62-6	10881-10885	rate	_	
62-7	10886-10888	to	_	
62-8	10889-10900	participate	_	
62-9	10901-10903	in	_	
62-10	10904-10907	the	_	
62-11	10908-10913	study	_	
62-12	10914-10917	and	_	
62-13	10918-10930	additionally	_	
62-14	10931-10939	received	_	
62-15	10940-10943	any	_	
62-16	10944-10949	money	_	
62-17	10950-10954	they	_	
62-18	10955-10958	won	_	
62-19	10959-10965	during	_	
62-20	10966-10969	the	_	
62-21	10970-10976	reward	_	
62-22	10977-10986	condition	_	
62-23	10986-10987	.	_	

#Text=PET imaging
#Text=PET scans were acquired with a Siemens (Knoxville, TN) HR+ scanner in 3-D mode (reconstructed full-width at half maximum resolution, ∼5.5 mm in-plane and 5.0 mm axially).
63-1	10988-10991	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
63-2	10992-10999	imaging	_	
63-3	11000-11003	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
63-4	11004-11009	scans	_	
63-5	11010-11014	were	_	
63-6	11015-11023	acquired	_	
63-7	11024-11028	with	_	
63-8	11029-11030	a	_	
63-9	11031-11038	Siemens	_	
63-10	11039-11040	(	_	
63-11	11040-11049	Knoxville	_	
63-12	11049-11050	,	_	
63-13	11051-11053	TN	_	
63-14	11053-11054	)	_	
63-15	11055-11057	HR	_	
63-16	11057-11058	+	_	
63-17	11059-11066	scanner	_	
63-18	11067-11069	in	_	
63-19	11070-11071	3	_	
63-20	11071-11072	-	_	
63-21	11072-11073	D	_	
63-22	11074-11078	mode	_	
63-23	11079-11080	(	_	
63-24	11080-11093	reconstructed	_	
63-25	11094-11104	full-width	_	
63-26	11105-11107	at	_	
63-27	11108-11112	half	_	
63-28	11113-11120	maximum	_	
63-29	11121-11131	resolution	_	
63-30	11131-11132	,	_	
63-31	11133-11134	∼	_	
63-32	11134-11137	5.5	_	
63-33	11138-11140	mm	_	
63-34	11141-11149	in-plane	_	
63-35	11150-11153	and	_	
63-36	11154-11157	5.0	_	
63-37	11158-11160	mm	_	
63-38	11161-11168	axially	_	
63-39	11168-11169	)	_	
63-40	11169-11170	.	_	

#Text=Radiotracer synthesis and image acquisition, coregistration and reconstruction protocols were identical to those used previously.
64-1	11171-11182	Radiotracer	_	
64-2	11183-11192	synthesis	_	
64-3	11193-11196	and	_	
64-4	11197-11202	image	_	
64-5	11203-11214	acquisition	_	
64-6	11214-11215	,	_	
64-7	11216-11230	coregistration	_	
64-8	11231-11234	and	_	
64-9	11235-11249	reconstruction	_	
64-10	11250-11259	protocols	_	
64-11	11260-11264	were	_	
64-12	11265-11274	identical	_	
64-13	11275-11277	to	_	
64-14	11278-11283	those	_	
64-15	11284-11288	used	_	
64-16	11289-11299	previously	_	
64-17	11299-11300	.	_	

#Text=Briefly, images were reconstructed, attenuation and motion corrected, and co-registered to each other.
65-1	11301-11308	Briefly	_	
65-2	11308-11309	,	_	
65-3	11310-11316	images	_	
65-4	11317-11321	were	_	
65-5	11322-11335	reconstructed	_	
65-6	11335-11336	,	_	
65-7	11337-11348	attenuation	_	
65-8	11349-11352	and	_	
65-9	11353-11359	motion	_	
65-10	11360-11369	corrected	_	
65-11	11369-11370	,	_	
65-12	11371-11374	and	_	
65-13	11375-11388	co-registered	_	
65-14	11389-11391	to	_	
65-15	11392-11396	each	_	
65-16	11397-11402	other	_	
65-17	11402-11403	.	_	

#Text=Time points were then decay-corrected during data reconstruction.
66-1	11404-11408	Time	_	
66-2	11409-11415	points	_	
66-3	11416-11420	were	_	
66-4	11421-11425	then	_	
66-5	11426-11441	decay-corrected	_	
66-6	11442-11448	during	_	
66-7	11449-11453	data	_	
66-8	11454-11468	reconstruction	_	
66-9	11468-11469	.	_	

#Text=Approximately 15 millicuries (mCi) was administered for each scan (<40 μg total cold mass for raclopride).
67-1	11470-11483	Approximately	_	
67-2	11484-11486	15	_	
67-3	11487-11498	millicuries	_	
67-4	11499-11500	(	_	
67-5	11500-11503	mCi	_	
67-6	11503-11504	)	_	
67-7	11505-11508	was	_	
67-8	11509-11521	administered	_	
67-9	11522-11525	for	_	
67-10	11526-11530	each	_	
67-11	11531-11535	scan	_	
67-12	11536-11537	(	_	
67-13	11537-11538	<	_	
67-14	11538-11540	40	_	
67-15	11541-11543	μg	_	
67-16	11544-11549	total	_	
67-17	11550-11554	cold	_	
67-18	11555-11559	mass	_	
67-19	11560-11563	for	_	
67-20	11564-11574	raclopride	_	
67-21	11574-11575	)	_	
67-22	11575-11576	.	_	

#Text=Fifty percent of the radiotracer dose was administered as a bolus with the remainder delivered as a continuous infusion which allows for more rapid equilibration across compartments and is achieved within 5 min of radiotracer administration (Watabe et al., 2000).
68-1	11577-11582	Fifty	_	
68-2	11583-11590	percent	_	
68-3	11591-11593	of	_	
68-4	11594-11597	the	_	
68-5	11598-11609	radiotracer	_	
68-6	11610-11614	dose	_	
68-7	11615-11618	was	_	
68-8	11619-11631	administered	_	
68-9	11632-11634	as	_	
68-10	11635-11636	a	_	
68-11	11637-11642	bolus	_	
68-12	11643-11647	with	_	
68-13	11648-11651	the	_	
68-14	11652-11661	remainder	_	
68-15	11662-11671	delivered	_	
68-16	11672-11674	as	_	
68-17	11675-11676	a	_	
68-18	11677-11687	continuous	_	
68-19	11688-11696	infusion	_	
68-20	11697-11702	which	_	
68-21	11703-11709	allows	_	
68-22	11710-11713	for	_	
68-23	11714-11718	more	_	
68-24	11719-11724	rapid	_	
68-25	11725-11738	equilibration	_	
68-26	11739-11745	across	_	
68-27	11746-11758	compartments	_	
68-28	11759-11762	and	_	
68-29	11763-11765	is	_	
68-30	11766-11774	achieved	_	
68-31	11775-11781	within	_	
68-32	11782-11783	5	_	
68-33	11784-11787	min	_	
68-34	11788-11790	of	_	
68-35	11791-11802	radiotracer	_	
68-36	11803-11817	administration	_	
68-37	11818-11819	(	_	
68-38	11819-11825	Watabe	_	
68-39	11826-11828	et	_	
68-40	11829-11831	al	_	
68-41	11831-11832	.	_	
68-42	11832-11833	,	_	
68-43	11834-11838	2000	_	
68-44	11838-11839	)	_	
68-45	11839-11840	.	_	

#Text=Twenty-eight image frames were acquired over 90 minutes with an increasing duration (30 seconds up to 10 minutes).
69-1	11841-11853	Twenty-eight	_	
69-2	11854-11859	image	_	
69-3	11860-11866	frames	_	
69-4	11867-11871	were	_	
69-5	11872-11880	acquired	_	
69-6	11881-11885	over	_	
69-7	11886-11888	90	_	
69-8	11889-11896	minutes	_	
69-9	11897-11901	with	_	
69-10	11902-11904	an	_	
69-11	11905-11915	increasing	_	
69-12	11916-11924	duration	_	
69-13	11925-11926	(	_	
69-14	11926-11928	30	_	
69-15	11929-11936	seconds	_	
69-16	11937-11939	up	_	
69-17	11940-11942	to	_	
69-18	11943-11945	10	_	
69-19	11946-11953	minutes	_	
69-20	11953-11954	)	_	
69-21	11954-11955	.	_	

#Text=PET image processing
#Text=Dynamic images were transformed, on a voxel-by-voxel basis, into two coregistered sets of parametric maps: a tracer transport measure (K1 ratio); and a receptor-related measure at equilibrium BPND, yielding condition level images obtained from 35-45 min (control) and 60-80 min (reward) after tracer administration, using full equilibrium data, with the cerebellum as the non-displaceable reference region.
70-1	11956-11959	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
70-2	11960-11965	image	_	
70-3	11966-11976	processing	_	
70-4	11977-11984	Dynamic	_	
70-5	11985-11991	images	_	
70-6	11992-11996	were	_	
70-7	11997-12008	transformed	_	
70-8	12008-12009	,	_	
70-9	12010-12012	on	_	
70-10	12013-12014	a	_	
70-11	12015-12029	voxel-by-voxel	_	
70-12	12030-12035	basis	_	
70-13	12035-12036	,	_	
70-14	12037-12041	into	_	
70-15	12042-12045	two	_	
70-16	12046-12058	coregistered	_	
70-17	12059-12063	sets	_	
70-18	12064-12066	of	_	
70-19	12067-12077	parametric	_	
70-20	12078-12082	maps	_	
70-21	12082-12083	:	_	
70-22	12084-12085	a	_	
70-23	12086-12092	tracer	_	
70-24	12093-12102	transport	_	
70-25	12103-12110	measure	_	
70-26	12111-12112	(	_	
70-27	12112-12114	K1	_	
70-28	12115-12120	ratio	_	
70-29	12120-12121	)	_	
70-30	12121-12122	;	_	
70-31	12123-12126	and	_	
70-32	12127-12128	a	_	
70-33	12129-12145	receptor-related	_	
70-34	12146-12153	measure	_	
70-35	12154-12156	at	_	
70-36	12157-12168	equilibrium	_	
70-37	12169-12173	BPND	_	
70-38	12173-12174	,	_	
70-39	12175-12183	yielding	_	
70-40	12184-12193	condition	_	
70-41	12194-12199	level	_	
70-42	12200-12206	images	_	
70-43	12207-12215	obtained	_	
70-44	12216-12220	from	_	
70-45	12221-12223	35	_	
70-46	12223-12224	-	_	
70-47	12224-12226	45	_	
70-48	12227-12230	min	_	
70-49	12231-12232	(	_	
70-50	12232-12239	control	_	
70-51	12239-12240	)	_	
70-52	12241-12244	and	_	
70-53	12245-12247	60	_	
70-54	12247-12248	-	_	
70-55	12248-12250	80	_	
70-56	12251-12254	min	_	
70-57	12255-12256	(	_	
70-58	12256-12262	reward	_	
70-59	12262-12263	)	_	
70-60	12264-12269	after	_	
70-61	12270-12276	tracer	_	
70-62	12277-12291	administration	_	
70-63	12291-12292	,	_	
70-64	12293-12298	using	_	
70-65	12299-12303	full	_	
70-66	12304-12315	equilibrium	_	
70-67	12316-12320	data	_	
70-68	12320-12321	,	_	
70-69	12322-12326	with	_	
70-70	12327-12330	the	_	
70-71	12331-12341	cerebellum	_	
70-72	12342-12344	as	_	
70-73	12345-12348	the	_	
70-74	12349-12365	non-displaceable	_	
70-75	12366-12375	reference	_	
70-76	12376-12382	region	_	
70-77	12382-12383	.	_	

#Text=Under these experimental conditions, reductions in in vivo DA D2/D3 receptor availability (BPND) are thought to reflect DA release and neurotransmitter-receptor interactions as [11C]raclopride binds to D2/D3 receptors in the striatum and is sensitive to endogenous striatal DA release .
71-1	12384-12389	Under	_	
71-2	12390-12395	these	_	
71-3	12396-12408	experimental	_	
71-4	12409-12419	conditions	_	
71-5	12419-12420	,	_	
71-6	12421-12431	reductions	_	
71-7	12432-12434	in	_	
71-8	12435-12437	in	_	
71-9	12438-12442	vivo	_	
71-10	12443-12445	DA	_	
71-11	12446-12448	D2	_	
71-12	12448-12449	/	_	
71-13	12449-12451	D3	_	
71-14	12452-12460	receptor	_	
71-15	12461-12473	availability	_	
71-16	12474-12475	(	_	
71-17	12475-12479	BPND	_	
71-18	12479-12480	)	_	
71-19	12481-12484	are	_	
71-20	12485-12492	thought	_	
71-21	12493-12495	to	_	
71-22	12496-12503	reflect	_	
71-23	12504-12506	DA	_	
71-24	12507-12514	release	_	
71-25	12515-12518	and	_	
71-26	12519-12544	neurotransmitter-receptor	_	
71-27	12545-12557	interactions	_	
71-28	12558-12560	as	_	
71-29	12561-12562	[	_	
71-30	12562-12565	11C	_	
71-31	12565-12566	]	_	
71-32	12566-12576	raclopride	_	
71-33	12577-12582	binds	_	
71-34	12583-12585	to	_	
71-35	12586-12588	D2	_	
71-36	12588-12589	/	_	
71-37	12589-12591	D3	_	
71-38	12592-12601	receptors	_	
71-39	12602-12604	in	_	
71-40	12605-12608	the	_	
71-41	12609-12617	striatum	_	
71-42	12618-12621	and	_	
71-43	12622-12624	is	_	
71-44	12625-12634	sensitive	_	
71-45	12635-12637	to	_	
71-46	12638-12648	endogenous	_	
71-47	12649-12657	striatal	_	
71-48	12658-12660	DA	_	
71-49	12661-12668	release	_	
71-50	12669-12670	.	_	

#Text=With a priori interest in the NAcc and given the poor spatial discrimination of PET images, 10 mm spherical masks were created centered on the area of peak ventral striatal radioligand displacement, BPND, from the 35-45 minute map for each individual using the MarsBaR region of interest (ROI) toolbox.
72-1	12671-12675	With	_	
72-2	12676-12677	a	_	
72-3	12678-12684	priori	_	
72-4	12685-12693	interest	_	
72-5	12694-12696	in	_	
72-6	12697-12700	the	_	
72-7	12701-12705	NAcc	_	
72-8	12706-12709	and	_	
72-9	12710-12715	given	_	
72-10	12716-12719	the	_	
72-11	12720-12724	poor	_	
72-12	12725-12732	spatial	_	
72-13	12733-12747	discrimination	_	
72-14	12748-12750	of	_	
72-15	12751-12754	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
72-16	12755-12761	images	_	
72-17	12761-12762	,	_	
72-18	12763-12765	10	_	
72-19	12766-12768	mm	_	
72-20	12769-12778	spherical	_	
72-21	12779-12784	masks	_	
72-22	12785-12789	were	_	
72-23	12790-12797	created	_	
72-24	12798-12806	centered	_	
72-25	12807-12809	on	_	
72-26	12810-12813	the	_	
72-27	12814-12818	area	_	
72-28	12819-12821	of	_	
72-29	12822-12826	peak	_	
72-30	12827-12834	ventral	_	
72-31	12835-12843	striatal	_	
72-32	12844-12855	radioligand	_	
72-33	12856-12868	displacement	_	
72-34	12868-12869	,	_	
72-35	12870-12874	BPND	_	
72-36	12874-12875	,	_	
72-37	12876-12880	from	_	
72-38	12881-12884	the	_	
72-39	12885-12887	35	_	
72-40	12887-12888	-	_	
72-41	12888-12890	45	_	
72-42	12891-12897	minute	_	
72-43	12898-12901	map	_	
72-44	12902-12905	for	_	
72-45	12906-12910	each	_	
72-46	12911-12921	individual	_	
72-47	12922-12927	using	_	
72-48	12928-12931	the	_	
72-49	12932-12939	MarsBaR	_	
72-50	12940-12946	region	_	
72-51	12947-12949	of	_	
72-52	12950-12958	interest	_	
72-53	12959-12960	(	_	
72-54	12960-12963	ROI	_	
72-55	12963-12964	)	_	
72-56	12965-12972	toolbox	_	
72-57	12972-12973	.	_	

#Text=For all individuals, the peak BPND lay within 10 mm masks previously used as ventral striatum (10, 13, −8; 11, 13, −8).
73-1	12974-12977	For	_	
73-2	12978-12981	all	_	
73-3	12982-12993	individuals	_	
73-4	12993-12994	,	_	
73-5	12995-12998	the	_	
73-6	12999-13003	peak	_	
73-7	13004-13008	BPND	_	
73-8	13009-13012	lay	_	
73-9	13013-13019	within	_	
73-10	13020-13022	10	_	
73-11	13023-13025	mm	_	
73-12	13026-13031	masks	_	
73-13	13032-13042	previously	_	
73-14	13043-13047	used	_	
73-15	13048-13050	as	_	
73-16	13051-13058	ventral	_	
73-17	13059-13067	striatum	_	
73-18	13068-13069	(	_	
73-19	13069-13071	10	_	
73-20	13071-13072	,	_	
73-21	13073-13075	13	_	
73-22	13075-13076	,	_	
73-23	13077-13078	−	_	
73-24	13078-13079	8	_	
73-25	13079-13080	;	_	
73-26	13081-13083	11	_	
73-27	13083-13084	,	_	
73-28	13085-13087	13	_	
73-29	13087-13088	,	_	
73-30	13089-13090	−	_	
73-31	13090-13091	8	_	
73-32	13091-13092	)	_	
73-33	13092-13093	.	_	

#Text=Data from individual control and reward maps were extracted for quantification of regional BPND and calculation of percent change, ΔBPND, for use in statistical analyses.
74-1	13094-13098	Data	_	
74-2	13099-13103	from	_	
74-3	13104-13114	individual	_	
74-4	13115-13122	control	_	
74-5	13123-13126	and	_	
74-6	13127-13133	reward	_	
74-7	13134-13138	maps	_	
74-8	13139-13143	were	_	
74-9	13144-13153	extracted	_	
74-10	13154-13157	for	_	
74-11	13158-13172	quantification	_	
74-12	13173-13175	of	_	
74-13	13176-13184	regional	_	
74-14	13185-13189	BPND	_	
74-15	13190-13193	and	_	
74-16	13194-13205	calculation	_	
74-17	13206-13208	of	_	
74-18	13209-13216	percent	_	
74-19	13217-13223	change	_	
74-20	13223-13224	,	_	
74-21	13225-13230	ΔBPND	_	
74-22	13230-13231	,	_	
74-23	13232-13235	for	_	
74-24	13236-13239	use	_	
74-25	13240-13242	in	_	
74-26	13243-13254	statistical	_	
74-27	13255-13263	analyses	_	
74-28	13263-13264	.	_	

#Text=Reductions in ΔBPND from control to active conditions reflect activation of DA D2/D3 neurotransmission.
75-1	13265-13275	Reductions	_	
75-2	13276-13278	in	_	
75-3	13279-13284	ΔBPND	_	
75-4	13285-13289	from	_	
75-5	13290-13297	control	_	
75-6	13298-13300	to	_	
75-7	13301-13307	active	_	
75-8	13308-13318	conditions	_	
75-9	13319-13326	reflect	_	
75-10	13327-13337	activation	_	
75-11	13338-13340	of	_	
75-12	13341-13343	DA	_	
75-13	13344-13346	D2	_	
75-14	13346-13347	/	_	
75-15	13347-13349	D3	_	
75-16	13350-13367	neurotransmission	_	
75-17	13367-13368	.	_	

#Text=Hereafter we refer to this as incentive/reward-associated DA release although we note that the reward condition included loss trials and, due to the temporal resolution of PET, combines all events (i.e. cue presentation, anticipation, outcome, etc.) into a single metric.
#Text=fMRI paradigm
#Text=Brain response during anticipation and feedback of incentive stimuli was probed in a fMRI experiment using a version of the MID task similar to that performed in the PET scan, see Figure 1.
76-1	13369-13378	Hereafter	_	
76-2	13379-13381	we	_	
76-3	13382-13387	refer	_	
76-4	13388-13390	to	_	
76-5	13391-13395	this	_	
76-6	13396-13398	as	_	
76-7	13399-13408	incentive	_	
76-8	13408-13409	/	_	
76-9	13409-13426	reward-associated	_	
76-10	13427-13429	DA	_	
76-11	13430-13437	release	_	
76-12	13438-13446	although	_	
76-13	13447-13449	we	_	
76-14	13450-13454	note	_	
76-15	13455-13459	that	_	
76-16	13460-13463	the	_	
76-17	13464-13470	reward	_	
76-18	13471-13480	condition	_	
76-19	13481-13489	included	_	
76-20	13490-13494	loss	_	
76-21	13495-13501	trials	_	
76-22	13502-13505	and	_	
76-23	13505-13506	,	_	
76-24	13507-13510	due	_	
76-25	13511-13513	to	_	
76-26	13514-13517	the	_	
76-27	13518-13526	temporal	_	
76-28	13527-13537	resolution	_	
76-29	13538-13540	of	_	
76-30	13541-13544	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography	
76-31	13544-13545	,	_	
76-32	13546-13554	combines	_	
76-33	13555-13558	all	_	
76-34	13559-13565	events	_	
76-35	13566-13567	(	_	
76-36	13567-13570	i.e	_	
76-37	13570-13571	.	_	
76-38	13572-13575	cue	_	
76-39	13576-13588	presentation	_	
76-40	13588-13589	,	_	
76-41	13590-13602	anticipation	_	
76-42	13602-13603	,	_	
76-43	13604-13611	outcome	_	
76-44	13611-13612	,	_	
76-45	13613-13616	etc	_	
76-46	13616-13617	.	_	
76-47	13617-13618	)	_	
76-48	13619-13623	into	_	
76-49	13624-13625	a	_	
76-50	13626-13632	single	_	
76-51	13633-13639	metric	_	
76-52	13639-13640	.	_	
76-53	13641-13645	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]	
76-54	13646-13654	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]	
76-55	13655-13660	Brain	_	
76-56	13661-13669	response	_	
76-57	13670-13676	during	_	
76-58	13677-13689	anticipation	_	
76-59	13690-13693	and	_	
76-60	13694-13702	feedback	_	
76-61	13703-13705	of	_	
76-62	13706-13715	incentive	_	
76-63	13716-13723	stimuli	_	
76-64	13724-13727	was	_	
76-65	13728-13734	probed	_	
76-66	13735-13737	in	_	
76-67	13738-13739	a	_	
76-68	13740-13744	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-69	13745-13755	experiment	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-70	13756-13761	using	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-71	13762-13763	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-72	13764-13771	version	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-73	13772-13774	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-74	13775-13778	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-75	13779-13782	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-76	13783-13787	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[33]	
76-77	13788-13795	similar	_	
76-78	13796-13798	to	_	
76-79	13799-13803	that	_	
76-80	13804-13813	performed	_	
76-81	13814-13816	in	_	
76-82	13817-13820	the	_	
76-83	13821-13824	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[34]	
76-84	13825-13829	scan	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[34]	
76-85	13829-13830	,	_	
76-86	13831-13834	see	_	
76-87	13835-13841	Figure	_	
76-88	13842-13843	1	_	
76-89	13843-13844	.	_	

#Text=Each session involved 72 6-second trials consisting of four events.
77-1	13845-13849	Each	_	
77-2	13850-13857	session	_	
77-3	13858-13866	involved	_	
77-4	13867-13869	72	_	
77-5	13870-13871	6	_	
77-6	13871-13872	-	_	
77-7	13872-13878	second	_	
77-8	13879-13885	trials	_	
77-9	13886-13896	consisting	_	
77-10	13897-13899	of	_	
77-11	13900-13904	four	_	
77-12	13905-13911	events	_	
77-13	13911-13912	.	_	

#Text=First, subjects were presented with an incentive cue (2000 ms) of seven possible values (gain of $0.20, $1.00 $5.00; loss of $0.20, $1.00 $5.00; or no change $0).
78-1	13913-13918	First	_	
78-2	13918-13919	,	_	
78-3	13920-13928	subjects	_	
78-4	13929-13933	were	_	
78-5	13934-13943	presented	_	
78-6	13944-13948	with	_	
78-7	13949-13951	an	_	
78-8	13952-13961	incentive	_	
78-9	13962-13965	cue	_	
78-10	13966-13967	(	_	
78-11	13967-13971	2000	_	
78-12	13972-13974	ms	_	
78-13	13974-13975	)	_	
78-14	13976-13978	of	_	
78-15	13979-13984	seven	_	
78-16	13985-13993	possible	_	
78-17	13994-14000	values	_	
78-18	14001-14002	(	_	
78-19	14002-14006	gain	_	
78-20	14007-14009	of	_	
78-21	14010-14015	$0.20	_	
78-22	14015-14016	,	_	
78-23	14017-14022	$1.00	_	
78-24	14023-14028	$5.00	_	
78-25	14028-14029	;	_	
78-26	14030-14034	loss	_	
78-27	14035-14037	of	_	
78-28	14038-14043	$0.20	_	
78-29	14043-14044	,	_	
78-30	14045-14050	$1.00	_	
78-31	14051-14056	$5.00	_	
78-32	14056-14057	;	_	
78-33	14058-14060	or	_	
78-34	14061-14063	no	_	
78-35	14064-14070	change	_	
78-36	14071-14073	$0	_	
78-37	14073-14074	)	_	
78-38	14074-14075	.	_	

#Text=This was followed by a 2000 ms anticipation delay.
79-1	14076-14080	This	_	
79-2	14081-14084	was	_	
79-3	14085-14093	followed	_	
79-4	14094-14096	by	_	
79-5	14097-14098	a	_	
79-6	14099-14103	2000	_	
79-7	14104-14106	ms	_	
79-8	14107-14119	anticipation	_	
79-9	14120-14125	delay	_	
79-10	14125-14126	.	_	

#Text=Next, a target appeared for a variable length of time (200- 300 ms) during which subjects made a button press response in an attempt to gain or avoid losing the money.
80-1	14127-14131	Next	_	
80-2	14131-14132	,	_	
80-3	14133-14134	a	_	
80-4	14135-14141	target	_	
80-5	14142-14150	appeared	_	
80-6	14151-14154	for	_	
80-7	14155-14156	a	_	
80-8	14157-14165	variable	_	
80-9	14166-14172	length	_	
80-10	14173-14175	of	_	
80-11	14176-14180	time	_	
80-12	14181-14182	(	_	
80-13	14182-14185	200	_	
80-14	14185-14186	-	_	
80-15	14187-14190	300	_	
80-16	14191-14193	ms	_	
80-17	14193-14194	)	_	
80-18	14195-14201	during	_	
80-19	14202-14207	which	_	
80-20	14208-14216	subjects	_	
80-21	14217-14221	made	_	
80-22	14222-14223	a	_	
80-23	14224-14230	button	_	
80-24	14231-14236	press	_	
80-25	14237-14245	response	_	
80-26	14246-14248	in	_	
80-27	14249-14251	an	_	
80-28	14252-14259	attempt	_	
80-29	14260-14262	to	_	
80-30	14263-14267	gain	_	
80-31	14268-14270	or	_	
80-32	14271-14276	avoid	_	
80-33	14277-14283	losing	_	
80-34	14284-14287	the	_	
80-35	14288-14293	money	_	
80-36	14293-14294	.	_	

#Text=Subjects were instructed to respond to neutral targets despite the lack of incentive value.
81-1	14295-14303	Subjects	_	
81-2	14304-14308	were	_	
81-3	14309-14319	instructed	_	
81-4	14320-14322	to	_	
81-5	14323-14330	respond	_	
81-6	14331-14333	to	_	
81-7	14334-14341	neutral	_	
81-8	14342-14349	targets	_	
81-9	14350-14357	despite	_	
81-10	14358-14361	the	_	
81-11	14362-14366	lack	_	
81-12	14367-14369	of	_	
81-13	14370-14379	incentive	_	
81-14	14380-14385	value	_	
81-15	14385-14386	.	_	

#Text=A feedback message then informed them of the trial outcome.
82-1	14387-14388	A	_	
82-2	14389-14397	feedback	_	
82-3	14398-14405	message	_	
82-4	14406-14410	then	_	
82-5	14411-14419	informed	_	
82-6	14420-14424	them	_	
82-7	14425-14427	of	_	
82-8	14428-14431	the	_	
82-9	14432-14437	trial	_	
82-10	14438-14445	outcome	_	
82-11	14445-14446	.	_	

#Text=The incentive trials were presented in a pseudorandom order.
83-1	14447-14450	The	_	
83-2	14451-14460	incentive	_	
83-3	14461-14467	trials	_	
83-4	14468-14472	were	_	
83-5	14473-14482	presented	_	
83-6	14483-14485	in	_	
83-7	14486-14487	a	_	
83-8	14488-14500	pseudorandom	_	
83-9	14501-14506	order	_	
83-10	14506-14507	.	_	

#Text=The duration of the response target was calculated based on the individual subject's reaction time during a practice session prior to scanning and dynamically adjusted during the task such that overall success rate was ∼60%.
84-1	14508-14511	The	_	
84-2	14512-14520	duration	_	
84-3	14521-14523	of	_	
84-4	14524-14527	the	_	
84-5	14528-14536	response	_	
84-6	14537-14543	target	_	
84-7	14544-14547	was	_	
84-8	14548-14558	calculated	_	
84-9	14559-14564	based	_	
84-10	14565-14567	on	_	
84-11	14568-14571	the	_	
84-12	14572-14582	individual	_	
84-13	14583-14592	subject's	_	
84-14	14593-14601	reaction	_	
84-15	14602-14606	time	_	
84-16	14607-14613	during	_	
84-17	14614-14615	a	_	
84-18	14616-14624	practice	_	
84-19	14625-14632	session	_	
84-20	14633-14638	prior	_	
84-21	14639-14641	to	_	
84-22	14642-14650	scanning	_	
84-23	14651-14654	and	_	
84-24	14655-14666	dynamically	_	
84-25	14667-14675	adjusted	_	
84-26	14676-14682	during	_	
84-27	14683-14686	the	_	
84-28	14687-14691	task	_	
84-29	14692-14696	such	_	
84-30	14697-14701	that	_	
84-31	14702-14709	overall	_	
84-32	14710-14717	success	_	
84-33	14718-14722	rate	_	
84-34	14723-14726	was	_	
84-35	14727-14728	∼	_	
84-36	14728-14731	60%	_	
84-37	14731-14732	.	_	

#Text=Participants were paid fixed participation rates plus additional money won during the task.
#Text=fMRI imaging
#Text=Whole-brain BOLD functional images were acquired on a 3.0 Tesla GE Signa scanner (Milwaukee, WI) using T2*-weighted single-shot combined spiral in/out sequences (Glover and Law 2001), parameters: repetition time (TR)=2000 ms, echo time (TE)=30 ms, flip angle (FA)=90°; field-of-view (FOV)=200 mm; matrix size=64×64; slice thickness=4 mm, 29 slices.
85-1	14733-14745	Participants	_	
85-2	14746-14750	were	_	
85-3	14751-14755	paid	_	
85-4	14756-14761	fixed	_	
85-5	14762-14775	participation	_	
85-6	14776-14781	rates	_	
85-7	14782-14786	plus	_	
85-8	14787-14797	additional	_	
85-9	14798-14803	money	_	
85-10	14804-14807	won	_	
85-11	14808-14814	during	_	
85-12	14815-14818	the	_	
85-13	14819-14823	task	_	
85-14	14823-14824	.	_	
85-15	14825-14829	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
85-16	14830-14837	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
85-17	14838-14849	Whole-brain	_	
85-18	14850-14854	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
85-19	14855-14865	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
85-20	14866-14872	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]	
85-21	14873-14877	were	_	
85-22	14878-14886	acquired	_	
85-23	14887-14889	on	_	
85-24	14890-14891	a	_	
85-25	14892-14895	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[37]	
85-26	14896-14901	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[37]	
85-27	14902-14904	GE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[37]	
85-28	14905-14910	Signa	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[37]	
85-29	14911-14918	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[37]	
85-30	14919-14920	(	_	
85-31	14920-14929	Milwaukee	_	
85-32	14929-14930	,	_	
85-33	14931-14933	WI	_	
85-34	14933-14934	)	_	
85-35	14935-14940	using	_	
85-36	14941-14943	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-37	14943-14944	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-38	14944-14945	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-39	14945-14953	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-40	14954-14965	single-shot	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-41	14966-14974	combined	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-42	14975-14981	spiral	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-43	14982-14984	in	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-44	14984-14985	/	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-45	14985-14988	out	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-46	14989-14998	sequences	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[38]	
85-47	14999-15000	(	_	
85-48	15000-15006	Glover	_	
85-49	15007-15010	and	_	
85-50	15011-15014	Law	_	
85-51	15015-15019	2001	_	
85-52	15019-15020	)	_	
85-53	15020-15021	,	_	
85-54	15022-15032	parameters	_	
85-55	15032-15033	:	_	
85-56	15034-15044	repetition	_	
85-57	15045-15049	time	_	
85-58	15050-15051	(	_	
85-59	15051-15053	TR	_	
85-60	15053-15054	)	_	
85-61	15054-15055	=	_	
85-62	15055-15059	2000	_	
85-63	15060-15062	ms	_	
85-64	15062-15063	,	_	
85-65	15064-15068	echo	_	
85-66	15069-15073	time	_	
85-67	15074-15075	(	_	
85-68	15075-15077	TE	_	
85-69	15077-15078	)	_	
85-70	15078-15079	=	_	
85-71	15079-15081	30	_	
85-72	15082-15084	ms	_	
85-73	15084-15085	,	_	
85-74	15086-15090	flip	_	
85-75	15091-15096	angle	_	
85-76	15097-15098	(	_	
85-77	15098-15100	FA	_	
85-78	15100-15101	)	_	
85-79	15101-15102	=	_	
85-80	15102-15104	90	_	
85-81	15104-15105	°	_	
85-82	15105-15106	;	_	
85-83	15107-15120	field-of-view	_	
85-84	15121-15122	(	_	
85-85	15122-15125	FOV	_	
85-86	15125-15126	)	_	
85-87	15126-15127	=	_	
85-88	15127-15130	200	_	
85-89	15131-15133	mm	_	
85-90	15133-15134	;	_	
85-91	15135-15141	matrix	_	
85-92	15142-15146	size	_	
85-93	15146-15147	=	_	
85-94	15147-15149	64	_	
85-95	15149-15150	×	_	
85-96	15150-15152	64	_	
85-97	15152-15153	;	_	
85-98	15154-15159	slice	_	
85-99	15160-15169	thickness	_	
85-100	15169-15170	=	_	
85-101	15170-15171	4	_	
85-102	15172-15174	mm	_	
85-103	15174-15175	,	_	
85-104	15176-15178	29	_	
85-105	15179-15185	slices	_	
85-106	15185-15186	.	_	

#Text=High-resolution anatomical T1 scans were obtained for spatial normalization.
86-1	15187-15202	High-resolution	_	
86-2	15203-15213	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
86-3	15214-15216	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
86-4	15217-15222	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
86-5	15223-15227	were	_	
86-6	15228-15236	obtained	_	
86-7	15237-15240	for	_	
86-8	15241-15248	spatial	_	
86-9	15249-15262	normalization	_	
86-10	15262-15263	.	_	

#Text=Motion was minimized with foam pads and emphasis on importance of keeping still.
#Text=fMRI image processing
#Text=Functional images were reconstructed using an iterative algorithm and motion corrected using statistical parametric mapping (SPM8, Wellcome Institute of Cognitive Neurology, Oxford, UK).
87-1	15264-15270	Motion	_	
87-2	15271-15274	was	_	
87-3	15275-15284	minimized	_	
87-4	15285-15289	with	_	
87-5	15290-15294	foam	_	
87-6	15295-15299	pads	_	
87-7	15300-15303	and	_	
87-8	15304-15312	emphasis	_	
87-9	15313-15315	on	_	
87-10	15316-15326	importance	_	
87-11	15327-15329	of	_	
87-12	15330-15337	keeping	_	
87-13	15338-15343	still	_	
87-14	15343-15344	.	_	
87-15	15345-15349	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
87-16	15350-15355	image	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
87-17	15356-15366	processing	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
87-18	15367-15377	Functional	_	
87-19	15378-15384	images	_	
87-20	15385-15389	were	_	
87-21	15390-15403	reconstructed	_	
87-22	15404-15409	using	_	
87-23	15410-15412	an	_	
87-24	15413-15422	iterative	_	
87-25	15423-15432	algorithm	_	
87-26	15433-15436	and	_	
87-27	15437-15443	motion	_	
87-28	15444-15453	corrected	_	
87-29	15454-15459	using	_	
87-30	15460-15471	statistical	_	
87-31	15472-15482	parametric	_	
87-32	15483-15490	mapping	_	
87-33	15491-15492	(	_	
87-34	15492-15496	SPM8	_	
87-35	15496-15497	,	_	
87-36	15498-15506	Wellcome	_	
87-37	15507-15516	Institute	_	
87-38	15517-15519	of	_	
87-39	15520-15529	Cognitive	_	
87-40	15530-15539	Neurology	_	
87-41	15539-15540	,	_	
87-42	15541-15547	Oxford	_	
87-43	15547-15548	,	_	
87-44	15549-15551	UK	_	
87-45	15551-15552	)	_	
87-46	15552-15553	.	_	

#Text=All runs for all subjects met the motion inclusion criteria of less than 2 mm translation or 2° rotation.
88-1	15554-15557	All	_	
88-2	15558-15562	runs	_	
88-3	15563-15566	for	_	
88-4	15567-15570	all	_	
88-5	15571-15579	subjects	_	
88-6	15580-15583	met	_	
88-7	15584-15587	the	_	
88-8	15588-15594	motion	_	
88-9	15595-15604	inclusion	_	
88-10	15605-15613	criteria	_	
88-11	15614-15616	of	_	
88-12	15617-15621	less	_	
88-13	15622-15626	than	_	
88-14	15627-15628	2	_	
88-15	15629-15631	mm	_	
88-16	15632-15643	translation	_	
88-17	15644-15646	or	_	
88-18	15647-15648	2	_	
88-19	15648-15649	°	_	
88-20	15650-15658	rotation	_	
88-21	15658-15659	.	_	

#Text=Images were spatially normalized to Montreal Neurological Institute space and spatially smoothed with a 6mm isotropic kernel.
89-1	15660-15666	Images	_	
89-2	15667-15671	were	_	
89-3	15672-15681	spatially	_	
89-4	15682-15692	normalized	_	
89-5	15693-15695	to	_	
89-6	15696-15704	Montreal	_	
89-7	15705-15717	Neurological	_	
89-8	15718-15727	Institute	_	
89-9	15728-15733	space	_	
89-10	15734-15737	and	_	
89-11	15738-15747	spatially	_	
89-12	15748-15756	smoothed	_	
89-13	15757-15761	with	_	
89-14	15762-15763	a	_	
89-15	15764-15767	6mm	_	
89-16	15768-15777	isotropic	_	
89-17	15778-15784	kernel	_	
89-18	15784-15785	.	_	

#Text=A GLM using SPM's canonical hemodynamic response function, modeled all events (cues: win $0.20, win $5.0, lose $0.20, lose $5.0 and neutral $0; anticipation delay for each cue type; positive outcome for each cue type; negative outcome for each cue type) incentive anticipation for each cue type ($0.20 win, $1.00 win, $5.00 win, $0.20 loss, $1.00 loss, $5.00 loss, $0) convolved with the canonical hemodynamic response function.
90-1	15786-15787	A	_	
90-2	15788-15791	GLM	_	
90-3	15792-15797	using	_	
90-4	15798-15803	SPM's	_	
90-5	15804-15813	canonical	_	
90-6	15814-15825	hemodynamic	_	
90-7	15826-15834	response	_	
90-8	15835-15843	function	_	
90-9	15843-15844	,	_	
90-10	15845-15852	modeled	_	
90-11	15853-15856	all	_	
90-12	15857-15863	events	_	
90-13	15864-15865	(	_	
90-14	15865-15869	cues	_	
90-15	15869-15870	:	_	
90-16	15871-15874	win	_	
90-17	15875-15880	$0.20	_	
90-18	15880-15881	,	_	
90-19	15882-15885	win	_	
90-20	15886-15890	$5.0	_	
90-21	15890-15891	,	_	
90-22	15892-15896	lose	_	
90-23	15897-15902	$0.20	_	
90-24	15902-15903	,	_	
90-25	15904-15908	lose	_	
90-26	15909-15913	$5.0	_	
90-27	15914-15917	and	_	
90-28	15918-15925	neutral	_	
90-29	15926-15928	$0	_	
90-30	15928-15929	;	_	
90-31	15930-15942	anticipation	_	
90-32	15943-15948	delay	_	
90-33	15949-15952	for	_	
90-34	15953-15957	each	_	
90-35	15958-15961	cue	_	
90-36	15962-15966	type	_	
90-37	15966-15967	;	_	
90-38	15968-15976	positive	_	
90-39	15977-15984	outcome	_	
90-40	15985-15988	for	_	
90-41	15989-15993	each	_	
90-42	15994-15997	cue	_	
90-43	15998-16002	type	_	
90-44	16002-16003	;	_	
90-45	16004-16012	negative	_	
90-46	16013-16020	outcome	_	
90-47	16021-16024	for	_	
90-48	16025-16029	each	_	
90-49	16030-16033	cue	_	
90-50	16034-16038	type	_	
90-51	16038-16039	)	_	
90-52	16040-16049	incentive	_	
90-53	16050-16062	anticipation	_	
90-54	16063-16066	for	_	
90-55	16067-16071	each	_	
90-56	16072-16075	cue	_	
90-57	16076-16080	type	_	
90-58	16081-16082	(	_	
90-59	16082-16087	$0.20	_	
90-60	16088-16091	win	_	
90-61	16091-16092	,	_	
90-62	16093-16098	$1.00	_	
90-63	16099-16102	win	_	
90-64	16102-16103	,	_	
90-65	16104-16109	$5.00	_	
90-66	16110-16113	win	_	
90-67	16113-16114	,	_	
90-68	16115-16120	$0.20	_	
90-69	16121-16125	loss	_	
90-70	16125-16126	,	_	
90-71	16127-16132	$1.00	_	
90-72	16133-16137	loss	_	
90-73	16137-16138	,	_	
90-74	16139-16144	$5.00	_	
90-75	16145-16149	loss	_	
90-76	16149-16150	,	_	
90-77	16151-16153	$0	_	
90-78	16153-16154	)	_	
90-79	16155-16164	convolved	_	
90-80	16165-16169	with	_	
90-81	16170-16173	the	_	
90-82	16174-16183	canonical	_	
90-83	16184-16195	hemodynamic	_	
90-84	16196-16204	response	_	
90-85	16205-16213	function	_	
90-86	16213-16214	.	_	

#Text=In addition, regressors for six motion parameters and white matter signal intensity were included to reduce residual motion artifacts and capture non-task-related noise.
91-1	16215-16217	In	_	
91-2	16218-16226	addition	_	
91-3	16226-16227	,	_	
91-4	16228-16238	regressors	_	
91-5	16239-16242	for	_	
91-6	16243-16246	six	_	
91-7	16247-16253	motion	_	
91-8	16254-16264	parameters	_	
91-9	16265-16268	and	_	
91-10	16269-16274	white	_	
91-11	16275-16281	matter	_	
91-12	16282-16288	signal	_	
91-13	16289-16298	intensity	_	
91-14	16299-16303	were	_	
91-15	16304-16312	included	_	
91-16	16313-16315	to	_	
91-17	16316-16322	reduce	_	
91-18	16323-16331	residual	_	
91-19	16332-16338	motion	_	
91-20	16339-16348	artifacts	_	
91-21	16349-16352	and	_	
91-22	16353-16360	capture	_	
91-23	16361-16377	non-task-related	_	
91-24	16378-16383	noise	_	
91-25	16383-16384	.	_	

#Text=Contrasts for anticipation of monetary gain trials ($0.20, $1.00 and $5.00 combined) versus neutral trials and feedback of positive monetary gain trials versus of negative monetary gain trials were calculated for each individual.
92-1	16385-16394	Contrasts	_	
92-2	16395-16398	for	_	
92-3	16399-16411	anticipation	_	
92-4	16412-16414	of	_	
92-5	16415-16423	monetary	_	
92-6	16424-16428	gain	_	
92-7	16429-16435	trials	_	
92-8	16436-16437	(	_	
92-9	16437-16442	$0.20	_	
92-10	16442-16443	,	_	
92-11	16444-16449	$1.00	_	
92-12	16450-16453	and	_	
92-13	16454-16459	$5.00	_	
92-14	16460-16468	combined	_	
92-15	16468-16469	)	_	
92-16	16470-16476	versus	_	
92-17	16477-16484	neutral	_	
92-18	16485-16491	trials	_	
92-19	16492-16495	and	_	
92-20	16496-16504	feedback	_	
92-21	16505-16507	of	_	
92-22	16508-16516	positive	_	
92-23	16517-16525	monetary	_	
92-24	16526-16530	gain	_	
92-25	16531-16537	trials	_	
92-26	16538-16544	versus	_	
92-27	16545-16547	of	_	
92-28	16548-16556	negative	_	
92-29	16557-16565	monetary	_	
92-30	16566-16570	gain	_	
92-31	16571-16577	trials	_	
92-32	16578-16582	were	_	
92-33	16583-16593	calculated	_	
92-34	16594-16597	for	_	
92-35	16598-16602	each	_	
92-36	16603-16613	individual	_	
92-37	16613-16614	.	_	

#Text=These contrasts, referred to as “reward anticipation” and “reward feedback” for the remainder of the text, were for used in second-level one-sample t-test and correlation analyses.
93-1	16615-16620	These	_	
93-2	16621-16630	contrasts	_	
93-3	16630-16631	,	_	
93-4	16632-16640	referred	_	
93-5	16641-16643	to	_	
93-6	16644-16646	as	_	
93-7	16647-16648	“	_	
93-8	16648-16654	reward	_	
93-9	16655-16667	anticipation	_	
93-10	16667-16668	”	_	
93-11	16669-16672	and	_	
93-12	16673-16674	“	_	
93-13	16674-16680	reward	_	
93-14	16681-16689	feedback	_	
93-15	16689-16690	”	_	
93-16	16691-16694	for	_	
93-17	16695-16698	the	_	
93-18	16699-16708	remainder	_	
93-19	16709-16711	of	_	
93-20	16712-16715	the	_	
93-21	16716-16720	text	_	
93-22	16720-16721	,	_	
93-23	16722-16726	were	_	
93-24	16727-16730	for	_	
93-25	16731-16735	used	_	
93-26	16736-16738	in	_	
93-27	16739-16751	second-level	_	
93-28	16752-16762	one-sample	_	
93-29	16763-16769	t-test	_	
93-30	16770-16773	and	_	
93-31	16774-16785	correlation	_	
93-32	16786-16794	analyses	_	
93-33	16794-16795	.	_	

#Text=Loss contrasts were not further analyzed for this study.
94-1	16796-16800	Loss	_	
94-2	16801-16810	contrasts	_	
94-3	16811-16815	were	_	
94-4	16816-16819	not	_	
94-5	16820-16827	further	_	
94-6	16828-16836	analyzed	_	
94-7	16837-16840	for	_	
94-8	16841-16845	this	_	
94-9	16846-16851	study	_	
94-10	16851-16852	.	_	

#Text=Again, with a priori interest in the ventral striatum, left and right NAcc ROI effect sizes were calculated from parameter estimates using the MarsBaR toolbox using anatomical masks as described in previous work.
95-1	16853-16858	Again	_	
95-2	16858-16859	,	_	
95-3	16860-16864	with	_	
95-4	16865-16866	a	_	
95-5	16867-16873	priori	_	
95-6	16874-16882	interest	_	
95-7	16883-16885	in	_	
95-8	16886-16889	the	_	
95-9	16890-16897	ventral	_	
95-10	16898-16906	striatum	_	
95-11	16906-16907	,	_	
95-12	16908-16912	left	_	
95-13	16913-16916	and	_	
95-14	16917-16922	right	_	
95-15	16923-16927	NAcc	_	
95-16	16928-16931	ROI	_	
95-17	16932-16938	effect	_	
95-18	16939-16944	sizes	_	
95-19	16945-16949	were	_	
95-20	16950-16960	calculated	_	
95-21	16961-16965	from	_	
95-22	16966-16975	parameter	_	
95-23	16976-16985	estimates	_	
95-24	16986-16991	using	_	
95-25	16992-16995	the	_	
95-26	16996-17003	MarsBaR	_	
95-27	17004-17011	toolbox	_	
95-28	17012-17017	using	_	
95-29	17018-17028	anatomical	_	
95-30	17029-17034	masks	_	
95-31	17035-17037	as	_	
95-32	17038-17047	described	_	
95-33	17048-17050	in	_	
95-34	17051-17059	previous	_	
95-35	17060-17064	work	_	
95-36	17064-17065	.	_	

#Text=Statistical Analyses
#Text=All data were analyzed using the Statistical Package of Social Sciences-22 (SPSS-22).
96-1	17066-17077	Statistical	_	
96-2	17078-17086	Analyses	_	
96-3	17087-17090	All	_	
96-4	17091-17095	data	_	
96-5	17096-17100	were	_	
96-6	17101-17109	analyzed	_	
96-7	17110-17115	using	_	
96-8	17116-17119	the	_	
96-9	17120-17131	Statistical	_	
96-10	17132-17139	Package	_	
96-11	17140-17142	of	_	
96-12	17143-17149	Social	_	
96-13	17150-17158	Sciences	_	
96-14	17158-17159	-	_	
96-15	17159-17161	22	_	
96-16	17162-17163	(	_	
96-17	17163-17167	SPSS	_	
96-18	17167-17168	-	_	
96-19	17168-17170	22	_	
96-20	17170-17171	)	_	
96-21	17171-17172	.	_	

#Text=Group differences in scan age were assessed using a generalized linear model with three levels for group (FH- Control, FH+ Low Risk, FH+ High Risk).
97-1	17173-17178	Group	_	
97-2	17179-17190	differences	_	
97-3	17191-17193	in	_	
97-4	17194-17198	scan	_	
97-5	17199-17202	age	_	
97-6	17203-17207	were	_	
97-7	17208-17216	assessed	_	
97-8	17217-17222	using	_	
97-9	17223-17224	a	_	
97-10	17225-17236	generalized	_	
97-11	17237-17243	linear	_	
97-12	17244-17249	model	_	
97-13	17250-17254	with	_	
97-14	17255-17260	three	_	
97-15	17261-17267	levels	_	
97-16	17268-17271	for	_	
97-17	17272-17277	group	_	
97-18	17278-17279	(	_	
97-19	17279-17281	FH	_	
97-20	17281-17282	-	_	
97-21	17283-17290	Control	_	
97-22	17290-17291	,	_	
97-23	17292-17294	FH	_	
97-24	17294-17295	+	_	
97-25	17296-17299	Low	_	
97-26	17300-17304	Risk	_	
97-27	17304-17305	,	_	
97-28	17306-17308	FH	_	
97-29	17308-17309	+	_	
97-30	17310-17314	High	_	
97-31	17315-17319	Risk	_	
97-32	17319-17320	)	_	
97-33	17320-17321	.	_	

#Text=There was an effect of group (F2,43 = 4.11, p = 0.024), which was driven by an older mean age in the FH+ High-Risk group versus the FH- Controls (24.2±2.9 years > 20.6±2.7 years, t = 0.2.875, p = 0.01); therefore scan age was used as a covariate in the remainder of statistical analyses.
98-1	17322-17327	There	_	
98-2	17328-17331	was	_	
98-3	17332-17334	an	_	
98-4	17335-17341	effect	_	
98-5	17342-17344	of	_	
98-6	17345-17350	group	_	
98-7	17351-17352	(	_	
98-8	17352-17357	F2,43	_	
98-9	17358-17359	=	_	
98-10	17360-17364	4.11	_	
98-11	17364-17365	,	_	
98-12	17366-17367	p	_	
98-13	17368-17369	=	_	
98-14	17370-17375	0.024	_	
98-15	17375-17376	)	_	
98-16	17376-17377	,	_	
98-17	17378-17383	which	_	
98-18	17384-17387	was	_	
98-19	17388-17394	driven	_	
98-20	17395-17397	by	_	
98-21	17398-17400	an	_	
98-22	17401-17406	older	_	
98-23	17407-17411	mean	_	
98-24	17412-17415	age	_	
98-25	17416-17418	in	_	
98-26	17419-17422	the	_	
98-27	17423-17425	FH	_	
98-28	17425-17426	+	_	
98-29	17427-17436	High-Risk	_	
98-30	17437-17442	group	_	
98-31	17443-17449	versus	_	
98-32	17450-17453	the	_	
98-33	17454-17456	FH	_	
98-34	17456-17457	-	_	
98-35	17458-17466	Controls	_	
98-36	17467-17468	(	_	
98-37	17468-17472	24.2	_	
98-38	17472-17473	±	_	
98-39	17473-17476	2.9	_	
98-40	17477-17482	years	_	
98-41	17483-17484	>	_	
98-42	17485-17489	20.6	_	
98-43	17489-17490	±	_	
98-44	17490-17493	2.7	_	
98-45	17494-17499	years	_	
98-46	17499-17500	,	_	
98-47	17501-17502	t	_	
98-48	17503-17504	=	_	
98-49	17505-17512	0.2.875	_	
98-50	17512-17513	,	_	
98-51	17514-17515	p	_	
98-52	17516-17517	=	_	
98-53	17518-17522	0.01	_	
98-54	17522-17523	)	_	
98-55	17523-17524	;	_	
98-56	17525-17534	therefore	_	
98-57	17535-17539	scan	_	
98-58	17540-17543	age	_	
98-59	17544-17547	was	_	
98-60	17548-17552	used	_	
98-61	17553-17555	as	_	
98-62	17556-17557	a	_	
98-63	17558-17567	covariate	_	
98-64	17568-17570	in	_	
98-65	17571-17574	the	_	
98-66	17575-17584	remainder	_	
98-67	17585-17587	of	_	
98-68	17588-17599	statistical	_	
98-69	17600-17608	analyses	_	
98-70	17608-17609	.	_	

#Text=Data distribution was assessed using the Kolmogorov-Smirnov Z-test; drug use variables did not meet the assumption of normality and were log transformed (after first adding one to each value).
99-1	17610-17614	Data	_	
99-2	17615-17627	distribution	_	
99-3	17628-17631	was	_	
99-4	17632-17640	assessed	_	
99-5	17641-17646	using	_	
99-6	17647-17650	the	_	
99-7	17651-17669	Kolmogorov-Smirnov	_	
99-8	17670-17676	Z-test	_	
99-9	17676-17677	;	_	
99-10	17678-17682	drug	_	
99-11	17683-17686	use	_	
99-12	17687-17696	variables	_	
99-13	17697-17700	did	_	
99-14	17701-17704	not	_	
99-15	17705-17709	meet	_	
99-16	17710-17713	the	_	
99-17	17714-17724	assumption	_	
99-18	17725-17727	of	_	
99-19	17728-17737	normality	_	
99-20	17738-17741	and	_	
99-21	17742-17746	were	_	
99-22	17747-17750	log	_	
99-23	17751-17762	transformed	_	
99-24	17763-17764	(	_	
99-25	17764-17769	after	_	
99-26	17770-17775	first	_	
99-27	17776-17782	adding	_	
99-28	17783-17786	one	_	
99-29	17787-17789	to	_	
99-30	17790-17794	each	_	
99-31	17795-17800	value	_	
99-32	17800-17801	)	_	
99-33	17801-17802	.	_	

#Text=Due to high collinearity of reported use of alcohol, tobacco and marijuana, principal component analysis of lifetime cumulative use was performed, resulting in a one factor solution explaining 66.4% of the variance (factor loadings: cumulative drink volume = 0.887, cumulative cigarette smoking days = 0.720, cumulative marijuana smoking days = 0.828).
100-1	17803-17806	Due	_	
100-2	17807-17809	to	_	
100-3	17810-17814	high	_	
100-4	17815-17827	collinearity	_	
100-5	17828-17830	of	_	
100-6	17831-17839	reported	_	
100-7	17840-17843	use	_	
100-8	17844-17846	of	_	
100-9	17847-17854	alcohol	_	
100-10	17854-17855	,	_	
100-11	17856-17863	tobacco	_	
100-12	17864-17867	and	_	
100-13	17868-17877	marijuana	_	
100-14	17877-17878	,	_	
100-15	17879-17888	principal	_	
100-16	17889-17898	component	_	
100-17	17899-17907	analysis	_	
100-18	17908-17910	of	_	
100-19	17911-17919	lifetime	_	
100-20	17920-17930	cumulative	_	
100-21	17931-17934	use	_	
100-22	17935-17938	was	_	
100-23	17939-17948	performed	_	
100-24	17948-17949	,	_	
100-25	17950-17959	resulting	_	
100-26	17960-17962	in	_	
100-27	17963-17964	a	_	
100-28	17965-17968	one	_	
100-29	17969-17975	factor	_	
100-30	17976-17984	solution	_	
100-31	17985-17995	explaining	_	
100-32	17996-18001	66.4%	_	
100-33	18002-18004	of	_	
100-34	18005-18008	the	_	
100-35	18009-18017	variance	_	
100-36	18018-18019	(	_	
100-37	18019-18025	factor	_	
100-38	18026-18034	loadings	_	
100-39	18034-18035	:	_	
100-40	18036-18046	cumulative	_	
100-41	18047-18052	drink	_	
100-42	18053-18059	volume	_	
100-43	18060-18061	=	_	
100-44	18062-18067	0.887	_	
100-45	18067-18068	,	_	
100-46	18069-18079	cumulative	_	
100-47	18080-18089	cigarette	_	
100-48	18090-18097	smoking	_	
100-49	18098-18102	days	_	
100-50	18103-18104	=	_	
100-51	18105-18110	0.720	_	
100-52	18110-18111	,	_	
100-53	18112-18122	cumulative	_	
100-54	18123-18132	marijuana	_	
100-55	18133-18140	smoking	_	
100-56	18141-18145	days	_	
100-57	18146-18147	=	_	
100-58	18148-18153	0.828	_	
100-59	18153-18154	)	_	
100-60	18154-18155	.	_	

#Text=This factor was used as a covariate when assessing group differences in PET and fMRI measures.
101-1	18156-18160	This	_	
101-2	18161-18167	factor	_	
101-3	18168-18171	was	_	
101-4	18172-18176	used	_	
101-5	18177-18179	as	_	
101-6	18180-18181	a	_	
101-7	18182-18191	covariate	_	
101-8	18192-18196	when	_	
101-9	18197-18206	assessing	_	
101-10	18207-18212	group	_	
101-11	18213-18224	differences	_	
101-12	18225-18227	in	_	
101-13	18228-18231	PET	_	
101-14	18232-18235	and	_	
101-15	18236-18240	fMRI	_	
101-16	18241-18249	measures	_	
101-17	18249-18250	.	_	

#Text=GLMs were used to assess group differences modeling two levels of the within-subject factor hemisphere (left and right) and three levels of the between-subject factor, group (FH- Control, FH+ Low Risk, FH+ High Risk).
102-1	18251-18255	GLMs	_	
102-2	18256-18260	were	_	
102-3	18261-18265	used	_	
102-4	18266-18268	to	_	
102-5	18269-18275	assess	_	
102-6	18276-18281	group	_	
102-7	18282-18293	differences	_	
102-8	18294-18302	modeling	_	
102-9	18303-18306	two	_	
102-10	18307-18313	levels	_	
102-11	18314-18316	of	_	
102-12	18317-18320	the	_	
102-13	18321-18335	within-subject	_	
102-14	18336-18342	factor	_	
102-15	18343-18353	hemisphere	_	
102-16	18354-18355	(	_	
102-17	18355-18359	left	_	
102-18	18360-18363	and	_	
102-19	18364-18369	right	_	
102-20	18369-18370	)	_	
102-21	18371-18374	and	_	
102-22	18375-18380	three	_	
102-23	18381-18387	levels	_	
102-24	18388-18390	of	_	
102-25	18391-18394	the	_	
102-26	18395-18410	between-subject	_	
102-27	18411-18417	factor	_	
102-28	18417-18418	,	_	
102-29	18419-18424	group	_	
102-30	18425-18426	(	_	
102-31	18426-18428	FH	_	
102-32	18428-18429	-	_	
102-33	18430-18437	Control	_	
102-34	18437-18438	,	_	
102-35	18439-18441	FH	_	
102-36	18441-18442	+	_	
102-37	18443-18446	Low	_	
102-38	18447-18451	Risk	_	
102-39	18451-18452	,	_	
102-40	18453-18455	FH	_	
102-41	18455-18456	+	_	
102-42	18457-18461	High	_	
102-43	18462-18466	Risk	_	
102-44	18466-18467	)	_	
102-45	18467-18468	.	_	

#Text=With concern that nonspecific effects were part of the structure of influence when including the general consumption factor, these analyses were repeated excluding this factor.
103-1	18469-18473	With	_	
103-2	18474-18481	concern	_	
103-3	18482-18486	that	_	
103-4	18487-18498	nonspecific	_	
103-5	18499-18506	effects	_	
103-6	18507-18511	were	_	
103-7	18512-18516	part	_	
103-8	18517-18519	of	_	
103-9	18520-18523	the	_	
103-10	18524-18533	structure	_	
103-11	18534-18536	of	_	
103-12	18537-18546	influence	_	
103-13	18547-18551	when	_	
103-14	18552-18561	including	_	
103-15	18562-18565	the	_	
103-16	18566-18573	general	_	
103-17	18574-18585	consumption	_	
103-18	18586-18592	factor	_	
103-19	18592-18593	,	_	
103-20	18594-18599	these	_	
103-21	18600-18608	analyses	_	
103-22	18609-18613	were	_	
103-23	18614-18622	repeated	_	
103-24	18623-18632	excluding	_	
103-25	18633-18637	this	_	
103-26	18638-18644	factor	_	
103-27	18644-18645	.	_	

#Text=However, statistics for GLMs with and without the consumption factor were essentially the same so the latter are not reported in results.
104-1	18646-18653	However	_	
104-2	18653-18654	,	_	
104-3	18655-18665	statistics	_	
104-4	18666-18669	for	_	
104-5	18670-18674	GLMs	_	
104-6	18675-18679	with	_	
104-7	18680-18683	and	_	
104-8	18684-18691	without	_	
104-9	18692-18695	the	_	
104-10	18696-18707	consumption	_	
104-11	18708-18714	factor	_	
104-12	18715-18719	were	_	
104-13	18720-18731	essentially	_	
104-14	18732-18735	the	_	
104-15	18736-18740	same	_	
104-16	18741-18743	so	_	
104-17	18744-18747	the	_	
104-18	18748-18754	latter	_	
104-19	18755-18758	are	_	
104-20	18759-18762	not	_	
104-21	18763-18771	reported	_	
104-22	18772-18774	in	_	
104-23	18775-18782	results	_	
104-24	18782-18783	.	_	

#Text=Finally, as exploratory analyses, partial correlations, controlling for scan age and the cumulative substance use factor, were used to assess relationships between PET and fMRI data and substance use measures.
105-1	18784-18791	Finally	_	
105-2	18791-18792	,	_	
105-3	18793-18795	as	_	
105-4	18796-18807	exploratory	_	
105-5	18808-18816	analyses	_	
105-6	18816-18817	,	_	
105-7	18818-18825	partial	_	
105-8	18826-18838	correlations	_	
105-9	18838-18839	,	_	
105-10	18840-18851	controlling	_	
105-11	18852-18855	for	_	
105-12	18856-18860	scan	_	
105-13	18861-18864	age	_	
105-14	18865-18868	and	_	
105-15	18869-18872	the	_	
105-16	18873-18883	cumulative	_	
105-17	18884-18893	substance	_	
105-18	18894-18897	use	_	
105-19	18898-18904	factor	_	
105-20	18904-18905	,	_	
105-21	18906-18910	were	_	
105-22	18911-18915	used	_	
105-23	18916-18918	to	_	
105-24	18919-18925	assess	_	
105-25	18926-18939	relationships	_	
105-26	18940-18947	between	_	
105-27	18948-18951	PET	_	
105-28	18952-18955	and	_	
105-29	18956-18960	fMRI	_	
105-30	18961-18965	data	_	
105-31	18966-18969	and	_	
105-32	18970-18979	substance	_	
105-33	18980-18983	use	_	
105-34	18984-18992	measures	_	
105-35	18992-18993	.	_	

#Text=Results
#Text=Subject Characteristics
#Text=Forty-four subjects (age: range, mean±standard deviation: 18.0 – 26.7, 22.91±3.0 years) were recruited into the study comprising three groups: FH- control subjects and two FH+ groups differentiated as Low or High Risk with the latter having initiated drunkenness by age 15.
106-1	18994-19001	Results	_	
106-2	19002-19009	Subject	_	
106-3	19010-19025	Characteristics	_	
106-4	19026-19036	Forty-four	_	
106-5	19037-19045	subjects	_	
106-6	19046-19047	(	_	
106-7	19047-19050	age	_	
106-8	19050-19051	:	_	
106-9	19052-19057	range	_	
106-10	19057-19058	,	_	
106-11	19059-19063	mean	_	
106-12	19063-19064	±	_	
106-13	19064-19072	standard	_	
106-14	19073-19082	deviation	_	
106-15	19082-19083	:	_	
106-16	19084-19088	18.0	_	
106-17	19089-19090	–	_	
106-18	19091-19095	26.7	_	
106-19	19095-19096	,	_	
106-20	19097-19102	22.91	_	
106-21	19102-19103	±	_	
106-22	19103-19106	3.0	_	
106-23	19107-19112	years	_	
106-24	19112-19113	)	_	
106-25	19114-19118	were	_	
106-26	19119-19128	recruited	_	
106-27	19129-19133	into	_	
106-28	19134-19137	the	_	
106-29	19138-19143	study	_	
106-30	19144-19154	comprising	_	
106-31	19155-19160	three	_	
106-32	19161-19167	groups	_	
106-33	19167-19168	:	_	
106-34	19169-19171	FH	_	
106-35	19171-19172	-	_	
106-36	19173-19180	control	_	
106-37	19181-19189	subjects	_	
106-38	19190-19193	and	_	
106-39	19194-19197	two	_	
106-40	19198-19200	FH	_	
106-41	19200-19201	+	_	
106-42	19202-19208	groups	_	
106-43	19209-19223	differentiated	_	
106-44	19224-19226	as	_	
106-45	19227-19230	Low	_	
106-46	19231-19233	or	_	
106-47	19234-19238	High	_	
106-48	19239-19243	Risk	_	
106-49	19244-19248	with	_	
106-50	19249-19252	the	_	
106-51	19253-19259	latter	_	
106-52	19260-19266	having	_	
106-53	19267-19276	initiated	_	
106-54	19277-19288	drunkenness	_	
106-55	19289-19291	by	_	
106-56	19292-19295	age	_	
106-57	19296-19298	15	_	
106-58	19298-19299	.	_	

#Text=Subject characteristics are presented in Table 1.
107-1	19300-19307	Subject	_	
107-2	19308-19323	characteristics	_	
107-3	19324-19327	are	_	
107-4	19328-19337	presented	_	
107-5	19338-19340	in	_	
107-6	19341-19346	Table	_	
107-7	19347-19348	1	_	
107-8	19348-19349	.	_	

#Text=There were no significant differences in demographic, personality, or substance use measures between the FH- Control and FH+ Low Risk groups (p's > 0.153).
108-1	19350-19355	There	_	
108-2	19356-19360	were	_	
108-3	19361-19363	no	_	
108-4	19364-19375	significant	_	
108-5	19376-19387	differences	_	
108-6	19388-19390	in	_	
108-7	19391-19402	demographic	_	
108-8	19402-19403	,	_	
108-9	19404-19415	personality	_	
108-10	19415-19416	,	_	
108-11	19417-19419	or	_	
108-12	19420-19429	substance	_	
108-13	19430-19433	use	_	
108-14	19434-19442	measures	_	
108-15	19443-19450	between	_	
108-16	19451-19454	the	_	
108-17	19455-19457	FH	_	
108-18	19457-19458	-	_	
108-19	19459-19466	Control	_	
108-20	19467-19470	and	_	
108-21	19471-19473	FH	_	
108-22	19473-19474	+	_	
108-23	19475-19478	Low	_	
108-24	19479-19483	Risk	_	
108-25	19484-19490	groups	_	
108-26	19491-19492	(	_	
108-27	19492-19495	p's	_	
108-28	19496-19497	>	_	
108-29	19498-19503	0.153	_	
108-30	19503-19504	)	_	
108-31	19504-19505	.	_	

#Text=The FH+ groups differed on sensation-seeking and all cumulative substance use measures (with the exception of number of cigarette smoking days).
109-1	19506-19509	The	_	
109-2	19510-19512	FH	_	
109-3	19512-19513	+	_	
109-4	19514-19520	groups	_	
109-5	19521-19529	differed	_	
109-6	19530-19532	on	_	
109-7	19533-19550	sensation-seeking	_	
109-8	19551-19554	and	_	
109-9	19555-19558	all	_	
109-10	19559-19569	cumulative	_	
109-11	19570-19579	substance	_	
109-12	19580-19583	use	_	
109-13	19584-19592	measures	_	
109-14	19593-19594	(	_	
109-15	19594-19598	with	_	
109-16	19599-19602	the	_	
109-17	19603-19612	exception	_	
109-18	19613-19615	of	_	
109-19	19616-19622	number	_	
109-20	19623-19625	of	_	
109-21	19626-19635	cigarette	_	
109-22	19636-19643	smoking	_	
109-23	19644-19648	days	_	
109-24	19648-19649	)	_	
109-25	19649-19650	.	_	

#Text=For past month use, the FH+ High Risk group reported more alcohol but not cigarette or marijuana use.
110-1	19651-19654	For	_	
110-2	19655-19659	past	_	
110-3	19660-19665	month	_	
110-4	19666-19669	use	_	
110-5	19669-19670	,	_	
110-6	19671-19674	the	_	
110-7	19675-19677	FH	_	
110-8	19677-19678	+	_	
110-9	19679-19683	High	_	
110-10	19684-19688	Risk	_	
110-11	19689-19694	group	_	
110-12	19695-19703	reported	_	
110-13	19704-19708	more	_	
110-14	19709-19716	alcohol	_	
110-15	19717-19720	but	_	
110-16	19721-19724	not	_	
110-17	19725-19734	cigarette	_	
110-18	19735-19737	or	_	
110-19	19738-19747	marijuana	_	
110-20	19748-19751	use	_	
110-21	19751-19752	.	_	

#Text=With the exception of a single subject from the FH+ Low Risk group reporting use of vicodin, no subjects reported recent use of other illicit substances.
111-1	19753-19757	With	_	
111-2	19758-19761	the	_	
111-3	19762-19771	exception	_	
111-4	19772-19774	of	_	
111-5	19775-19776	a	_	
111-6	19777-19783	single	_	
111-7	19784-19791	subject	_	
111-8	19792-19796	from	_	
111-9	19797-19800	the	_	
111-10	19801-19803	FH	_	
111-11	19803-19804	+	_	
111-12	19805-19808	Low	_	
111-13	19809-19813	Risk	_	
111-14	19814-19819	group	_	
111-15	19820-19829	reporting	_	
111-16	19830-19833	use	_	
111-17	19834-19836	of	_	
111-18	19837-19844	vicodin	_	
111-19	19844-19845	,	_	
111-20	19846-19848	no	_	
111-21	19849-19857	subjects	_	
111-22	19858-19866	reported	_	
111-23	19867-19873	recent	_	
111-24	19874-19877	use	_	
111-25	19878-19880	of	_	
111-26	19881-19886	other	_	
111-27	19887-19894	illicit	_	
111-28	19895-19905	substances	_	
111-29	19905-19906	.	_	

#Text=MID task during PET
#Text=BPND for the control condition, somewhat a proxy for baseline D2/D3 receptor availability, did not differ between groups for the NAcc ROIs (p's > 0.795) although there was an effect of age significant in the left but not right NAcc (L/R: F1,43 = 4.763, p = 0.035; F2,43 = 2.861, p = 0.099).
112-1	19907-19910	MID	_	
112-2	19911-19915	task	_	
112-3	19916-19922	during	_	
112-4	19923-19926	PET	_	
112-5	19927-19931	BPND	_	
112-6	19932-19935	for	_	
112-7	19936-19939	the	_	
112-8	19940-19947	control	_	
112-9	19948-19957	condition	_	
112-10	19957-19958	,	_	
112-11	19959-19967	somewhat	_	
112-12	19968-19969	a	_	
112-13	19970-19975	proxy	_	
112-14	19976-19979	for	_	
112-15	19980-19988	baseline	_	
112-16	19989-19991	D2	_	
112-17	19991-19992	/	_	
112-18	19992-19994	D3	_	
112-19	19995-20003	receptor	_	
112-20	20004-20016	availability	_	
112-21	20016-20017	,	_	
112-22	20018-20021	did	_	
112-23	20022-20025	not	_	
112-24	20026-20032	differ	_	
112-25	20033-20040	between	_	
112-26	20041-20047	groups	_	
112-27	20048-20051	for	_	
112-28	20052-20055	the	_	
112-29	20056-20060	NAcc	_	
112-30	20061-20065	ROIs	_	
112-31	20066-20067	(	_	
112-32	20067-20070	p's	_	
112-33	20071-20072	>	_	
112-34	20073-20078	0.795	_	
112-35	20078-20079	)	_	
112-36	20080-20088	although	_	
112-37	20089-20094	there	_	
112-38	20095-20098	was	_	
112-39	20099-20101	an	_	
112-40	20102-20108	effect	_	
112-41	20109-20111	of	_	
112-42	20112-20115	age	_	
112-43	20116-20127	significant	_	
112-44	20128-20130	in	_	
112-45	20131-20134	the	_	
112-46	20135-20139	left	_	
112-47	20140-20143	but	_	
112-48	20144-20147	not	_	
112-49	20148-20153	right	_	
112-50	20154-20158	NAcc	_	
112-51	20159-20160	(	_	
112-52	20160-20161	L	_	
112-53	20161-20162	/	_	
112-54	20162-20163	R	_	
112-55	20163-20164	:	_	
112-56	20165-20170	F1,43	_	
112-57	20171-20172	=	_	
112-58	20173-20178	4.763	_	
112-59	20178-20179	,	_	
112-60	20180-20181	p	_	
112-61	20182-20183	=	_	
112-62	20184-20189	0.035	_	
112-63	20189-20190	;	_	
112-64	20191-20196	F2,43	_	
112-65	20197-20198	=	_	
112-66	20199-20204	2.861	_	
112-67	20204-20205	,	_	
112-68	20206-20207	p	_	
112-69	20208-20209	=	_	
112-70	20210-20215	0.099	_	
112-71	20215-20216	)	_	
112-72	20216-20217	.	_	

#Text=Across all subjects, the NAcc ROIs demonstrated modest, non-significant behavioral reward-induced reductions in the receptor availability measure, BPND, consistent with the activation of DA D2/D3 neurotransmission (paired t-tests, L/R: t = -1.277, p = 0.104; t = -1.343, p = 0.093, one-tailed).
113-1	20218-20224	Across	_	
113-2	20225-20228	all	_	
113-3	20229-20237	subjects	_	
113-4	20237-20238	,	_	
113-5	20239-20242	the	_	
113-6	20243-20247	NAcc	_	
113-7	20248-20252	ROIs	_	
113-8	20253-20265	demonstrated	_	
113-9	20266-20272	modest	_	
113-10	20272-20273	,	_	
113-11	20274-20289	non-significant	_	
113-12	20290-20300	behavioral	_	
113-13	20301-20315	reward-induced	_	
113-14	20316-20326	reductions	_	
113-15	20327-20329	in	_	
113-16	20330-20333	the	_	
113-17	20334-20342	receptor	_	
113-18	20343-20355	availability	_	
113-19	20356-20363	measure	_	
113-20	20363-20364	,	_	
113-21	20365-20369	BPND	_	
113-22	20369-20370	,	_	
113-23	20371-20381	consistent	_	
113-24	20382-20386	with	_	
113-25	20387-20390	the	_	
113-26	20391-20401	activation	_	
113-27	20402-20404	of	_	
113-28	20405-20407	DA	_	
113-29	20408-20410	D2	_	
113-30	20410-20411	/	_	
113-31	20411-20413	D3	_	
113-32	20414-20431	neurotransmission	_	
113-33	20432-20433	(	_	
113-34	20433-20439	paired	_	
113-35	20440-20447	t-tests	_	
113-36	20447-20448	,	_	
113-37	20449-20450	L	_	
113-38	20450-20451	/	_	
113-39	20451-20452	R	_	
113-40	20452-20453	:	_	
113-41	20454-20455	t	_	
113-42	20456-20457	=	_	
113-43	20458-20459	-	_	
113-44	20459-20464	1.277	_	
113-45	20464-20465	,	_	
113-46	20466-20467	p	_	
113-47	20468-20469	=	_	
113-48	20470-20475	0.104	_	
113-49	20475-20476	;	_	
113-50	20477-20478	t	_	
113-51	20479-20480	=	_	
113-52	20481-20482	-	_	
113-53	20482-20487	1.343	_	
113-54	20487-20488	,	_	
113-55	20489-20490	p	_	
113-56	20491-20492	=	_	
113-57	20493-20498	0.093	_	
113-58	20498-20499	,	_	
113-59	20500-20510	one-tailed	_	
113-60	20510-20511	)	_	
113-61	20511-20512	.	_	

#Text=However, for the FH+ High Risk group, the effect was significant (L/R: t = -3.013, p = 0.009; t = -3.198; p = 0.007), suggestive of positive DA release in response to the task.
114-1	20513-20520	However	_	
114-2	20520-20521	,	_	
114-3	20522-20525	for	_	
114-4	20526-20529	the	_	
114-5	20530-20532	FH	_	
114-6	20532-20533	+	_	
114-7	20534-20538	High	_	
114-8	20539-20543	Risk	_	
114-9	20544-20549	group	_	
114-10	20549-20550	,	_	
114-11	20551-20554	the	_	
114-12	20555-20561	effect	_	
114-13	20562-20565	was	_	
114-14	20566-20577	significant	_	
114-15	20578-20579	(	_	
114-16	20579-20580	L	_	
114-17	20580-20581	/	_	
114-18	20581-20582	R	_	
114-19	20582-20583	:	_	
114-20	20584-20585	t	_	
114-21	20586-20587	=	_	
114-22	20588-20589	-	_	
114-23	20589-20594	3.013	_	
114-24	20594-20595	,	_	
114-25	20596-20597	p	_	
114-26	20598-20599	=	_	
114-27	20600-20605	0.009	_	
114-28	20605-20606	;	_	
114-29	20607-20608	t	_	
114-30	20609-20610	=	_	
114-31	20611-20612	-	_	
114-32	20612-20617	3.198	_	
114-33	20617-20618	;	_	
114-34	20619-20620	p	_	
114-35	20621-20622	=	_	
114-36	20623-20628	0.007	_	
114-37	20628-20629	)	_	
114-38	20629-20630	,	_	
114-39	20631-20641	suggestive	_	
114-40	20642-20644	of	_	
114-41	20645-20653	positive	_	
114-42	20654-20656	DA	_	
114-43	20657-20664	release	_	
114-44	20665-20667	in	_	
114-45	20668-20676	response	_	
114-46	20677-20679	to	_	
114-47	20680-20683	the	_	
114-48	20684-20688	task	_	
114-49	20688-20689	.	_	

#Text=The GLM analysis of ΔBPND, indicative of dopamine response/release, identified an effect of group in the NAcc ROIs, (L/R: F2,43 = 6.278, p = 0.004; F2,43 = 3.157, p = 0.054), see Figure 2.
115-1	20690-20693	The	_	
115-2	20694-20697	GLM	_	
115-3	20698-20706	analysis	_	
115-4	20707-20709	of	_	
115-5	20710-20715	ΔBPND	_	
115-6	20715-20716	,	_	
115-7	20717-20727	indicative	_	
115-8	20728-20730	of	_	
115-9	20731-20739	dopamine	_	
115-10	20740-20748	response	_	
115-11	20748-20749	/	_	
115-12	20749-20756	release	_	
115-13	20756-20757	,	_	
115-14	20758-20768	identified	_	
115-15	20769-20771	an	_	
115-16	20772-20778	effect	_	
115-17	20779-20781	of	_	
115-18	20782-20787	group	_	
115-19	20788-20790	in	_	
115-20	20791-20794	the	_	
115-21	20795-20799	NAcc	_	
115-22	20800-20804	ROIs	_	
115-23	20804-20805	,	_	
115-24	20806-20807	(	_	
115-25	20807-20808	L	_	
115-26	20808-20809	/	_	
115-27	20809-20810	R	_	
115-28	20810-20811	:	_	
115-29	20812-20817	F2,43	_	
115-30	20818-20819	=	_	
115-31	20820-20825	6.278	_	
115-32	20825-20826	,	_	
115-33	20827-20828	p	_	
115-34	20829-20830	=	_	
115-35	20831-20836	0.004	_	
115-36	20836-20837	;	_	
115-37	20838-20843	F2,43	_	
115-38	20844-20845	=	_	
115-39	20846-20851	3.157	_	
115-40	20851-20852	,	_	
115-41	20853-20854	p	_	
115-42	20855-20856	=	_	
115-43	20857-20862	0.054	_	
115-44	20862-20863	)	_	
115-45	20863-20864	,	_	
115-46	20865-20868	see	_	
115-47	20869-20875	Figure	_	
115-48	20876-20877	2	_	
115-49	20877-20878	.	_	

#Text=See Supplemental Table 1 for BPND values for ROIs for each task condition.
116-1	20879-20882	See	_	
116-2	20883-20895	Supplemental	_	
116-3	20896-20901	Table	_	
116-4	20902-20903	1	_	
116-5	20904-20907	for	_	
116-6	20908-20912	BPND	_	
116-7	20913-20919	values	_	
116-8	20920-20923	for	_	
116-9	20924-20928	ROIs	_	
116-10	20929-20932	for	_	
116-11	20933-20937	each	_	
116-12	20938-20942	task	_	
116-13	20943-20952	condition	_	
116-14	20952-20953	.	_	

#Text=To insure that alcohol or marijuana dependence was not driving this finding, we repeated this analysis excluding the individuals (FH- Control, n = 1; FH+ High Risk, n = 1) who had met diagnoses, still finding a group effect in both the left (F2,41 = 7.783, p = 0.008) and right NAcc (F2,41 = 6.506, p = 0.015)
#Text=MID task during fMRI
#Text=The GLM analyses of neural task activation did not identify an effect of group in the NAcc ROIs for reward anticipation (p's > 0.326) or reward feedback (p's > 0.769), see Figure 2.
117-1	20954-20956	To	_	
117-2	20957-20963	insure	_	
117-3	20964-20968	that	_	
117-4	20969-20976	alcohol	_	
117-5	20977-20979	or	_	
117-6	20980-20989	marijuana	_	
117-7	20990-21000	dependence	_	
117-8	21001-21004	was	_	
117-9	21005-21008	not	_	
117-10	21009-21016	driving	_	
117-11	21017-21021	this	_	
117-12	21022-21029	finding	_	
117-13	21029-21030	,	_	
117-14	21031-21033	we	_	
117-15	21034-21042	repeated	_	
117-16	21043-21047	this	_	
117-17	21048-21056	analysis	_	
117-18	21057-21066	excluding	_	
117-19	21067-21070	the	_	
117-20	21071-21082	individuals	_	
117-21	21083-21084	(	_	
117-22	21084-21086	FH	_	
117-23	21086-21087	-	_	
117-24	21088-21095	Control	_	
117-25	21095-21096	,	_	
117-26	21097-21098	n	_	
117-27	21099-21100	=	_	
117-28	21101-21102	1	_	
117-29	21102-21103	;	_	
117-30	21104-21106	FH	_	
117-31	21106-21107	+	_	
117-32	21108-21112	High	_	
117-33	21113-21117	Risk	_	
117-34	21117-21118	,	_	
117-35	21119-21120	n	_	
117-36	21121-21122	=	_	
117-37	21123-21124	1	_	
117-38	21124-21125	)	_	
117-39	21126-21129	who	_	
117-40	21130-21133	had	_	
117-41	21134-21137	met	_	
117-42	21138-21147	diagnoses	_	
117-43	21147-21148	,	_	
117-44	21149-21154	still	_	
117-45	21155-21162	finding	_	
117-46	21163-21164	a	_	
117-47	21165-21170	group	_	
117-48	21171-21177	effect	_	
117-49	21178-21180	in	_	
117-50	21181-21185	both	_	
117-51	21186-21189	the	_	
117-52	21190-21194	left	_	
117-53	21195-21196	(	_	
117-54	21196-21201	F2,41	_	
117-55	21202-21203	=	_	
117-56	21204-21209	7.783	_	
117-57	21209-21210	,	_	
117-58	21211-21212	p	_	
117-59	21213-21214	=	_	
117-60	21215-21220	0.008	_	
117-61	21220-21221	)	_	
117-62	21222-21225	and	_	
117-63	21226-21231	right	_	
117-64	21232-21236	NAcc	_	
117-65	21237-21238	(	_	
117-66	21238-21243	F2,41	_	
117-67	21244-21245	=	_	
117-68	21246-21251	6.506	_	
117-69	21251-21252	,	_	
117-70	21253-21254	p	_	
117-71	21255-21256	=	_	
117-72	21257-21262	0.015	_	
117-73	21262-21263	)	_	
117-74	21264-21267	MID	_	
117-75	21268-21272	task	_	
117-76	21273-21279	during	_	
117-77	21280-21284	fMRI	_	
117-78	21285-21288	The	_	
117-79	21289-21292	GLM	_	
117-80	21293-21301	analyses	_	
117-81	21302-21304	of	_	
117-82	21305-21311	neural	_	
117-83	21312-21316	task	_	
117-84	21317-21327	activation	_	
117-85	21328-21331	did	_	
117-86	21332-21335	not	_	
117-87	21336-21344	identify	_	
117-88	21345-21347	an	_	
117-89	21348-21354	effect	_	
117-90	21355-21357	of	_	
117-91	21358-21363	group	_	
117-92	21364-21366	in	_	
117-93	21367-21370	the	_	
117-94	21371-21375	NAcc	_	
117-95	21376-21380	ROIs	_	
117-96	21381-21384	for	_	
117-97	21385-21391	reward	_	
117-98	21392-21404	anticipation	_	
117-99	21405-21406	(	_	
117-100	21406-21409	p's	_	
117-101	21410-21411	>	_	
117-102	21412-21417	0.326	_	
117-103	21417-21418	)	_	
117-104	21419-21421	or	_	
117-105	21422-21428	reward	_	
117-106	21429-21437	feedback	_	
117-107	21438-21439	(	_	
117-108	21439-21442	p's	_	
117-109	21443-21444	>	_	
117-110	21445-21450	0.769	_	
117-111	21450-21451	)	_	
117-112	21451-21452	,	_	
117-113	21453-21456	see	_	
117-114	21457-21463	Figure	_	
117-115	21464-21465	2	_	
117-116	21465-21466	.	_	

#Text=Correlation of PET and fMRI data
#Text=Across all subjects, NAcc DA release was not related to BOLD activation during reward anticipation (p's > 0.242) but was positively correlated with activation during reward feedback (L/R: r = 0.418, p = 0.006; r = 0.393, p = 0.010).
118-1	21467-21478	Correlation	_	
118-2	21479-21481	of	_	
118-3	21482-21485	PET	_	
118-4	21486-21489	and	_	
118-5	21490-21494	fMRI	_	
118-6	21495-21499	data	_	
118-7	21500-21506	Across	_	
118-8	21507-21510	all	_	
118-9	21511-21519	subjects	_	
118-10	21519-21520	,	_	
118-11	21521-21525	NAcc	_	
118-12	21526-21528	DA	_	
118-13	21529-21536	release	_	
118-14	21537-21540	was	_	
118-15	21541-21544	not	_	
118-16	21545-21552	related	_	
118-17	21553-21555	to	_	
118-18	21556-21560	BOLD	_	
118-19	21561-21571	activation	_	
118-20	21572-21578	during	_	
118-21	21579-21585	reward	_	
118-22	21586-21598	anticipation	_	
118-23	21599-21600	(	_	
118-24	21600-21603	p's	_	
118-25	21604-21605	>	_	
118-26	21606-21611	0.242	_	
118-27	21611-21612	)	_	
118-28	21613-21616	but	_	
118-29	21617-21620	was	_	
118-30	21621-21631	positively	_	
118-31	21632-21642	correlated	_	
118-32	21643-21647	with	_	
118-33	21648-21658	activation	_	
118-34	21659-21665	during	_	
118-35	21666-21672	reward	_	
118-36	21673-21681	feedback	_	
118-37	21682-21683	(	_	
118-38	21683-21684	L	_	
118-39	21684-21685	/	_	
118-40	21685-21686	R	_	
118-41	21686-21687	:	_	
118-42	21688-21689	r	_	
118-43	21690-21691	=	_	
118-44	21692-21697	0.418	_	
118-45	21697-21698	,	_	
118-46	21699-21700	p	_	
118-47	21701-21702	=	_	
118-48	21703-21708	0.006	_	
118-49	21708-21709	;	_	
118-50	21710-21711	r	_	
118-51	21712-21713	=	_	
118-52	21714-21719	0.393	_	
118-53	21719-21720	,	_	
118-54	21721-21722	p	_	
118-55	21723-21724	=	_	
118-56	21725-21730	0.010	_	
118-57	21730-21731	)	_	
118-58	21731-21732	.	_	

#Text=Thus, a negative striatal ΔBPND, or positive dopamine response/release during the PET version of the MID task, correlated with increased striatal activation during the positive notification of reward receipt during the fMRI version of the MID task, see Figure 3.
119-1	21733-21737	Thus	_	
119-2	21737-21738	,	_	
119-3	21739-21740	a	_	
119-4	21741-21749	negative	_	
119-5	21750-21758	striatal	_	
119-6	21759-21764	ΔBPND	_	
119-7	21764-21765	,	_	
119-8	21766-21768	or	_	
119-9	21769-21777	positive	_	
119-10	21778-21786	dopamine	_	
119-11	21787-21795	response	_	
119-12	21795-21796	/	_	
119-13	21796-21803	release	_	
119-14	21804-21810	during	_	
119-15	21811-21814	the	_	
119-16	21815-21818	PET	_	
119-17	21819-21826	version	_	
119-18	21827-21829	of	_	
119-19	21830-21833	the	_	
119-20	21834-21837	MID	_	
119-21	21838-21842	task	_	
119-22	21842-21843	,	_	
119-23	21844-21854	correlated	_	
119-24	21855-21859	with	_	
119-25	21860-21869	increased	_	
119-26	21870-21878	striatal	_	
119-27	21879-21889	activation	_	
119-28	21890-21896	during	_	
119-29	21897-21900	the	_	
119-30	21901-21909	positive	_	
119-31	21910-21922	notification	_	
119-32	21923-21925	of	_	
119-33	21926-21932	reward	_	
119-34	21933-21940	receipt	_	
119-35	21941-21947	during	_	
119-36	21948-21951	the	_	
119-37	21952-21956	fMRI	_	
119-38	21957-21964	version	_	
119-39	21965-21967	of	_	
119-40	21968-21971	the	_	
119-41	21972-21975	MID	_	
119-42	21976-21980	task	_	
119-43	21980-21981	,	_	
119-44	21982-21985	see	_	
119-45	21986-21992	Figure	_	
119-46	21993-21994	3	_	
119-47	21994-21995	.	_	

#Text=Correlation of PET and fMRI data with substance use
#Text=No associations were found with ventral striatal DA release, anticipatory response, or feedback response with the cumulative substance use measure.
120-1	21996-22007	Correlation	_	
120-2	22008-22010	of	_	
120-3	22011-22014	PET	_	
120-4	22015-22018	and	_	
120-5	22019-22023	fMRI	_	
120-6	22024-22028	data	_	
120-7	22029-22033	with	_	
120-8	22034-22043	substance	_	
120-9	22044-22047	use	_	
120-10	22048-22050	No	_	
120-11	22051-22063	associations	_	
120-12	22064-22068	were	_	
120-13	22069-22074	found	_	
120-14	22075-22079	with	_	
120-15	22080-22087	ventral	_	
120-16	22088-22096	striatal	_	
120-17	22097-22099	DA	_	
120-18	22100-22107	release	_	
120-19	22107-22108	,	_	
120-20	22109-22121	anticipatory	_	
120-21	22122-22130	response	_	
120-22	22130-22131	,	_	
120-23	22132-22134	or	_	
120-24	22135-22143	feedback	_	
120-25	22144-22152	response	_	
120-26	22153-22157	with	_	
120-27	22158-22161	the	_	
120-28	22162-22172	cumulative	_	
120-29	22173-22182	substance	_	
120-30	22183-22186	use	_	
120-31	22187-22194	measure	_	
120-32	22194-22195	.	_	

#Text=For all subjects, DA release was negatively associated with age of first drunk in the left NAcc (t = -0.455, p = 0.017) showing a trend in the right NAcc (t = -0.363, p = 0.063), see Figure 4, such that subjects that experienced drunkenness at a younger age had higher ventral striatal release during the MID task in the PET study.
121-1	22196-22199	For	_	
121-2	22200-22203	all	_	
121-3	22204-22212	subjects	_	
121-4	22212-22213	,	_	
121-5	22214-22216	DA	_	
121-6	22217-22224	release	_	
121-7	22225-22228	was	_	
121-8	22229-22239	negatively	_	
121-9	22240-22250	associated	_	
121-10	22251-22255	with	_	
121-11	22256-22259	age	_	
121-12	22260-22262	of	_	
121-13	22263-22268	first	_	
121-14	22269-22274	drunk	_	
121-15	22275-22277	in	_	
121-16	22278-22281	the	_	
121-17	22282-22286	left	_	
121-18	22287-22291	NAcc	_	
121-19	22292-22293	(	_	
121-20	22293-22294	t	_	
121-21	22295-22296	=	_	
121-22	22297-22298	-	_	
121-23	22298-22303	0.455	_	
121-24	22303-22304	,	_	
121-25	22305-22306	p	_	
121-26	22307-22308	=	_	
121-27	22309-22314	0.017	_	
121-28	22314-22315	)	_	
121-29	22316-22323	showing	_	
121-30	22324-22325	a	_	
121-31	22326-22331	trend	_	
121-32	22332-22334	in	_	
121-33	22335-22338	the	_	
121-34	22339-22344	right	_	
121-35	22345-22349	NAcc	_	
121-36	22350-22351	(	_	
121-37	22351-22352	t	_	
121-38	22353-22354	=	_	
121-39	22355-22356	-	_	
121-40	22356-22361	0.363	_	
121-41	22361-22362	,	_	
121-42	22363-22364	p	_	
121-43	22365-22366	=	_	
121-44	22367-22372	0.063	_	
121-45	22372-22373	)	_	
121-46	22373-22374	,	_	
121-47	22375-22378	see	_	
121-48	22379-22385	Figure	_	
121-49	22386-22387	4	_	
121-50	22387-22388	,	_	
121-51	22389-22393	such	_	
121-52	22394-22398	that	_	
121-53	22399-22407	subjects	_	
121-54	22408-22412	that	_	
121-55	22413-22424	experienced	_	
121-56	22425-22436	drunkenness	_	
121-57	22437-22439	at	_	
121-58	22440-22441	a	_	
121-59	22442-22449	younger	_	
121-60	22450-22453	age	_	
121-61	22454-22457	had	_	
121-62	22458-22464	higher	_	
121-63	22465-22472	ventral	_	
121-64	22473-22481	striatal	_	
121-65	22482-22489	release	_	
121-66	22490-22496	during	_	
121-67	22497-22500	the	_	
121-68	22501-22504	MID	_	
121-69	22505-22509	task	_	
121-70	22510-22512	in	_	
121-71	22513-22516	the	_	
121-72	22517-22520	PET	_	
121-73	22521-22526	study	_	
121-74	22526-22527	.	_	

#Text=Age of first drink was negatively associated with NAcc reward feedback neural activation during the MID task in the fMRI study (L/R: r = 0.378, p = 0.030; r = 0.467, p = 0.006).
122-1	22528-22531	Age	_	
122-2	22532-22534	of	_	
122-3	22535-22540	first	_	
122-4	22541-22546	drink	_	
122-5	22547-22550	was	_	
122-6	22551-22561	negatively	_	
122-7	22562-22572	associated	_	
122-8	22573-22577	with	_	
122-9	22578-22582	NAcc	_	
122-10	22583-22589	reward	_	
122-11	22590-22598	feedback	_	
122-12	22599-22605	neural	_	
122-13	22606-22616	activation	_	
122-14	22617-22623	during	_	
122-15	22624-22627	the	_	
122-16	22628-22631	MID	_	
122-17	22632-22636	task	_	
122-18	22637-22639	in	_	
122-19	22640-22643	the	_	
122-20	22644-22648	fMRI	_	
122-21	22649-22654	study	_	
122-22	22655-22656	(	_	
122-23	22656-22657	L	_	
122-24	22657-22658	/	_	
122-25	22658-22659	R	_	
122-26	22659-22660	:	_	
122-27	22661-22662	r	_	
122-28	22663-22664	=	_	
122-29	22665-22670	0.378	_	
122-30	22670-22671	,	_	
122-31	22672-22673	p	_	
122-32	22674-22675	=	_	
122-33	22676-22681	0.030	_	
122-34	22681-22682	;	_	
122-35	22683-22684	r	_	
122-36	22685-22686	=	_	
122-37	22687-22692	0.467	_	
122-38	22692-22693	,	_	
122-39	22694-22695	p	_	
122-40	22696-22697	=	_	
122-41	22698-22703	0.006	_	
122-42	22703-22704	)	_	
122-43	22704-22705	.	_	

#Text=Discussion
#Text=Given the key role for the NAcc in reward processing and reinforcement, D2/D3 receptor availability and dopamine neurotransmission in this structure has been suggested as a potential biomarker for vulnerability for substance use disorders, particularly in individuals with familial loading.
123-1	22706-22716	Discussion	_	
123-2	22717-22722	Given	_	
123-3	22723-22726	the	_	
123-4	22727-22730	key	_	
123-5	22731-22735	role	_	
123-6	22736-22739	for	_	
123-7	22740-22743	the	_	
123-8	22744-22748	NAcc	_	
123-9	22749-22751	in	_	
123-10	22752-22758	reward	_	
123-11	22759-22769	processing	_	
123-12	22770-22773	and	_	
123-13	22774-22787	reinforcement	_	
123-14	22787-22788	,	_	
123-15	22789-22791	D2	_	
123-16	22791-22792	/	_	
123-17	22792-22794	D3	_	
123-18	22795-22803	receptor	_	
123-19	22804-22816	availability	_	
123-20	22817-22820	and	_	
123-21	22821-22829	dopamine	_	
123-22	22830-22847	neurotransmission	_	
123-23	22848-22850	in	_	
123-24	22851-22855	this	_	
123-25	22856-22865	structure	_	
123-26	22866-22869	has	_	
123-27	22870-22874	been	_	
123-28	22875-22884	suggested	_	
123-29	22885-22887	as	_	
123-30	22888-22889	a	_	
123-31	22890-22899	potential	_	
123-32	22900-22909	biomarker	_	
123-33	22910-22913	for	_	
123-34	22914-22927	vulnerability	_	
123-35	22928-22931	for	_	
123-36	22932-22941	substance	_	
123-37	22942-22945	use	_	
123-38	22946-22955	disorders	_	
123-39	22955-22956	,	_	
123-40	22957-22969	particularly	_	
123-41	22970-22972	in	_	
123-42	22973-22984	individuals	_	
123-43	22985-22989	with	_	
123-44	22990-22998	familial	_	
123-45	22999-23006	loading	_	
123-46	23006-23007	.	_	

#Text=The present study used multimodal imaging to evaluate reward responsivity in at-risk individuals using both PET and fMRI.
124-1	23008-23011	The	_	
124-2	23012-23019	present	_	
124-3	23020-23025	study	_	
124-4	23026-23030	used	_	
124-5	23031-23041	multimodal	_	
124-6	23042-23049	imaging	_	
124-7	23050-23052	to	_	
124-8	23053-23061	evaluate	_	
124-9	23062-23068	reward	_	
124-10	23069-23081	responsivity	_	
124-11	23082-23084	in	_	
124-12	23085-23092	at-risk	_	
124-13	23093-23104	individuals	_	
124-14	23105-23110	using	_	
124-15	23111-23115	both	_	
124-16	23116-23119	PET	_	
124-17	23120-23123	and	_	
124-18	23124-23128	fMRI	_	
124-19	23128-23129	.	_	

#Text=We report that FH+ subjects who report early drunkenness have heightened striatal dopamine response to monetary reward than either FH+ or FH- control subjects.
125-1	23130-23132	We	_	
125-2	23133-23139	report	_	
125-3	23140-23144	that	_	
125-4	23145-23147	FH	_	
125-5	23147-23148	+	_	
125-6	23149-23157	subjects	_	
125-7	23158-23161	who	_	
125-8	23162-23168	report	_	
125-9	23169-23174	early	_	
125-10	23175-23186	drunkenness	_	
125-11	23187-23191	have	_	
125-12	23192-23202	heightened	_	
125-13	23203-23211	striatal	_	
125-14	23212-23220	dopamine	_	
125-15	23221-23229	response	_	
125-16	23230-23232	to	_	
125-17	23233-23241	monetary	_	
125-18	23242-23248	reward	_	
125-19	23249-23253	than	_	
125-20	23254-23260	either	_	
125-21	23261-23263	FH	_	
125-22	23263-23264	+	_	
125-23	23265-23267	or	_	
125-24	23268-23270	FH	_	
125-25	23270-23271	-	_	
125-26	23272-23279	control	_	
125-27	23280-23288	subjects	_	
125-28	23288-23289	.	_	

#Text=Further, for all subjects, higher ventral striatal dopamine release was associated with earlier age of first drunkenness.
126-1	23290-23297	Further	_	
126-2	23297-23298	,	_	
126-3	23299-23302	for	_	
126-4	23303-23306	all	_	
126-5	23307-23315	subjects	_	
126-6	23315-23316	,	_	
126-7	23317-23323	higher	_	
126-8	23324-23331	ventral	_	
126-9	23332-23340	striatal	_	
126-10	23341-23349	dopamine	_	
126-11	23350-23357	release	_	
126-12	23358-23361	was	_	
126-13	23362-23372	associated	_	
126-14	23373-23377	with	_	
126-15	23378-23385	earlier	_	
126-16	23386-23389	age	_	
126-17	23390-23392	of	_	
126-18	23393-23398	first	_	
126-19	23399-23410	drunkenness	_	
126-20	23410-23411	.	_	

#Text=In addition, we found no group differences, by family history or early risk, in neural reactivity to monetary reward anticipation or feedback but we report across all subjects a positive relationship between dopaminergic release and neural response to reward receipt.
127-1	23412-23414	In	_	
127-2	23415-23423	addition	_	
127-3	23423-23424	,	_	
127-4	23425-23427	we	_	
127-5	23428-23433	found	_	
127-6	23434-23436	no	_	
127-7	23437-23442	group	_	
127-8	23443-23454	differences	_	
127-9	23454-23455	,	_	
127-10	23456-23458	by	_	
127-11	23459-23465	family	_	
127-12	23466-23473	history	_	
127-13	23474-23476	or	_	
127-14	23477-23482	early	_	
127-15	23483-23487	risk	_	
127-16	23487-23488	,	_	
127-17	23489-23491	in	_	
127-18	23492-23498	neural	_	
127-19	23499-23509	reactivity	_	
127-20	23510-23512	to	_	
127-21	23513-23521	monetary	_	
127-22	23522-23528	reward	_	
127-23	23529-23541	anticipation	_	
127-24	23542-23544	or	_	
127-25	23545-23553	feedback	_	
127-26	23554-23557	but	_	
127-27	23558-23560	we	_	
127-28	23561-23567	report	_	
127-29	23568-23574	across	_	
127-30	23575-23578	all	_	
127-31	23579-23587	subjects	_	
127-32	23588-23589	a	_	
127-33	23590-23598	positive	_	
127-34	23599-23611	relationship	_	
127-35	23612-23619	between	_	
127-36	23620-23632	dopaminergic	_	
127-37	23633-23640	release	_	
127-38	23641-23644	and	_	
127-39	23645-23651	neural	_	
127-40	23652-23660	response	_	
127-41	23661-23663	to	_	
127-42	23664-23670	reward	_	
127-43	23671-23678	receipt	_	
127-44	23678-23679	.	_	

#Text=These results suggest that in FH+ individuals, greater dopamine release associated with monetary reward may represent a particularly useful neurobiological phenotype.
128-1	23680-23685	These	_	
128-2	23686-23693	results	_	
128-3	23694-23701	suggest	_	
128-4	23702-23706	that	_	
128-5	23707-23709	in	_	
128-6	23710-23712	FH	_	
128-7	23712-23713	+	_	
128-8	23714-23725	individuals	_	
128-9	23725-23726	,	_	
128-10	23727-23734	greater	_	
128-11	23735-23743	dopamine	_	
128-12	23744-23751	release	_	
128-13	23752-23762	associated	_	
128-14	23763-23767	with	_	
128-15	23768-23776	monetary	_	
128-16	23777-23783	reward	_	
128-17	23784-23787	may	_	
128-18	23788-23797	represent	_	
128-19	23798-23799	a	_	
128-20	23800-23812	particularly	_	
128-21	23813-23819	useful	_	
128-22	23820-23835	neurobiological	_	
128-23	23836-23845	phenotype	_	
128-24	23845-23846	.	_	

#Text=Further, a behaviorally-induced method to interrogate dopamine function may be both practical, and in some cases, preferable to probing this system pharmacologically.
129-1	23847-23854	Further	_	
129-2	23854-23855	,	_	
129-3	23856-23857	a	_	
129-4	23858-23878	behaviorally-induced	_	
129-5	23879-23885	method	_	
129-6	23886-23888	to	_	
129-7	23889-23900	interrogate	_	
129-8	23901-23909	dopamine	_	
129-9	23910-23918	function	_	
129-10	23919-23922	may	_	
129-11	23923-23925	be	_	
129-12	23926-23930	both	_	
129-13	23931-23940	practical	_	
129-14	23940-23941	,	_	
129-15	23942-23945	and	_	
129-16	23946-23948	in	_	
129-17	23949-23953	some	_	
129-18	23954-23959	cases	_	
129-19	23959-23960	,	_	
129-20	23961-23971	preferable	_	
129-21	23972-23974	to	_	
129-22	23975-23982	probing	_	
129-23	23983-23987	this	_	
129-24	23988-23994	system	_	
129-25	23995-24012	pharmacologically	_	
129-26	24012-24013	.	_	

#Text=Much of the previous work evaluating the responsivity of the dopamine reward system has used stimulant challenges.
130-1	24014-24018	Much	_	
130-2	24019-24021	of	_	
130-3	24022-24025	the	_	
130-4	24026-24034	previous	_	
130-5	24035-24039	work	_	
130-6	24040-24050	evaluating	_	
130-7	24051-24054	the	_	
130-8	24055-24067	responsivity	_	
130-9	24068-24070	of	_	
130-10	24071-24074	the	_	
130-11	24075-24083	dopamine	_	
130-12	24084-24090	reward	_	
130-13	24091-24097	system	_	
130-14	24098-24101	has	_	
130-15	24102-24106	used	_	
130-16	24107-24116	stimulant	_	
130-17	24117-24127	challenges	_	
130-18	24127-24128	.	_	

#Text=Some early, important PET studies of substance use reported negative relationships between D2 receptor availability and self-reported pleasurable response to methylphenidate.
131-1	24129-24133	Some	_	
131-2	24134-24139	early	_	
131-3	24139-24140	,	_	
131-4	24141-24150	important	_	
131-5	24151-24154	PET	_	
131-6	24155-24162	studies	_	
131-7	24163-24165	of	_	
131-8	24166-24175	substance	_	
131-9	24176-24179	use	_	
131-10	24180-24188	reported	_	
131-11	24189-24197	negative	_	
131-12	24198-24211	relationships	_	
131-13	24212-24219	between	_	
131-14	24220-24222	D2	_	
131-15	24223-24231	receptor	_	
131-16	24232-24244	availability	_	
131-17	24245-24248	and	_	
131-18	24249-24262	self-reported	_	
131-19	24263-24274	pleasurable	_	
131-20	24275-24283	response	_	
131-21	24284-24286	to	_	
131-22	24287-24302	methylphenidate	_	
131-23	24302-24303	.	_	

#Text=These studies were followed with reports finding attenuated response to amphetamine administration in both alcohol and cocaine dependent individuals.
132-1	24304-24309	These	_	
132-2	24310-24317	studies	_	
132-3	24318-24322	were	_	
132-4	24323-24331	followed	_	
132-5	24332-24336	with	_	
132-6	24337-24344	reports	_	
132-7	24345-24352	finding	_	
132-8	24353-24363	attenuated	_	
132-9	24364-24372	response	_	
132-10	24373-24375	to	_	
132-11	24376-24387	amphetamine	_	
132-12	24388-24402	administration	_	
132-13	24403-24405	in	_	
132-14	24406-24410	both	_	
132-15	24411-24418	alcohol	_	
132-16	24419-24422	and	_	
132-17	24423-24430	cocaine	_	
132-18	24431-24440	dependent	_	
132-19	24441-24452	individuals	_	
132-20	24452-24453	.	_	

#Text=Moving the focus from substance-abusing populations to those at-risk, similar attenuated response to amphetamine was reported in FH+ subjects that engaged in recreational use of psychostimulants compared with FH- subjects that were drug-naïve as well as those with matched drug use.
133-1	24454-24460	Moving	_	
133-2	24461-24464	the	_	
133-3	24465-24470	focus	_	
133-4	24471-24475	from	_	
133-5	24476-24493	substance-abusing	_	
133-6	24494-24505	populations	_	
133-7	24506-24508	to	_	
133-8	24509-24514	those	_	
133-9	24515-24522	at-risk	_	
133-10	24522-24523	,	_	
133-11	24524-24531	similar	_	
133-12	24532-24542	attenuated	_	
133-13	24543-24551	response	_	
133-14	24552-24554	to	_	
133-15	24555-24566	amphetamine	_	
133-16	24567-24570	was	_	
133-17	24571-24579	reported	_	
133-18	24580-24582	in	_	
133-19	24583-24585	FH	_	
133-20	24585-24586	+	_	
133-21	24587-24595	subjects	_	
133-22	24596-24600	that	_	
133-23	24601-24608	engaged	_	
133-24	24609-24611	in	_	
133-25	24612-24624	recreational	_	
133-26	24625-24628	use	_	
133-27	24629-24631	of	_	
133-28	24632-24648	psychostimulants	_	
133-29	24649-24657	compared	_	
133-30	24658-24662	with	_	
133-31	24663-24665	FH	_	
133-32	24665-24666	-	_	
133-33	24667-24675	subjects	_	
133-34	24676-24680	that	_	
133-35	24681-24685	were	_	
133-36	24686-24696	drug-naïve	_	
133-37	24697-24699	as	_	
133-38	24700-24704	well	_	
133-39	24705-24707	as	_	
133-40	24708-24713	those	_	
133-41	24714-24718	with	_	
133-42	24719-24726	matched	_	
133-43	24727-24731	drug	_	
133-44	24732-24735	use	_	
133-45	24735-24736	.	_	

#Text=While a conflicting study reported no differences in striatal amphetamine response associated with familial loading, the level of risk in the latter study was lower both in terms of loading (fewer affected relatives) and behavior (less substance use).
134-1	24737-24742	While	_	
134-2	24743-24744	a	_	
134-3	24745-24756	conflicting	_	
134-4	24757-24762	study	_	
134-5	24763-24771	reported	_	
134-6	24772-24774	no	_	
134-7	24775-24786	differences	_	
134-8	24787-24789	in	_	
134-9	24790-24798	striatal	_	
134-10	24799-24810	amphetamine	_	
134-11	24811-24819	response	_	
134-12	24820-24830	associated	_	
134-13	24831-24835	with	_	
134-14	24836-24844	familial	_	
134-15	24845-24852	loading	_	
134-16	24852-24853	,	_	
134-17	24854-24857	the	_	
134-18	24858-24863	level	_	
134-19	24864-24866	of	_	
134-20	24867-24871	risk	_	
134-21	24872-24874	in	_	
134-22	24875-24878	the	_	
134-23	24879-24885	latter	_	
134-24	24886-24891	study	_	
134-25	24892-24895	was	_	
134-26	24896-24901	lower	_	
134-27	24902-24906	both	_	
134-28	24907-24909	in	_	
134-29	24910-24915	terms	_	
134-30	24916-24918	of	_	
134-31	24919-24926	loading	_	
134-32	24927-24928	(	_	
134-33	24928-24933	fewer	_	
134-34	24934-24942	affected	_	
134-35	24943-24952	relatives	_	
134-36	24952-24953	)	_	
134-37	24954-24957	and	_	
134-38	24958-24966	behavior	_	
134-39	24967-24968	(	_	
134-40	24968-24972	less	_	
134-41	24973-24982	substance	_	
134-42	24983-24986	use	_	
134-43	24986-24987	)	_	
134-44	24987-24988	.	_	

#Text=Other work has evaluated striatal dopamine response following alcohol consumption.
135-1	24989-24994	Other	_	
135-2	24995-24999	work	_	
135-3	25000-25003	has	_	
135-4	25004-25013	evaluated	_	
135-5	25014-25022	striatal	_	
135-6	25023-25031	dopamine	_	
135-7	25032-25040	response	_	
135-8	25041-25050	following	_	
135-9	25051-25058	alcohol	_	
135-10	25059-25070	consumption	_	
135-11	25070-25071	.	_	

#Text=In healthy individuals, increased striatal response followed oral consumption in some studies, but not all, with responses potentially dependent on spatial determination of striatal release or genetic polymorphisms.
136-1	25072-25074	In	_	
136-2	25075-25082	healthy	_	
136-3	25083-25094	individuals	_	
136-4	25094-25095	,	_	
136-5	25096-25105	increased	_	
136-6	25106-25114	striatal	_	
136-7	25115-25123	response	_	
136-8	25124-25132	followed	_	
136-9	25133-25137	oral	_	
136-10	25138-25149	consumption	_	
136-11	25150-25152	in	_	
136-12	25153-25157	some	_	
136-13	25158-25165	studies	_	
136-14	25165-25166	,	_	
136-15	25167-25170	but	_	
136-16	25171-25174	not	_	
136-17	25175-25178	all	_	
136-18	25178-25179	,	_	
136-19	25180-25184	with	_	
136-20	25185-25194	responses	_	
136-21	25195-25206	potentially	_	
136-22	25207-25216	dependent	_	
136-23	25217-25219	on	_	
136-24	25220-25227	spatial	_	
136-25	25228-25241	determination	_	
136-26	25242-25244	of	_	
136-27	25245-25253	striatal	_	
136-28	25254-25261	release	_	
136-29	25262-25264	or	_	
136-30	25265-25272	genetic	_	
136-31	25273-25286	polymorphisms	_	
136-32	25286-25287	.	_	

#Text=With respect to risk, Setiawan and colleagues found that subjects designated high-risk based on subjective sensitivity to alcohol had increased dopamine transmission following an oral challenge, and higher familial loading, than subjects with lower sensitivity.
137-1	25288-25292	With	_	
137-2	25293-25300	respect	_	
137-3	25301-25303	to	_	
137-4	25304-25308	risk	_	
137-5	25308-25309	,	_	
137-6	25310-25318	Setiawan	_	
137-7	25319-25322	and	_	
137-8	25323-25333	colleagues	_	
137-9	25334-25339	found	_	
137-10	25340-25344	that	_	
137-11	25345-25353	subjects	_	
137-12	25354-25364	designated	_	
137-13	25365-25374	high-risk	_	
137-14	25375-25380	based	_	
137-15	25381-25383	on	_	
137-16	25384-25394	subjective	_	
137-17	25395-25406	sensitivity	_	
137-18	25407-25409	to	_	
137-19	25410-25417	alcohol	_	
137-20	25418-25421	had	_	
137-21	25422-25431	increased	_	
137-22	25432-25440	dopamine	_	
137-23	25441-25453	transmission	_	
137-24	25454-25463	following	_	
137-25	25464-25466	an	_	
137-26	25467-25471	oral	_	
137-27	25472-25481	challenge	_	
137-28	25481-25482	,	_	
137-29	25483-25486	and	_	
137-30	25487-25493	higher	_	
137-31	25494-25502	familial	_	
137-32	25503-25510	loading	_	
137-33	25510-25511	,	_	
137-34	25512-25516	than	_	
137-35	25517-25525	subjects	_	
137-36	25526-25530	with	_	
137-37	25531-25536	lower	_	
137-38	25537-25548	sensitivity	_	
137-39	25548-25549	.	_	

#Text=Given the heterogeneous results of both stimulant and alcohol induction of dopamine response, as well as a concern of using drug challenges in at-risk populations, the use of the MID task in PET studies represents a feasible method of discriminating risk.
138-1	25550-25555	Given	_	
138-2	25556-25559	the	_	
138-3	25560-25573	heterogeneous	_	
138-4	25574-25581	results	_	
138-5	25582-25584	of	_	
138-6	25585-25589	both	_	
138-7	25590-25599	stimulant	_	
138-8	25600-25603	and	_	
138-9	25604-25611	alcohol	_	
138-10	25612-25621	induction	_	
138-11	25622-25624	of	_	
138-12	25625-25633	dopamine	_	
138-13	25634-25642	response	_	
138-14	25642-25643	,	_	
138-15	25644-25646	as	_	
138-16	25647-25651	well	_	
138-17	25652-25654	as	_	
138-18	25655-25656	a	_	
138-19	25657-25664	concern	_	
138-20	25665-25667	of	_	
138-21	25668-25673	using	_	
138-22	25674-25678	drug	_	
138-23	25679-25689	challenges	_	
138-24	25690-25692	in	_	
138-25	25693-25700	at-risk	_	
138-26	25701-25712	populations	_	
138-27	25712-25713	,	_	
138-28	25714-25717	the	_	
138-29	25718-25721	use	_	
138-30	25722-25724	of	_	
138-31	25725-25728	the	_	
138-32	25729-25732	MID	_	
138-33	25733-25737	task	_	
138-34	25738-25740	in	_	
138-35	25741-25744	PET	_	
138-36	25745-25752	studies	_	
138-37	25753-25763	represents	_	
138-38	25764-25765	a	_	
138-39	25766-25774	feasible	_	
138-40	25775-25781	method	_	
138-41	25782-25784	of	_	
138-42	25785-25799	discriminating	_	
138-43	25800-25804	risk	_	
138-44	25804-25805	.	_	

#Text=Our results suggest that high-risk subjects, indexed by their early intoxication, have increased response to monetary reward.
139-1	25806-25809	Our	_	
139-2	25810-25817	results	_	
139-3	25818-25825	suggest	_	
139-4	25826-25830	that	_	
139-5	25831-25840	high-risk	_	
139-6	25841-25849	subjects	_	
139-7	25849-25850	,	_	
139-8	25851-25858	indexed	_	
139-9	25859-25861	by	_	
139-10	25862-25867	their	_	
139-11	25868-25873	early	_	
139-12	25874-25886	intoxication	_	
139-13	25886-25887	,	_	
139-14	25888-25892	have	_	
139-15	25893-25902	increased	_	
139-16	25903-25911	response	_	
139-17	25912-25914	to	_	
139-18	25915-25923	monetary	_	
139-19	25924-25930	reward	_	
139-20	25930-25931	.	_	

#Text=The current levels of alcohol consumption (∼12 drinks/week) are similar to those of the high-risk group in the alcohol challenge study (∼13 drinks/week) by.
140-1	25932-25935	The	_	
140-2	25936-25943	current	_	
140-3	25944-25950	levels	_	
140-4	25951-25953	of	_	
140-5	25954-25961	alcohol	_	
140-6	25962-25973	consumption	_	
140-7	25974-25975	(	_	
140-8	25975-25976	∼	_	
140-9	25976-25978	12	_	
140-10	25979-25985	drinks	_	
140-11	25985-25986	/	_	
140-12	25986-25990	week	_	
140-13	25990-25991	)	_	
140-14	25992-25995	are	_	
140-15	25996-26003	similar	_	
140-16	26004-26006	to	_	
140-17	26007-26012	those	_	
140-18	26013-26015	of	_	
140-19	26016-26019	the	_	
140-20	26020-26029	high-risk	_	
140-21	26030-26035	group	_	
140-22	26036-26038	in	_	
140-23	26039-26042	the	_	
140-24	26043-26050	alcohol	_	
140-25	26051-26060	challenge	_	
140-26	26061-26066	study	_	
140-27	26067-26068	(	_	
140-28	26068-26069	∼	_	
140-29	26069-26071	13	_	
140-30	26072-26078	drinks	_	
140-31	26078-26079	/	_	
140-32	26079-26083	week	_	
140-33	26083-26084	)	_	
140-34	26085-26087	by	_	
140-35	26087-26088	.	_	

#Text=In fact, both the present study and that study lend support to a recent neurodevelopmental model of vulnerability to addiction presented by.
141-1	26089-26091	In	_	
141-2	26092-26096	fact	_	
141-3	26096-26097	,	_	
141-4	26098-26102	both	_	
141-5	26103-26106	the	_	
141-6	26107-26114	present	_	
141-7	26115-26120	study	_	
141-8	26121-26124	and	_	
141-9	26125-26129	that	_	
141-10	26130-26135	study	_	
141-11	26136-26140	lend	_	
141-12	26141-26148	support	_	
141-13	26149-26151	to	_	
141-14	26152-26153	a	_	
141-15	26154-26160	recent	_	
141-16	26161-26179	neurodevelopmental	_	
141-17	26180-26185	model	_	
141-18	26186-26188	of	_	
141-19	26189-26202	vulnerability	_	
141-20	26203-26205	to	_	
141-21	26206-26215	addiction	_	
141-22	26216-26225	presented	_	
141-23	26226-26228	by	_	
141-24	26228-26229	.	_	

#Text=This model hypothesizes that vulnerable individuals may have heightened responsivity to a variety of salient stimuli which may translate into risk-taking behaviors, including experimentation with drugs.
142-1	26230-26234	This	_	
142-2	26235-26240	model	_	
142-3	26241-26253	hypothesizes	_	
142-4	26254-26258	that	_	
142-5	26259-26269	vulnerable	_	
142-6	26270-26281	individuals	_	
142-7	26282-26285	may	_	
142-8	26286-26290	have	_	
142-9	26291-26301	heightened	_	
142-10	26302-26314	responsivity	_	
142-11	26315-26317	to	_	
142-12	26318-26319	a	_	
142-13	26320-26327	variety	_	
142-14	26328-26330	of	_	
142-15	26331-26338	salient	_	
142-16	26339-26346	stimuli	_	
142-17	26347-26352	which	_	
142-18	26353-26356	may	_	
142-19	26357-26366	translate	_	
142-20	26367-26371	into	_	
142-21	26372-26383	risk-taking	_	
142-22	26384-26393	behaviors	_	
142-23	26393-26394	,	_	
142-24	26395-26404	including	_	
142-25	26405-26420	experimentation	_	
142-26	26421-26425	with	_	
142-27	26426-26431	drugs	_	
142-28	26431-26432	.	_	

#Text=If substance use is initiated and continued, this use would become associated with cues through conditioning and sensitization, eventually leading to accentuated response to drug-cues and attenuated response to non-drug rewards.
143-1	26433-26435	If	_	
143-2	26436-26445	substance	_	
143-3	26446-26449	use	_	
143-4	26450-26452	is	_	
143-5	26453-26462	initiated	_	
143-6	26463-26466	and	_	
143-7	26467-26476	continued	_	
143-8	26476-26477	,	_	
143-9	26478-26482	this	_	
143-10	26483-26486	use	_	
143-11	26487-26492	would	_	
143-12	26493-26499	become	_	
143-13	26500-26510	associated	_	
143-14	26511-26515	with	_	
143-15	26516-26520	cues	_	
143-16	26521-26528	through	_	
143-17	26529-26541	conditioning	_	
143-18	26542-26545	and	_	
143-19	26546-26559	sensitization	_	
143-20	26559-26560	,	_	
143-21	26561-26571	eventually	_	
143-22	26572-26579	leading	_	
143-23	26580-26582	to	_	
143-24	26583-26594	accentuated	_	
143-25	26595-26603	response	_	
143-26	26604-26606	to	_	
143-27	26607-26616	drug-cues	_	
143-28	26617-26620	and	_	
143-29	26621-26631	attenuated	_	
143-30	26632-26640	response	_	
143-31	26641-26643	to	_	
143-32	26644-26652	non-drug	_	
143-33	26653-26660	rewards	_	
143-34	26660-26661	.	_	

#Text=In support of this model, Casey et al. has shown that current substance users had low dopamine release associated with an amphetamine challenges which had no drug cues present in contrast to the increased dopamine release associated with an alcohol challenge which involves multiple sensory cues associated with oral consumption.
144-1	26662-26664	In	_	
144-2	26665-26672	support	_	
144-3	26673-26675	of	_	
144-4	26676-26680	this	_	
144-5	26681-26686	model	_	
144-6	26686-26687	,	_	
144-7	26688-26693	Casey	_	
144-8	26694-26696	et	_	
144-9	26697-26699	al	_	
144-10	26699-26700	.	_	
144-11	26701-26704	has	_	
144-12	26705-26710	shown	_	
144-13	26711-26715	that	_	
144-14	26716-26723	current	_	
144-15	26724-26733	substance	_	
144-16	26734-26739	users	_	
144-17	26740-26743	had	_	
144-18	26744-26747	low	_	
144-19	26748-26756	dopamine	_	
144-20	26757-26764	release	_	
144-21	26765-26775	associated	_	
144-22	26776-26780	with	_	
144-23	26781-26783	an	_	
144-24	26784-26795	amphetamine	_	
144-25	26796-26806	challenges	_	
144-26	26807-26812	which	_	
144-27	26813-26816	had	_	
144-28	26817-26819	no	_	
144-29	26820-26824	drug	_	
144-30	26825-26829	cues	_	
144-31	26830-26837	present	_	
144-32	26838-26840	in	_	
144-33	26841-26849	contrast	_	
144-34	26850-26852	to	_	
144-35	26853-26856	the	_	
144-36	26857-26866	increased	_	
144-37	26867-26875	dopamine	_	
144-38	26876-26883	release	_	
144-39	26884-26894	associated	_	
144-40	26895-26899	with	_	
144-41	26900-26902	an	_	
144-42	26903-26910	alcohol	_	
144-43	26911-26920	challenge	_	
144-44	26921-26926	which	_	
144-45	26927-26935	involves	_	
144-46	26936-26944	multiple	_	
144-47	26945-26952	sensory	_	
144-48	26953-26957	cues	_	
144-49	26958-26968	associated	_	
144-50	26969-26973	with	_	
144-51	26974-26978	oral	_	
144-52	26979-26990	consumption	_	
144-53	26990-26991	.	_	

#Text=Given that none of our high-risk subjects have reached a diagnosis of alcohol dependence, and analysis without the single subject with a marijuana dependence diagnosis had no effect on our findings, we would suggest that these subjects are still in the ‘early’ vulnerability stage where the reward system has not become conditioned to focus on drug cues.
145-1	26992-26997	Given	_	
145-2	26998-27002	that	_	
145-3	27003-27007	none	_	
145-4	27008-27010	of	_	
145-5	27011-27014	our	_	
145-6	27015-27024	high-risk	_	
145-7	27025-27033	subjects	_	
145-8	27034-27038	have	_	
145-9	27039-27046	reached	_	
145-10	27047-27048	a	_	
145-11	27049-27058	diagnosis	_	
145-12	27059-27061	of	_	
145-13	27062-27069	alcohol	_	
145-14	27070-27080	dependence	_	
145-15	27080-27081	,	_	
145-16	27082-27085	and	_	
145-17	27086-27094	analysis	_	
145-18	27095-27102	without	_	
145-19	27103-27106	the	_	
145-20	27107-27113	single	_	
145-21	27114-27121	subject	_	
145-22	27122-27126	with	_	
145-23	27127-27128	a	_	
145-24	27129-27138	marijuana	_	
145-25	27139-27149	dependence	_	
145-26	27150-27159	diagnosis	_	
145-27	27160-27163	had	_	
145-28	27164-27166	no	_	
145-29	27167-27173	effect	_	
145-30	27174-27176	on	_	
145-31	27177-27180	our	_	
145-32	27181-27189	findings	_	
145-33	27189-27190	,	_	
145-34	27191-27193	we	_	
145-35	27194-27199	would	_	
145-36	27200-27207	suggest	_	
145-37	27208-27212	that	_	
145-38	27213-27218	these	_	
145-39	27219-27227	subjects	_	
145-40	27228-27231	are	_	
145-41	27232-27237	still	_	
145-42	27238-27240	in	_	
145-43	27241-27244	the	_	
145-44	27245-27246	‘	_	
145-45	27246-27251	early	_	
145-46	27251-27252	’	_	
145-47	27253-27266	vulnerability	_	
145-48	27267-27272	stage	_	
145-49	27273-27278	where	_	
145-50	27279-27282	the	_	
145-51	27283-27289	reward	_	
145-52	27290-27296	system	_	
145-53	27297-27300	has	_	
145-54	27301-27304	not	_	
145-55	27305-27311	become	_	
145-56	27312-27323	conditioned	_	
145-57	27324-27326	to	_	
145-58	27327-27332	focus	_	
145-59	27333-27335	on	_	
145-60	27336-27340	drug	_	
145-61	27341-27345	cues	_	
145-62	27345-27346	.	_	

#Text=Continued longitudinal scans, which are ongoing in our sample, may potentially identify a transition in cue responding in those subjects who reach diagnosis in the future.
146-1	27347-27356	Continued	_	
146-2	27357-27369	longitudinal	_	
146-3	27370-27375	scans	_	
146-4	27375-27376	,	_	
146-5	27377-27382	which	_	
146-6	27383-27386	are	_	
146-7	27387-27394	ongoing	_	
146-8	27395-27397	in	_	
146-9	27398-27401	our	_	
146-10	27402-27408	sample	_	
146-11	27408-27409	,	_	
146-12	27410-27413	may	_	
146-13	27414-27425	potentially	_	
146-14	27426-27434	identify	_	
146-15	27435-27436	a	_	
146-16	27437-27447	transition	_	
146-17	27448-27450	in	_	
146-18	27451-27454	cue	_	
146-19	27455-27465	responding	_	
146-20	27466-27468	in	_	
146-21	27469-27474	those	_	
146-22	27475-27483	subjects	_	
146-23	27484-27487	who	_	
146-24	27488-27493	reach	_	
146-25	27494-27503	diagnosis	_	
146-26	27504-27506	in	_	
146-27	27507-27510	the	_	
146-28	27511-27517	future	_	
146-29	27517-27518	.	_	

#Text=In addition, our lack of group differences, either by family history or risk level, in binding levels during the control condition, while not the conventional method of measurement, may suggest that preexisting receptor levels are not contributing to risk.
147-1	27519-27521	In	_	
147-2	27522-27530	addition	_	
147-3	27530-27531	,	_	
147-4	27532-27535	our	_	
147-5	27536-27540	lack	_	
147-6	27541-27543	of	_	
147-7	27544-27549	group	_	
147-8	27550-27561	differences	_	
147-9	27561-27562	,	_	
147-10	27563-27569	either	_	
147-11	27570-27572	by	_	
147-12	27573-27579	family	_	
147-13	27580-27587	history	_	
147-14	27588-27590	or	_	
147-15	27591-27595	risk	_	
147-16	27596-27601	level	_	
147-17	27601-27602	,	_	
147-18	27603-27605	in	_	
147-19	27606-27613	binding	_	
147-20	27614-27620	levels	_	
147-21	27621-27627	during	_	
147-22	27628-27631	the	_	
147-23	27632-27639	control	_	
147-24	27640-27649	condition	_	
147-25	27649-27650	,	_	
147-26	27651-27656	while	_	
147-27	27657-27660	not	_	
147-28	27661-27664	the	_	
147-29	27665-27677	conventional	_	
147-30	27678-27684	method	_	
147-31	27685-27687	of	_	
147-32	27688-27699	measurement	_	
147-33	27699-27700	,	_	
147-34	27701-27704	may	_	
147-35	27705-27712	suggest	_	
147-36	27713-27717	that	_	
147-37	27718-27729	preexisting	_	
147-38	27730-27738	receptor	_	
147-39	27739-27745	levels	_	
147-40	27746-27749	are	_	
147-41	27750-27753	not	_	
147-42	27754-27766	contributing	_	
147-43	27767-27769	to	_	
147-44	27770-27774	risk	_	
147-45	27774-27775	.	_	

#Text=In addition to dopamine BPND and release, neural reward responsivity has also been investigated as a potential biomarker of risk.
148-1	27776-27778	In	_	
148-2	27779-27787	addition	_	
148-3	27788-27790	to	_	
148-4	27791-27799	dopamine	_	
148-5	27800-27804	BPND	_	
148-6	27805-27808	and	_	
148-7	27809-27816	release	_	
148-8	27816-27817	,	_	
148-9	27818-27824	neural	_	
148-10	27825-27831	reward	_	
148-11	27832-27844	responsivity	_	
148-12	27845-27848	has	_	
148-13	27849-27853	also	_	
148-14	27854-27858	been	_	
148-15	27859-27871	investigated	_	
148-16	27872-27874	as	_	
148-17	27875-27876	a	_	
148-18	27877-27886	potential	_	
148-19	27887-27896	biomarker	_	
148-20	27897-27899	of	_	
148-21	27900-27904	risk	_	
148-22	27904-27905	.	_	

#Text=For example, our prior work reported blunted activation to reward anticipation in FH+ young adults with low levels of alcohol use compared with FH- young adults.
149-1	27906-27909	For	_	
149-2	27910-27917	example	_	
149-3	27917-27918	,	_	
149-4	27919-27922	our	_	
149-5	27923-27928	prior	_	
149-6	27929-27933	work	_	
149-7	27934-27942	reported	_	
149-8	27943-27950	blunted	_	
149-9	27951-27961	activation	_	
149-10	27962-27964	to	_	
149-11	27965-27971	reward	_	
149-12	27972-27984	anticipation	_	
149-13	27985-27987	in	_	
149-14	27988-27990	FH	_	
149-15	27990-27991	+	_	
149-16	27992-27997	young	_	
149-17	27998-28004	adults	_	
149-18	28005-28009	with	_	
149-19	28010-28013	low	_	
149-20	28014-28020	levels	_	
149-21	28021-28023	of	_	
149-22	28024-28031	alcohol	_	
149-23	28032-28035	use	_	
149-24	28036-28044	compared	_	
149-25	28045-28049	with	_	
149-26	28050-28052	FH	_	
149-27	28052-28053	-	_	
149-28	28054-28059	young	_	
149-29	28060-28066	adults	_	
149-30	28066-28067	.	_	

#Text=However, FH+ young adults who were risky drinkers did not differ from FH- young adults matched on drinking, which suggests that blunted activation may be a resilience mechanisms in FH+.
150-1	28068-28075	However	_	
150-2	28075-28076	,	_	
150-3	28077-28079	FH	_	
150-4	28079-28080	+	_	
150-5	28081-28086	young	_	
150-6	28087-28093	adults	_	
150-7	28094-28097	who	_	
150-8	28098-28102	were	_	
150-9	28103-28108	risky	_	
150-10	28109-28117	drinkers	_	
150-11	28118-28121	did	_	
150-12	28122-28125	not	_	
150-13	28126-28132	differ	_	
150-14	28133-28137	from	_	
150-15	28138-28140	FH	_	
150-16	28140-28141	-	_	
150-17	28142-28147	young	_	
150-18	28148-28154	adults	_	
150-19	28155-28162	matched	_	
150-20	28163-28165	on	_	
150-21	28166-28174	drinking	_	
150-22	28174-28175	,	_	
150-23	28176-28181	which	_	
150-24	28182-28190	suggests	_	
150-25	28191-28195	that	_	
150-26	28196-28203	blunted	_	
150-27	28204-28214	activation	_	
150-28	28215-28218	may	_	
150-29	28219-28221	be	_	
150-30	28222-28223	a	_	
150-31	28224-28234	resilience	_	
150-32	28235-28245	mechanisms	_	
150-33	28246-28248	in	_	
150-34	28249-28251	FH	_	
150-35	28251-28252	+	_	
150-36	28252-28253	.	_	

#Text=In a follow-up repeated measures analysis with a larger sample (n = 175; scans = 473), across a larger age range (8-27 years), we did not find an effect of family history but reported a quadratic association with age where adolescents displayed amplified striatal response which was related to later problem alcohol use.
151-1	28254-28256	In	_	
151-2	28257-28258	a	_	
151-3	28259-28268	follow-up	_	
151-4	28269-28277	repeated	_	
151-5	28278-28286	measures	_	
151-6	28287-28295	analysis	_	
151-7	28296-28300	with	_	
151-8	28301-28302	a	_	
151-9	28303-28309	larger	_	
151-10	28310-28316	sample	_	
151-11	28317-28318	(	_	
151-12	28318-28319	n	_	
151-13	28320-28321	=	_	
151-14	28322-28325	175	_	
151-15	28325-28326	;	_	
151-16	28327-28332	scans	_	
151-17	28333-28334	=	_	
151-18	28335-28338	473	_	
151-19	28338-28339	)	_	
151-20	28339-28340	,	_	
151-21	28341-28347	across	_	
151-22	28348-28349	a	_	
151-23	28350-28356	larger	_	
151-24	28357-28360	age	_	
151-25	28361-28366	range	_	
151-26	28367-28368	(	_	
151-27	28368-28369	8	_	
151-28	28369-28370	-	_	
151-29	28370-28372	27	_	
151-30	28373-28378	years	_	
151-31	28378-28379	)	_	
151-32	28379-28380	,	_	
151-33	28381-28383	we	_	
151-34	28384-28387	did	_	
151-35	28388-28391	not	_	
151-36	28392-28396	find	_	
151-37	28397-28399	an	_	
151-38	28400-28406	effect	_	
151-39	28407-28409	of	_	
151-40	28410-28416	family	_	
151-41	28417-28424	history	_	
151-42	28425-28428	but	_	
151-43	28429-28437	reported	_	
151-44	28438-28439	a	_	
151-45	28440-28449	quadratic	_	
151-46	28450-28461	association	_	
151-47	28462-28466	with	_	
151-48	28467-28470	age	_	
151-49	28471-28476	where	_	
151-50	28477-28488	adolescents	_	
151-51	28489-28498	displayed	_	
151-52	28499-28508	amplified	_	
151-53	28509-28517	striatal	_	
151-54	28518-28526	response	_	
151-55	28527-28532	which	_	
151-56	28533-28536	was	_	
151-57	28537-28544	related	_	
151-58	28545-28547	to	_	
151-59	28548-28553	later	_	
151-60	28554-28561	problem	_	
151-61	28562-28569	alcohol	_	
151-62	28570-28573	use	_	
151-63	28573-28574	.	_	

#Text=Indeed, the literature has been heterogeneous in establishing a familial effect, with some studies reporting differences based on family loading (i.e. while others – notably in younger samples - have not (i.e..
152-1	28575-28581	Indeed	_	
152-2	28581-28582	,	_	
152-3	28583-28586	the	_	
152-4	28587-28597	literature	_	
152-5	28598-28601	has	_	
152-6	28602-28606	been	_	
152-7	28607-28620	heterogeneous	_	
152-8	28621-28623	in	_	
152-9	28624-28636	establishing	_	
152-10	28637-28638	a	_	
152-11	28639-28647	familial	_	
152-12	28648-28654	effect	_	
152-13	28654-28655	,	_	
152-14	28656-28660	with	_	
152-15	28661-28665	some	_	
152-16	28666-28673	studies	_	
152-17	28674-28683	reporting	_	
152-18	28684-28695	differences	_	
152-19	28696-28701	based	_	
152-20	28702-28704	on	_	
152-21	28705-28711	family	_	
152-22	28712-28719	loading	_	
152-23	28720-28721	(	_	
152-24	28721-28724	i.e	_	
152-25	28724-28725	.	_	
152-26	28726-28731	while	_	
152-27	28732-28738	others	_	
152-28	28739-28740	–	_	
152-29	28741-28748	notably	_	
152-30	28749-28751	in	_	
152-31	28752-28759	younger	_	
152-32	28760-28767	samples	_	
152-33	28768-28769	-	_	
152-34	28770-28774	have	_	
152-35	28775-28778	not	_	
152-36	28779-28780	(	_	
152-37	28780-28783	i.e	_	
152-38	28783-28784	.	_	
152-39	28784-28785	.	_	

#Text=This heterogeneity may be related not only to development, but also to variations in task design and analysis methods (Balodis and Potenza).
153-1	28786-28790	This	_	
153-2	28791-28804	heterogeneity	_	
153-3	28805-28808	may	_	
153-4	28809-28811	be	_	
153-5	28812-28819	related	_	
153-6	28820-28823	not	_	
153-7	28824-28828	only	_	
153-8	28829-28831	to	_	
153-9	28832-28843	development	_	
153-10	28843-28844	,	_	
153-11	28845-28848	but	_	
153-12	28849-28853	also	_	
153-13	28854-28856	to	_	
153-14	28857-28867	variations	_	
153-15	28868-28870	in	_	
153-16	28871-28875	task	_	
153-17	28876-28882	design	_	
153-18	28883-28886	and	_	
153-19	28887-28895	analysis	_	
153-20	28896-28903	methods	_	
153-21	28904-28905	(	_	
153-22	28905-28912	Balodis	_	
153-23	28913-28916	and	_	
153-24	28917-28924	Potenza	_	
153-25	28924-28925	)	_	
153-26	28925-28926	.	_	

#Text=The lack of a family history effect is in agreement with our more recent work but may also be partly attributable to the relatively small sample size of the current study as an fMRI experiment.
154-1	28927-28930	The	_	
154-2	28931-28935	lack	_	
154-3	28936-28938	of	_	
154-4	28939-28940	a	_	
154-5	28941-28947	family	_	
154-6	28948-28955	history	_	
154-7	28956-28962	effect	_	
154-8	28963-28965	is	_	
154-9	28966-28968	in	_	
154-10	28969-28978	agreement	_	
154-11	28979-28983	with	_	
154-12	28984-28987	our	_	
154-13	28988-28992	more	_	
154-14	28993-28999	recent	_	
154-15	29000-29004	work	_	
154-16	29005-29008	but	_	
154-17	29009-29012	may	_	
154-18	29013-29017	also	_	
154-19	29018-29020	be	_	
154-20	29021-29027	partly	_	
154-21	29028-29040	attributable	_	
154-22	29041-29043	to	_	
154-23	29044-29047	the	_	
154-24	29048-29058	relatively	_	
154-25	29059-29064	small	_	
154-26	29065-29071	sample	_	
154-27	29072-29076	size	_	
154-28	29077-29079	of	_	
154-29	29080-29083	the	_	
154-30	29084-29091	current	_	
154-31	29092-29097	study	_	
154-32	29098-29100	as	_	
154-33	29101-29103	an	_	
154-34	29104-29108	fMRI	_	
154-35	29109-29119	experiment	_	
154-36	29119-29120	.	_	

#Text=Of particular interest, we report a positive relationship between striatal dopamine release associated with monetary reward and neural activation associated with positive reward feedback across all subjects.
155-1	29121-29123	Of	_	
155-2	29124-29134	particular	_	
155-3	29135-29143	interest	_	
155-4	29143-29144	,	_	
155-5	29145-29147	we	_	
155-6	29148-29154	report	_	
155-7	29155-29156	a	_	
155-8	29157-29165	positive	_	
155-9	29166-29178	relationship	_	
155-10	29179-29186	between	_	
155-11	29187-29195	striatal	_	
155-12	29196-29204	dopamine	_	
155-13	29205-29212	release	_	
155-14	29213-29223	associated	_	
155-15	29224-29228	with	_	
155-16	29229-29237	monetary	_	
155-17	29238-29244	reward	_	
155-18	29245-29248	and	_	
155-19	29249-29255	neural	_	
155-20	29256-29266	activation	_	
155-21	29267-29277	associated	_	
155-22	29278-29282	with	_	
155-23	29283-29291	positive	_	
155-24	29292-29298	reward	_	
155-25	29299-29307	feedback	_	
155-26	29308-29314	across	_	
155-27	29315-29318	all	_	
155-28	29319-29327	subjects	_	
155-29	29327-29328	.	_	

#Text=Other work using the MID in both PET and fMRI has reported a relationship between ventral striatal dopamine release and anticipatory accumbens activation with the suggestion that either local dopamine release may trigger local blood oxygenation level dependent signal or, conversely, be the consequence of increased neural activation.
156-1	29329-29334	Other	_	
156-2	29335-29339	work	_	
156-3	29340-29345	using	_	
156-4	29346-29349	the	_	
156-5	29350-29353	MID	_	
156-6	29354-29356	in	_	
156-7	29357-29361	both	_	
156-8	29362-29365	PET	_	
156-9	29366-29369	and	_	
156-10	29370-29374	fMRI	_	
156-11	29375-29378	has	_	
156-12	29379-29387	reported	_	
156-13	29388-29389	a	_	
156-14	29390-29402	relationship	_	
156-15	29403-29410	between	_	
156-16	29411-29418	ventral	_	
156-17	29419-29427	striatal	_	
156-18	29428-29436	dopamine	_	
156-19	29437-29444	release	_	
156-20	29445-29448	and	_	
156-21	29449-29461	anticipatory	_	
156-22	29462-29471	accumbens	_	
156-23	29472-29482	activation	_	
156-24	29483-29487	with	_	
156-25	29488-29491	the	_	
156-26	29492-29502	suggestion	_	
156-27	29503-29507	that	_	
156-28	29508-29514	either	_	
156-29	29515-29520	local	_	
156-30	29521-29529	dopamine	_	
156-31	29530-29537	release	_	
156-32	29538-29541	may	_	
156-33	29542-29549	trigger	_	
156-34	29550-29555	local	_	
156-35	29556-29561	blood	_	
156-36	29562-29573	oxygenation	_	
156-37	29574-29579	level	_	
156-38	29580-29589	dependent	_	
156-39	29590-29596	signal	_	
156-40	29597-29599	or	_	
156-41	29599-29600	,	_	
156-42	29601-29611	conversely	_	
156-43	29611-29612	,	_	
156-44	29613-29615	be	_	
156-45	29616-29619	the	_	
156-46	29620-29631	consequence	_	
156-47	29632-29634	of	_	
156-48	29635-29644	increased	_	
156-49	29645-29651	neural	_	
156-50	29652-29662	activation	_	
156-51	29662-29663	.	_	

#Text=Given the larger sample size in this study (n=44) compared to Schott et al (n=14), it is interesting that we did not duplicate their finding.
157-1	29664-29669	Given	_	
157-2	29670-29673	the	_	
157-3	29674-29680	larger	_	
157-4	29681-29687	sample	_	
157-5	29688-29692	size	_	
157-6	29693-29695	in	_	
157-7	29696-29700	this	_	
157-8	29701-29706	study	_	
157-9	29707-29708	(	_	
157-10	29708-29709	n	_	
157-11	29709-29710	=	_	
157-12	29710-29712	44	_	
157-13	29712-29713	)	_	
157-14	29714-29722	compared	_	
157-15	29723-29725	to	_	
157-16	29726-29732	Schott	_	
157-17	29733-29735	et	_	
157-18	29736-29738	al	_	
157-19	29739-29740	(	_	
157-20	29740-29741	n	_	
157-21	29741-29742	=	_	
157-22	29742-29744	14	_	
157-23	29744-29745	)	_	
157-24	29745-29746	,	_	
157-25	29747-29749	it	_	
157-26	29750-29752	is	_	
157-27	29753-29764	interesting	_	
157-28	29765-29769	that	_	
157-29	29770-29772	we	_	
157-30	29773-29776	did	_	
157-31	29777-29780	not	_	
157-32	29781-29790	duplicate	_	
157-33	29791-29796	their	_	
157-34	29797-29804	finding	_	
157-35	29804-29805	.	_	

#Text=That study performed a regression between NAcc dopamine release and anticipatory response but not feedback response.
158-1	29806-29810	That	_	
158-2	29811-29816	study	_	
158-3	29817-29826	performed	_	
158-4	29827-29828	a	_	
158-5	29829-29839	regression	_	
158-6	29840-29847	between	_	
158-7	29848-29852	NAcc	_	
158-8	29853-29861	dopamine	_	
158-9	29862-29869	release	_	
158-10	29870-29873	and	_	
158-11	29874-29886	anticipatory	_	
158-12	29887-29895	response	_	
158-13	29896-29899	but	_	
158-14	29900-29903	not	_	
158-15	29904-29912	feedback	_	
158-16	29913-29921	response	_	
158-17	29921-29922	.	_	

#Text=Dependent on study design, there is often considerable collinearity and potential confound between the anticipatory and feedback responses.
159-1	29923-29932	Dependent	_	
159-2	29933-29935	on	_	
159-3	29936-29941	study	_	
159-4	29942-29948	design	_	
159-5	29948-29949	,	_	
159-6	29950-29955	there	_	
159-7	29956-29958	is	_	
159-8	29959-29964	often	_	
159-9	29965-29977	considerable	_	
159-10	29978-29990	collinearity	_	
159-11	29991-29994	and	_	
159-12	29995-30004	potential	_	
159-13	30005-30013	confound	_	
159-14	30014-30021	between	_	
159-15	30022-30025	the	_	
159-16	30026-30038	anticipatory	_	
159-17	30039-30042	and	_	
159-18	30043-30051	feedback	_	
159-19	30052-30061	responses	_	
159-20	30061-30062	.	_	

#Text=Other fMRI studies have demonstrated that feedback of performance activates the ventral striatum and, in fact, as opposed to the dorsal striatum, its activation is increased by feedback when a monetary incentive in present.
160-1	30063-30068	Other	_	
160-2	30069-30073	fMRI	_	
160-3	30074-30081	studies	_	
160-4	30082-30086	have	_	
160-5	30087-30099	demonstrated	_	
160-6	30100-30104	that	_	
160-7	30105-30113	feedback	_	
160-8	30114-30116	of	_	
160-9	30117-30128	performance	_	
160-10	30129-30138	activates	_	
160-11	30139-30142	the	_	
160-12	30143-30150	ventral	_	
160-13	30151-30159	striatum	_	
160-14	30160-30163	and	_	
160-15	30163-30164	,	_	
160-16	30165-30167	in	_	
160-17	30168-30172	fact	_	
160-18	30172-30173	,	_	
160-19	30174-30176	as	_	
160-20	30177-30184	opposed	_	
160-21	30185-30187	to	_	
160-22	30188-30191	the	_	
160-23	30192-30198	dorsal	_	
160-24	30199-30207	striatum	_	
160-25	30207-30208	,	_	
160-26	30209-30212	its	_	
160-27	30213-30223	activation	_	
160-28	30224-30226	is	_	
160-29	30227-30236	increased	_	
160-30	30237-30239	by	_	
160-31	30240-30248	feedback	_	
160-32	30249-30253	when	_	
160-33	30254-30255	a	_	
160-34	30256-30264	monetary	_	
160-35	30265-30274	incentive	_	
160-36	30275-30277	in	_	
160-37	30278-30285	present	_	
160-38	30285-30286	.	_	

#Text=Removal of a monetary incentive leads to a significant drop in activation suggesting that feedback itself may serve as a task intrinsic reward.
161-1	30287-30294	Removal	_	
161-2	30295-30297	of	_	
161-3	30298-30299	a	_	
161-4	30300-30308	monetary	_	
161-5	30309-30318	incentive	_	
161-6	30319-30324	leads	_	
161-7	30325-30327	to	_	
161-8	30328-30329	a	_	
161-9	30330-30341	significant	_	
161-10	30342-30346	drop	_	
161-11	30347-30349	in	_	
161-12	30350-30360	activation	_	
161-13	30361-30371	suggesting	_	
161-14	30372-30376	that	_	
161-15	30377-30385	feedback	_	
161-16	30386-30392	itself	_	
161-17	30393-30396	may	_	
161-18	30397-30402	serve	_	
161-19	30403-30405	as	_	
161-20	30406-30407	a	_	
161-21	30408-30412	task	_	
161-22	30413-30422	intrinsic	_	
161-23	30423-30429	reward	_	
161-24	30429-30430	.	_	

#Text=As dopamine release during a video game has been shown to positively correlate with task performance, our study importantly links ventral striatal dopamine release with neural response to feedback.
162-1	30431-30433	As	_	
162-2	30434-30442	dopamine	_	
162-3	30443-30450	release	_	
162-4	30451-30457	during	_	
162-5	30458-30459	a	_	
162-6	30460-30465	video	_	
162-7	30466-30470	game	_	
162-8	30471-30474	has	_	
162-9	30475-30479	been	_	
162-10	30480-30485	shown	_	
162-11	30486-30488	to	_	
162-12	30489-30499	positively	_	
162-13	30500-30509	correlate	_	
162-14	30510-30514	with	_	
162-15	30515-30519	task	_	
162-16	30520-30531	performance	_	
162-17	30531-30532	,	_	
162-18	30533-30536	our	_	
162-19	30537-30542	study	_	
162-20	30543-30554	importantly	_	
162-21	30555-30560	links	_	
162-22	30561-30568	ventral	_	
162-23	30569-30577	striatal	_	
162-24	30578-30586	dopamine	_	
162-25	30587-30594	release	_	
162-26	30595-30599	with	_	
162-27	30600-30606	neural	_	
162-28	30607-30615	response	_	
162-29	30616-30618	to	_	
162-30	30619-30627	feedback	_	
162-31	30627-30628	.	_	

#Text=This may be a step in understanding the mechanisms of intrinsically motivated behaviors.
163-1	30629-30633	This	_	
163-2	30634-30637	may	_	
163-3	30638-30640	be	_	
163-4	30641-30642	a	_	
163-5	30643-30647	step	_	
163-6	30648-30650	in	_	
163-7	30651-30664	understanding	_	
163-8	30665-30668	the	_	
163-9	30669-30679	mechanisms	_	
163-10	30680-30682	of	_	
163-11	30683-30696	intrinsically	_	
163-12	30697-30706	motivated	_	
163-13	30707-30716	behaviors	_	
163-14	30716-30717	.	_	

#Text=It is important to acknowledge that, in contrast to our original study of the MID task to induce dopamine release, we did not see a strong effect of task in this study.
164-1	30718-30720	It	_	
164-2	30721-30723	is	_	
164-3	30724-30733	important	_	
164-4	30734-30736	to	_	
164-5	30737-30748	acknowledge	_	
164-6	30749-30753	that	_	
164-7	30753-30754	,	_	
164-8	30755-30757	in	_	
164-9	30758-30766	contrast	_	
164-10	30767-30769	to	_	
164-11	30770-30773	our	_	
164-12	30774-30782	original	_	
164-13	30783-30788	study	_	
164-14	30789-30791	of	_	
164-15	30792-30795	the	_	
164-16	30796-30799	MID	_	
164-17	30800-30804	task	_	
164-18	30805-30807	to	_	
164-19	30808-30814	induce	_	
164-20	30815-30823	dopamine	_	
164-21	30824-30831	release	_	
164-22	30831-30832	,	_	
164-23	30833-30835	we	_	
164-24	30836-30839	did	_	
164-25	30840-30843	not	_	
164-26	30844-30847	see	_	
164-27	30848-30849	a	_	
164-28	30850-30856	strong	_	
164-29	30857-30863	effect	_	
164-30	30864-30866	of	_	
164-31	30867-30871	task	_	
164-32	30872-30874	in	_	
164-33	30875-30879	this	_	
164-34	30880-30885	study	_	
164-35	30885-30886	.	_	

#Text=To reduce experimental complexity, the former study was limited to females.
165-1	30887-30889	To	_	
165-2	30890-30896	reduce	_	
165-3	30897-30909	experimental	_	
165-4	30910-30920	complexity	_	
165-5	30920-30921	,	_	
165-6	30922-30925	the	_	
165-7	30926-30932	former	_	
165-8	30933-30938	study	_	
165-9	30939-30942	was	_	
165-10	30943-30950	limited	_	
165-11	30951-30953	to	_	
165-12	30954-30961	females	_	
165-13	30961-30962	.	_	

#Text=However, the current study enrolled only male subjects to increase rates of high-risk behavior in the sample.
166-1	30963-30970	However	_	
166-2	30970-30971	,	_	
166-3	30972-30975	the	_	
166-4	30976-30983	current	_	
166-5	30984-30989	study	_	
166-6	30990-30998	enrolled	_	
166-7	30999-31003	only	_	
166-8	31004-31008	male	_	
166-9	31009-31017	subjects	_	
166-10	31018-31020	to	_	
166-11	31021-31029	increase	_	
166-12	31030-31035	rates	_	
166-13	31036-31038	of	_	
166-14	31039-31048	high-risk	_	
166-15	31049-31057	behavior	_	
166-16	31058-31060	in	_	
166-17	31061-31064	the	_	
166-18	31065-31071	sample	_	
166-19	31071-31072	.	_	

#Text=For several methodological reasons - including age range, familial liability, different versions of the fMRI task, etc. - these groups are not easily compared.
167-1	31073-31076	For	_	
167-2	31077-31084	several	_	
167-3	31085-31099	methodological	_	
167-4	31100-31107	reasons	_	
167-5	31108-31109	-	_	
167-6	31110-31119	including	_	
167-7	31120-31123	age	_	
167-8	31124-31129	range	_	
167-9	31129-31130	,	_	
167-10	31131-31139	familial	_	
167-11	31140-31149	liability	_	
167-12	31149-31150	,	_	
167-13	31151-31160	different	_	
167-14	31161-31169	versions	_	
167-15	31170-31172	of	_	
167-16	31173-31176	the	_	
167-17	31177-31181	fMRI	_	
167-18	31182-31186	task	_	
167-19	31186-31187	,	_	
167-20	31188-31191	etc	_	
167-21	31191-31192	.	_	
167-22	31193-31194	-	_	
167-23	31195-31200	these	_	
167-24	31201-31207	groups	_	
167-25	31208-31211	are	_	
167-26	31212-31215	not	_	
167-27	31216-31222	easily	_	
167-28	31223-31231	compared	_	
167-29	31231-31232	.	_	

#Text=We note, however, that other work has demonstrated greater dopamine release in many regions of the brain (with the exception of the dorsal striatum) in women.
168-1	31233-31235	We	_	
168-2	31236-31240	note	_	
168-3	31240-31241	,	_	
168-4	31242-31249	however	_	
168-5	31249-31250	,	_	
168-6	31251-31255	that	_	
168-7	31256-31261	other	_	
168-8	31262-31266	work	_	
168-9	31267-31270	has	_	
168-10	31271-31283	demonstrated	_	
168-11	31284-31291	greater	_	
168-12	31292-31300	dopamine	_	
168-13	31301-31308	release	_	
168-14	31309-31311	in	_	
168-15	31312-31316	many	_	
168-16	31317-31324	regions	_	
168-17	31325-31327	of	_	
168-18	31328-31331	the	_	
168-19	31332-31337	brain	_	
168-20	31338-31339	(	_	
168-21	31339-31343	with	_	
168-22	31344-31347	the	_	
168-23	31348-31357	exception	_	
168-24	31358-31360	of	_	
168-25	31361-31364	the	_	
168-26	31365-31371	dorsal	_	
168-27	31372-31380	striatum	_	
168-28	31380-31381	)	_	
168-29	31382-31384	in	_	
168-30	31385-31390	women	_	
168-31	31390-31391	.	_	

#Text=The fact that the task effect was highly significant in the High Risk group may support the use of behaviorally-induced dopamine release as a potential biomarker, particularly in male subjects.
169-1	31392-31395	The	_	
169-2	31396-31400	fact	_	
169-3	31401-31405	that	_	
169-4	31406-31409	the	_	
169-5	31410-31414	task	_	
169-6	31415-31421	effect	_	
169-7	31422-31425	was	_	
169-8	31426-31432	highly	_	
169-9	31433-31444	significant	_	
169-10	31445-31447	in	_	
169-11	31448-31451	the	_	
169-12	31452-31456	High	_	
169-13	31457-31461	Risk	_	
169-14	31462-31467	group	_	
169-15	31468-31471	may	_	
169-16	31472-31479	support	_	
169-17	31480-31483	the	_	
169-18	31484-31487	use	_	
169-19	31488-31490	of	_	
169-20	31491-31511	behaviorally-induced	_	
169-21	31512-31520	dopamine	_	
169-22	31521-31528	release	_	
169-23	31529-31531	as	_	
169-24	31532-31533	a	_	
169-25	31534-31543	potential	_	
169-26	31544-31553	biomarker	_	
169-27	31553-31554	,	_	
169-28	31555-31567	particularly	_	
169-29	31568-31570	in	_	
169-30	31571-31575	male	_	
169-31	31576-31584	subjects	_	
169-32	31584-31585	.	_	

#Text=Given demonstrated sex differences in dopamine response, further work is needed to examine the relationships between behavioral and pharmacological response to reward in both sexes.
170-1	31586-31591	Given	_	
170-2	31592-31604	demonstrated	_	
170-3	31605-31608	sex	_	
170-4	31609-31620	differences	_	
170-5	31621-31623	in	_	
170-6	31624-31632	dopamine	_	
170-7	31633-31641	response	_	
170-8	31641-31642	,	_	
170-9	31643-31650	further	_	
170-10	31651-31655	work	_	
170-11	31656-31658	is	_	
170-12	31659-31665	needed	_	
170-13	31666-31668	to	_	
170-14	31669-31676	examine	_	
170-15	31677-31680	the	_	
170-16	31681-31694	relationships	_	
170-17	31695-31702	between	_	
170-18	31703-31713	behavioral	_	
170-19	31714-31717	and	_	
170-20	31718-31733	pharmacological	_	
170-21	31734-31742	response	_	
170-22	31743-31745	to	_	
170-23	31746-31752	reward	_	
170-24	31753-31755	in	_	
170-25	31756-31760	both	_	
170-26	31761-31766	sexes	_	
170-27	31766-31767	.	_	

#Text=In summary, we find that behavioral induction of dopamine release may be a phenotypic marker of risk for substance use.
171-1	31768-31770	In	_	
171-2	31771-31778	summary	_	
171-3	31778-31779	,	_	
171-4	31780-31782	we	_	
171-5	31783-31787	find	_	
171-6	31788-31792	that	_	
171-7	31793-31803	behavioral	_	
171-8	31804-31813	induction	_	
171-9	31814-31816	of	_	
171-10	31817-31825	dopamine	_	
171-11	31826-31833	release	_	
171-12	31834-31837	may	_	
171-13	31838-31840	be	_	
171-14	31841-31842	a	_	
171-15	31843-31853	phenotypic	_	
171-16	31854-31860	marker	_	
171-17	31861-31863	of	_	
171-18	31864-31868	risk	_	
171-19	31869-31872	for	_	
171-20	31873-31882	substance	_	
171-21	31883-31886	use	_	
171-22	31886-31887	.	_	

#Text=Subjects with familial liability for risk that have also engaged in early drunkenness displayed higher ventral striatal dopamine response during a monetary task despite no differences in initial receptor levels.
172-1	31888-31896	Subjects	_	
172-2	31897-31901	with	_	
172-3	31902-31910	familial	_	
172-4	31911-31920	liability	_	
172-5	31921-31924	for	_	
172-6	31925-31929	risk	_	
172-7	31930-31934	that	_	
172-8	31935-31939	have	_	
172-9	31940-31944	also	_	
172-10	31945-31952	engaged	_	
172-11	31953-31955	in	_	
172-12	31956-31961	early	_	
172-13	31962-31973	drunkenness	_	
172-14	31974-31983	displayed	_	
172-15	31984-31990	higher	_	
172-16	31991-31998	ventral	_	
172-17	31999-32007	striatal	_	
172-18	32008-32016	dopamine	_	
172-19	32017-32025	response	_	
172-20	32026-32032	during	_	
172-21	32033-32034	a	_	
172-22	32035-32043	monetary	_	
172-23	32044-32048	task	_	
172-24	32049-32056	despite	_	
172-25	32057-32059	no	_	
172-26	32060-32071	differences	_	
172-27	32072-32074	in	_	
172-28	32075-32082	initial	_	
172-29	32083-32091	receptor	_	
172-30	32092-32098	levels	_	
172-31	32098-32099	.	_	

#Text=Given the challenges associated with pharmacological interrogation of reward systems, behavioral-induction of dopamine response may lead to a better understanding of molecular mechanisms underlying risk.
173-1	32100-32105	Given	_	
173-2	32106-32109	the	_	
173-3	32110-32120	challenges	_	
173-4	32121-32131	associated	_	
173-5	32132-32136	with	_	
173-6	32137-32152	pharmacological	_	
173-7	32153-32166	interrogation	_	
173-8	32167-32169	of	_	
173-9	32170-32176	reward	_	
173-10	32177-32184	systems	_	
173-11	32184-32185	,	_	
173-12	32186-32206	behavioral-induction	_	
173-13	32207-32209	of	_	
173-14	32210-32218	dopamine	_	
173-15	32219-32227	response	_	
173-16	32228-32231	may	_	
173-17	32232-32236	lead	_	
173-18	32237-32239	to	_	
173-19	32240-32241	a	_	
173-20	32242-32248	better	_	
173-21	32249-32262	understanding	_	
173-22	32263-32265	of	_	
173-23	32266-32275	molecular	_	
173-24	32276-32286	mechanisms	_	
173-25	32287-32297	underlying	_	
173-26	32298-32302	risk	_	
173-27	32302-32303	.	_	

#Text=Supplementary Material
#Text=Individuals Family History Positive for Alcoholism Show Functional Magnetic Resonance Imaging Differences in Reward Sensitivity That Are Related to Impulsivity Factors
#Text=Human Midbrain Sensitivity to Cognitive Feedback and Uncertainty During Classification Learning
#Text=Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task
#Text=Incentive-elicited striatal activation in adolescent children of alcoholics
#Text=Alcohol promotes dopamine release in the human nucleus accumbens
#Text=Quantification of Amphetamine-Induced Changes in [11C] Raclopride Binding with Continuous Infusion
#Text=Reduced dopamine response to amphetamine in subjects at ultra-high risk for addiction
#Text=The relations of regulation and emotionality to resiliency and competent social functioning in elementary school children
#Text=Effect of GABRA2 Genotype on Development of Incentive-Motivation Circuitry in a Sample Enriched for Alcoholism Risk
#Text=Imaging brain response to reward in addictive disorders
#Text=Consensus nomenclature for in vivo imaging of reversibly binding radioligands
#Text=
#Text=Dissociation of reward anticipation and outcome with event-related fMRI
#Text=Evidence for striatal dopamine release during a video game
#Text=Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model
#Text=The rewarding value of good motor performance in the context of monetary incentives
#Text=What can the monetary incentive delay task tell us about the neural processing of reward and punishment?
174-1	32304-32317	Supplementary	_	
174-2	32318-32326	Material	_	
174-3	32327-32338	Individuals	_	
174-4	32339-32345	Family	_	
174-5	32346-32353	History	_	
174-6	32354-32362	Positive	_	
174-7	32363-32366	for	_	
174-8	32367-32377	Alcoholism	_	
174-9	32378-32382	Show	_	
174-10	32383-32393	Functional	_	
174-11	32394-32402	Magnetic	_	
174-12	32403-32412	Resonance	_	
174-13	32413-32420	Imaging	_	
174-14	32421-32432	Differences	_	
174-15	32433-32435	in	_	
174-16	32436-32442	Reward	_	
174-17	32443-32454	Sensitivity	_	
174-18	32455-32459	That	_	
174-19	32460-32463	Are	_	
174-20	32464-32471	Related	_	
174-21	32472-32474	to	_	
174-22	32475-32486	Impulsivity	_	
174-23	32487-32494	Factors	_	
174-24	32495-32500	Human	_	
174-25	32501-32509	Midbrain	_	
174-26	32510-32521	Sensitivity	_	
174-27	32522-32524	to	_	
174-28	32525-32534	Cognitive	_	
174-29	32535-32543	Feedback	_	
174-30	32544-32547	and	_	
174-31	32548-32559	Uncertainty	_	
174-32	32560-32566	During	_	
174-33	32567-32581	Classification	_	
174-34	32582-32590	Learning	_	
174-35	32591-32603	Anticipatory	_	
174-36	32604-32610	Reward	_	
174-37	32611-32621	Processing	_	
174-38	32622-32624	in	_	
174-39	32625-32633	Addicted	_	
174-40	32634-32645	Populations	_	
174-41	32645-32646	:	_	
174-42	32647-32648	A	_	
174-43	32649-32654	Focus	_	
174-44	32655-32657	on	_	
174-45	32658-32661	the	_	
174-46	32662-32670	Monetary	_	
174-47	32671-32680	Incentive	_	
174-48	32681-32686	Delay	_	
174-49	32687-32691	Task	_	
174-50	32692-32710	Incentive-elicited	_	
174-51	32711-32719	striatal	_	
174-52	32720-32730	activation	_	
174-53	32731-32733	in	_	
174-54	32734-32744	adolescent	_	
174-55	32745-32753	children	_	
174-56	32754-32756	of	_	
174-57	32757-32767	alcoholics	_	
174-58	32768-32775	Alcohol	_	
174-59	32776-32784	promotes	_	
174-60	32785-32793	dopamine	_	
174-61	32794-32801	release	_	
174-62	32802-32804	in	_	
174-63	32805-32808	the	_	
174-64	32809-32814	human	_	
174-65	32815-32822	nucleus	_	
174-66	32823-32832	accumbens	_	
174-67	32833-32847	Quantification	_	
174-68	32848-32850	of	_	
174-69	32851-32870	Amphetamine-Induced	_	
174-70	32871-32878	Changes	_	
174-71	32879-32881	in	_	
174-72	32882-32883	[	_	
174-73	32883-32886	11C	_	
174-74	32886-32887	]	_	
174-75	32888-32898	Raclopride	_	
174-76	32899-32906	Binding	_	
174-77	32907-32911	with	_	
174-78	32912-32922	Continuous	_	
174-79	32923-32931	Infusion	_	
174-80	32932-32939	Reduced	_	
174-81	32940-32948	dopamine	_	
174-82	32949-32957	response	_	
174-83	32958-32960	to	_	
174-84	32961-32972	amphetamine	_	
174-85	32973-32975	in	_	
174-86	32976-32984	subjects	_	
174-87	32985-32987	at	_	
174-88	32988-32998	ultra-high	_	
174-89	32999-33003	risk	_	
174-90	33004-33007	for	_	
174-91	33008-33017	addiction	_	
174-92	33018-33021	The	_	
174-93	33022-33031	relations	_	
174-94	33032-33034	of	_	
174-95	33035-33045	regulation	_	
174-96	33046-33049	and	_	
174-97	33050-33062	emotionality	_	
174-98	33063-33065	to	_	
174-99	33066-33076	resiliency	_	
174-100	33077-33080	and	_	
174-101	33081-33090	competent	_	
174-102	33091-33097	social	_	
174-103	33098-33109	functioning	_	
174-104	33110-33112	in	_	
174-105	33113-33123	elementary	_	
174-106	33124-33130	school	_	
174-107	33131-33139	children	_	
174-108	33140-33146	Effect	_	
174-109	33147-33149	of	_	
174-110	33150-33156	GABRA2	_	
174-111	33157-33165	Genotype	_	
174-112	33166-33168	on	_	
174-113	33169-33180	Development	_	
174-114	33181-33183	of	_	
174-115	33184-33204	Incentive-Motivation	_	
174-116	33205-33214	Circuitry	_	
174-117	33215-33217	in	_	
174-118	33218-33219	a	_	
174-119	33220-33226	Sample	_	
174-120	33227-33235	Enriched	_	
174-121	33236-33239	for	_	
174-122	33240-33250	Alcoholism	_	
174-123	33251-33255	Risk	_	
174-124	33256-33263	Imaging	_	
174-125	33264-33269	brain	_	
174-126	33270-33278	response	_	
174-127	33279-33281	to	_	
174-128	33282-33288	reward	_	
174-129	33289-33291	in	_	
174-130	33292-33301	addictive	_	
174-131	33302-33311	disorders	_	
174-132	33312-33321	Consensus	_	
174-133	33322-33334	nomenclature	_	
174-134	33335-33338	for	_	
174-135	33339-33341	in	_	
174-136	33342-33346	vivo	_	
174-137	33347-33354	imaging	_	
174-138	33355-33357	of	_	
174-139	33358-33368	reversibly	_	
174-140	33369-33376	binding	_	
174-141	33377-33389	radioligands	_	
174-142	33391-33403	Dissociation	_	
174-143	33404-33406	of	_	
174-144	33407-33413	reward	_	
174-145	33414-33426	anticipation	_	
174-146	33427-33430	and	_	
174-147	33431-33438	outcome	_	
174-148	33439-33443	with	_	
174-149	33444-33457	event-related	_	
174-150	33458-33462	fMRI	_	
174-151	33463-33471	Evidence	_	
174-152	33472-33475	for	_	
174-153	33476-33484	striatal	_	
174-154	33485-33493	dopamine	_	
174-155	33494-33501	release	_	
174-156	33502-33508	during	_	
174-157	33509-33510	a	_	
174-158	33511-33516	video	_	
174-159	33517-33521	game	_	
174-160	33522-33530	Dopamine	_	
174-161	33531-33534	ups	_	
174-162	33535-33538	and	_	
174-163	33539-33544	downs	_	
174-164	33545-33547	in	_	
174-165	33548-33561	vulnerability	_	
174-166	33562-33564	to	_	
174-167	33565-33575	addictions	_	
174-168	33575-33576	:	_	
174-169	33577-33578	a	_	
174-170	33579-33597	neurodevelopmental	_	
174-171	33598-33603	model	_	
174-172	33604-33607	The	_	
174-173	33608-33617	rewarding	_	
174-174	33618-33623	value	_	
174-175	33624-33626	of	_	
174-176	33627-33631	good	_	
174-177	33632-33637	motor	_	
174-178	33638-33649	performance	_	
174-179	33650-33652	in	_	
174-180	33653-33656	the	_	
174-181	33657-33664	context	_	
174-182	33665-33667	of	_	
174-183	33668-33676	monetary	_	
174-184	33677-33687	incentives	_	
174-185	33688-33692	What	_	
174-186	33693-33696	can	_	
174-187	33697-33700	the	_	
174-188	33701-33709	monetary	_	
174-189	33710-33719	incentive	_	
174-190	33720-33725	delay	_	
174-191	33726-33730	task	_	
174-192	33731-33735	tell	_	
174-193	33736-33738	us	_	
174-194	33739-33744	about	_	
174-195	33745-33748	the	_	
174-196	33749-33755	neural	_	
174-197	33756-33766	processing	_	
174-198	33767-33769	of	_	
174-199	33770-33776	reward	_	
174-200	33777-33780	and	_	
174-201	33781-33791	punishment	_	
174-202	33791-33792	?	_	

#Text=Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum
#Text=Amphetamine-Induced Dopamine Release: Markedly Blunted in Cocaine Dependence and Predictive of the Choice to Self-Administer Cocaine
#Text=Automated detection of the intercommissural line for stereotactic localization of functional brain images
#Text=No differences in ventral striatum responsivity between adolescents with a positive family history of alcoholism and controls
#Text=Striatal Dopamine Release and Family History of Alcoholism
#Text=Neural basis of the undermining effect of monetary reward on intrinsic motivation
#Text=Alcohol involvement over the life course
#Text=Genes and addiction
#Text=A genetic determinant of the striatal dopamine response to alcohol in men
#Text=Sex Differences in Amphetamine-Induced Displacement of [18F]Fallypride in Striatal and Extrastriatal Regions: A PET Study
#Text=Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release
#Text=Human brain dopamine receptors in children and aging adults
#Text=Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus
#Text=Differential striatal dopamine responses following oral alcohol in individuals at varying risk for dependence
#Text=Timeline follow-back: a technique for assessing self-reported alcohol consumption
#Text=Factors in childhood and youth predicting alcohol dependence and abuse in Swedish women: findings from a general population study
#Text=Blunted dopamine release as a biomarker for vulnerability for substance use disorders
#Text=Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity
#Text=Sex Differences in Striatal Dopamine Release in Young Adults After Oral Alcohol Challenge: A Positron Emission Tomography Imaging Study With [11C]Raclopride
#Text=High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors
#Text=Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels
#Text=Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
#Text=Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement
#Text=Relationship between impulsivity, prefrontal anticipatory activation, and striatal dopamine release during rewarded task performance
#Text=Nucleus accumbens response to incentive stimuli anticipation in children of alcoholics: relationships with precursive behavioral risk and lifetime alcohol use
#Text=Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study
#Text=Dopamine D(2) receptor availability is associated with subjective responses to alcohol
#Text=Dopamine Transmission in the Human Striatum during Monetary Reward Tasks
#Text=
#Text=Other evidence for at least two alcoholisms II: Life course variation in antisociality and heterogeneity of alcoholic outcome
#Text=The clinical and social ecology of childhood for children of alcoholics: Description of a study and implications for a differentiated social policy
#Text=Drug usage as one manifestation of a sensation seeking trait
#Text=A) Schematic of reward condition of PET paradigm: Trials followed the same timing as the fMRI paradigm presented in a single run of 30 minutes with reward and loss cues.
175-1	33793-33800	Alcohol	_	
175-2	33801-33811	Dependence	_	
175-3	33812-33814	Is	_	
175-4	33815-33825	Associated	_	
175-5	33826-33830	with	_	
175-6	33831-33838	Blunted	_	
175-7	33839-33847	Dopamine	_	
175-8	33848-33860	Transmission	_	
175-9	33861-33863	in	_	
175-10	33864-33867	the	_	
175-11	33868-33875	Ventral	_	
175-12	33876-33884	Striatum	_	
175-13	33885-33904	Amphetamine-Induced	_	
175-14	33905-33913	Dopamine	_	
175-15	33914-33921	Release	_	
175-16	33921-33922	:	_	
175-17	33923-33931	Markedly	_	
175-18	33932-33939	Blunted	_	
175-19	33940-33942	in	_	
175-20	33943-33950	Cocaine	_	
175-21	33951-33961	Dependence	_	
175-22	33962-33965	and	_	
175-23	33966-33976	Predictive	_	
175-24	33977-33979	of	_	
175-25	33980-33983	the	_	
175-26	33984-33990	Choice	_	
175-27	33991-33993	to	_	
175-28	33994-34009	Self-Administer	_	
175-29	34010-34017	Cocaine	_	
175-30	34018-34027	Automated	_	
175-31	34028-34037	detection	_	
175-32	34038-34040	of	_	
175-33	34041-34044	the	_	
175-34	34045-34061	intercommissural	_	
175-35	34062-34066	line	_	
175-36	34067-34070	for	_	
175-37	34071-34083	stereotactic	_	
175-38	34084-34096	localization	_	
175-39	34097-34099	of	_	
175-40	34100-34110	functional	_	
175-41	34111-34116	brain	_	
175-42	34117-34123	images	_	
175-43	34124-34126	No	_	
175-44	34127-34138	differences	_	
175-45	34139-34141	in	_	
175-46	34142-34149	ventral	_	
175-47	34150-34158	striatum	_	
175-48	34159-34171	responsivity	_	
175-49	34172-34179	between	_	
175-50	34180-34191	adolescents	_	
175-51	34192-34196	with	_	
175-52	34197-34198	a	_	
175-53	34199-34207	positive	_	
175-54	34208-34214	family	_	
175-55	34215-34222	history	_	
175-56	34223-34225	of	_	
175-57	34226-34236	alcoholism	_	
175-58	34237-34240	and	_	
175-59	34241-34249	controls	_	
175-60	34250-34258	Striatal	_	
175-61	34259-34267	Dopamine	_	
175-62	34268-34275	Release	_	
175-63	34276-34279	and	_	
175-64	34280-34286	Family	_	
175-65	34287-34294	History	_	
175-66	34295-34297	of	_	
175-67	34298-34308	Alcoholism	_	
175-68	34309-34315	Neural	_	
175-69	34316-34321	basis	_	
175-70	34322-34324	of	_	
175-71	34325-34328	the	_	
175-72	34329-34340	undermining	_	
175-73	34341-34347	effect	_	
175-74	34348-34350	of	_	
175-75	34351-34359	monetary	_	
175-76	34360-34366	reward	_	
175-77	34367-34369	on	_	
175-78	34370-34379	intrinsic	_	
175-79	34380-34390	motivation	_	
175-80	34391-34398	Alcohol	_	
175-81	34399-34410	involvement	_	
175-82	34411-34415	over	_	
175-83	34416-34419	the	_	
175-84	34420-34424	life	_	
175-85	34425-34431	course	_	
175-86	34432-34437	Genes	_	
175-87	34438-34441	and	_	
175-88	34442-34451	addiction	_	
175-89	34452-34453	A	_	
175-90	34454-34461	genetic	_	
175-91	34462-34473	determinant	_	
175-92	34474-34476	of	_	
175-93	34477-34480	the	_	
175-94	34481-34489	striatal	_	
175-95	34490-34498	dopamine	_	
175-96	34499-34507	response	_	
175-97	34508-34510	to	_	
175-98	34511-34518	alcohol	_	
175-99	34519-34521	in	_	
175-100	34522-34525	men	_	
175-101	34526-34529	Sex	_	
175-102	34530-34541	Differences	_	
175-103	34542-34544	in	_	
175-104	34545-34564	Amphetamine-Induced	_	
175-105	34565-34577	Displacement	_	
175-106	34578-34580	of	_	
175-107	34581-34582	[	_	
175-108	34582-34585	18F	_	
175-109	34585-34586	]	_	
175-110	34586-34596	Fallypride	_	
175-111	34597-34599	in	_	
175-112	34600-34608	Striatal	_	
175-113	34609-34612	and	_	
175-114	34613-34626	Extrastriatal	_	
175-115	34627-34634	Regions	_	
175-116	34634-34635	:	_	
175-117	34636-34637	A	_	
175-118	34638-34641	PET	_	
175-119	34642-34647	Study	_	
175-120	34648-34658	Mesolimbic	_	
175-121	34659-34669	functional	_	
175-122	34670-34678	magnetic	_	
175-123	34679-34688	resonance	_	
175-124	34689-34696	imaging	_	
175-125	34697-34708	activations	_	
175-126	34709-34715	during	_	
175-127	34716-34722	reward	_	
175-128	34723-34735	anticipation	_	
175-129	34736-34745	correlate	_	
175-130	34746-34750	with	_	
175-131	34751-34765	reward-related	_	
175-132	34766-34773	ventral	_	
175-133	34774-34782	striatal	_	
175-134	34783-34791	dopamine	_	
175-135	34792-34799	release	_	
175-136	34800-34805	Human	_	
175-137	34806-34811	brain	_	
175-138	34812-34820	dopamine	_	
175-139	34821-34830	receptors	_	
175-140	34831-34833	in	_	
175-141	34834-34842	children	_	
175-142	34843-34846	and	_	
175-143	34847-34852	aging	_	
175-144	34853-34859	adults	_	
175-145	34860-34868	Dopamine	_	
175-146	34869-34871	D2	_	
175-147	34872-34875	and	_	
175-148	34876-34878	D3	_	
175-149	34879-34888	receptors	_	
175-150	34889-34891	in	_	
175-151	34892-34897	human	_	
175-152	34898-34905	putamen	_	
175-153	34905-34906	,	_	
175-154	34907-34914	caudate	_	
175-155	34915-34922	nucleus	_	
175-156	34922-34923	,	_	
175-157	34924-34927	and	_	
175-158	34928-34934	globus	_	
175-159	34935-34943	pallidus	_	
175-160	34944-34956	Differential	_	
175-161	34957-34965	striatal	_	
175-162	34966-34974	dopamine	_	
175-163	34975-34984	responses	_	
175-164	34985-34994	following	_	
175-165	34995-34999	oral	_	
175-166	35000-35007	alcohol	_	
175-167	35008-35010	in	_	
175-168	35011-35022	individuals	_	
175-169	35023-35025	at	_	
175-170	35026-35033	varying	_	
175-171	35034-35038	risk	_	
175-172	35039-35042	for	_	
175-173	35043-35053	dependence	_	
175-174	35054-35062	Timeline	_	
175-175	35063-35074	follow-back	_	
175-176	35074-35075	:	_	
175-177	35076-35077	a	_	
175-178	35078-35087	technique	_	
175-179	35088-35091	for	_	
175-180	35092-35101	assessing	_	
175-181	35102-35115	self-reported	_	
175-182	35116-35123	alcohol	_	
175-183	35124-35135	consumption	_	
175-184	35136-35143	Factors	_	
175-185	35144-35146	in	_	
175-186	35147-35156	childhood	_	
175-187	35157-35160	and	_	
175-188	35161-35166	youth	_	
175-189	35167-35177	predicting	_	
175-190	35178-35185	alcohol	_	
175-191	35186-35196	dependence	_	
175-192	35197-35200	and	_	
175-193	35201-35206	abuse	_	
175-194	35207-35209	in	_	
175-195	35210-35217	Swedish	_	
175-196	35218-35223	women	_	
175-197	35223-35224	:	_	
175-198	35225-35233	findings	_	
175-199	35234-35238	from	_	
175-200	35239-35240	a	_	
175-201	35241-35248	general	_	
175-202	35249-35259	population	_	
175-203	35260-35265	study	_	
175-204	35266-35273	Blunted	_	
175-205	35274-35282	dopamine	_	
175-206	35283-35290	release	_	
175-207	35291-35293	as	_	
175-208	35294-35295	a	_	
175-209	35296-35305	biomarker	_	
175-210	35306-35309	for	_	
175-211	35310-35323	vulnerability	_	
175-212	35324-35327	for	_	
175-213	35328-35337	substance	_	
175-214	35338-35341	use	_	
175-215	35342-35351	disorders	_	
175-216	35352-35359	Imaging	_	
175-217	35360-35369	addiction	_	
175-218	35369-35370	:	_	
175-219	35371-35373	D2	_	
175-220	35374-35383	receptors	_	
175-221	35384-35387	and	_	
175-222	35388-35396	dopamine	_	
175-223	35397-35406	signaling	_	
175-224	35407-35409	in	_	
175-225	35410-35413	the	_	
175-226	35414-35422	striatum	_	
175-227	35423-35425	as	_	
175-228	35426-35436	biomarkers	_	
175-229	35437-35440	for	_	
175-230	35441-35452	impulsivity	_	
175-231	35453-35456	Sex	_	
175-232	35457-35468	Differences	_	
175-233	35469-35471	in	_	
175-234	35472-35480	Striatal	_	
175-235	35481-35489	Dopamine	_	
175-236	35490-35497	Release	_	
175-237	35498-35500	in	_	
175-238	35501-35506	Young	_	
175-239	35507-35513	Adults	_	
175-240	35514-35519	After	_	
175-241	35520-35524	Oral	_	
175-242	35525-35532	Alcohol	_	
175-243	35533-35542	Challenge	_	
175-244	35542-35543	:	_	
175-245	35544-35545	A	_	
175-246	35546-35554	Positron	_	
175-247	35555-35563	Emission	_	
175-248	35564-35574	Tomography	_	
175-249	35575-35582	Imaging	_	
175-250	35583-35588	Study	_	
175-251	35589-35593	With	_	
175-252	35594-35595	[	_	
175-253	35595-35598	11C	_	
175-254	35598-35599	]	_	
175-255	35599-35609	Raclopride	_	
175-256	35610-35614	High	_	
175-257	35615-35621	levels	_	
175-258	35622-35624	of	_	
175-259	35625-35633	dopamine	_	
175-260	35634-35636	D2	_	
175-261	35637-35646	receptors	_	
175-262	35647-35649	in	_	
175-263	35650-35660	unaffected	_	
175-264	35661-35668	members	_	
175-265	35669-35671	of	_	
175-266	35672-35681	alcoholic	_	
175-267	35682-35690	families	_	
175-268	35690-35691	:	_	
175-269	35692-35700	possible	_	
175-270	35701-35711	protective	_	
175-271	35712-35719	factors	_	
175-272	35720-35730	Prediction	_	
175-273	35731-35733	of	_	
175-274	35734-35745	reinforcing	_	
175-275	35746-35755	responses	_	
175-276	35756-35758	to	_	
175-277	35759-35775	psychostimulants	_	
175-278	35776-35778	in	_	
175-279	35779-35785	humans	_	
175-280	35786-35788	by	_	
175-281	35789-35794	brain	_	
175-282	35795-35803	dopamine	_	
175-283	35804-35806	D2	_	
175-284	35807-35815	receptor	_	
175-285	35816-35822	levels	_	
175-286	35823-35832	Decreased	_	
175-287	35833-35841	striatal	_	
175-288	35842-35854	dopaminergic	_	
175-289	35855-35869	responsiveness	_	
175-290	35870-35872	in	_	
175-291	35873-35883	detoxified	_	
175-292	35884-35901	cocaine-dependent	_	
175-293	35902-35910	subjects	_	
175-294	35911-35919	Profound	_	
175-295	35920-35929	decreases	_	
175-296	35930-35932	in	_	
175-297	35933-35941	dopamine	_	
175-298	35942-35949	release	_	
175-299	35950-35952	in	_	
175-300	35953-35961	striatum	_	
175-301	35962-35964	in	_	
175-302	35965-35975	detoxified	_	
175-303	35976-35986	alcoholics	_	
175-304	35986-35987	:	_	
175-305	35988-35996	possible	_	
175-306	35997-36010	orbitofrontal	_	
175-307	36011-36022	involvement	_	
175-308	36023-36035	Relationship	_	
175-309	36036-36043	between	_	
175-310	36044-36055	impulsivity	_	
175-311	36055-36056	,	_	
175-312	36057-36067	prefrontal	_	
175-313	36068-36080	anticipatory	_	
175-314	36081-36091	activation	_	
175-315	36091-36092	,	_	
175-316	36093-36096	and	_	
175-317	36097-36105	striatal	_	
175-318	36106-36114	dopamine	_	
175-319	36115-36122	release	_	
175-320	36123-36129	during	_	
175-321	36130-36138	rewarded	_	
175-322	36139-36143	task	_	
175-323	36144-36155	performance	_	
175-324	36156-36163	Nucleus	_	
175-325	36164-36173	accumbens	_	
175-326	36174-36182	response	_	
175-327	36183-36185	to	_	
175-328	36186-36195	incentive	_	
175-329	36196-36203	stimuli	_	
175-330	36204-36216	anticipation	_	
175-331	36217-36219	in	_	
175-332	36220-36228	children	_	
175-333	36229-36231	of	_	
175-334	36232-36242	alcoholics	_	
175-335	36242-36243	:	_	
175-336	36244-36257	relationships	_	
175-337	36258-36262	with	_	
175-338	36263-36273	precursive	_	
175-339	36274-36284	behavioral	_	
175-340	36285-36289	risk	_	
175-341	36290-36293	and	_	
175-342	36294-36302	lifetime	_	
175-343	36303-36310	alcohol	_	
175-344	36311-36314	use	_	
175-345	36315-36328	Heterogeneous	_	
175-346	36329-36336	effects	_	
175-347	36337-36339	of	_	
175-348	36340-36347	alcohol	_	
175-349	36348-36350	on	_	
175-350	36351-36359	dopamine	_	
175-351	36360-36367	release	_	
175-352	36368-36370	in	_	
175-353	36371-36374	the	_	
175-354	36375-36383	striatum	_	
175-355	36383-36384	:	_	
175-356	36385-36386	a	_	
175-357	36387-36390	PET	_	
175-358	36391-36396	study	_	
175-359	36397-36405	Dopamine	_	
175-360	36406-36407	D	_	
175-361	36407-36408	(	_	
175-362	36408-36409	2	_	
175-363	36409-36410	)	_	
175-364	36411-36419	receptor	_	
175-365	36420-36432	availability	_	
175-366	36433-36435	is	_	
175-367	36436-36446	associated	_	
175-368	36447-36451	with	_	
175-369	36452-36462	subjective	_	
175-370	36463-36472	responses	_	
175-371	36473-36475	to	_	
175-372	36476-36483	alcohol	_	
175-373	36484-36492	Dopamine	_	
175-374	36493-36505	Transmission	_	
175-375	36506-36508	in	_	
175-376	36509-36512	the	_	
175-377	36513-36518	Human	_	
175-378	36519-36527	Striatum	_	
175-379	36528-36534	during	_	
175-380	36535-36543	Monetary	_	
175-381	36544-36550	Reward	_	
175-382	36551-36556	Tasks	_	
175-383	36558-36563	Other	_	
175-384	36564-36572	evidence	_	
175-385	36573-36576	for	_	
175-386	36577-36579	at	_	
175-387	36580-36585	least	_	
175-388	36586-36589	two	_	
175-389	36590-36601	alcoholisms	_	
175-390	36602-36604	II	_	
175-391	36604-36605	:	_	
175-392	36606-36610	Life	_	
175-393	36611-36617	course	_	
175-394	36618-36627	variation	_	
175-395	36628-36630	in	_	
175-396	36631-36644	antisociality	_	
175-397	36645-36648	and	_	
175-398	36649-36662	heterogeneity	_	
175-399	36663-36665	of	_	
175-400	36666-36675	alcoholic	_	
175-401	36676-36683	outcome	_	
175-402	36684-36687	The	_	
175-403	36688-36696	clinical	_	
175-404	36697-36700	and	_	
175-405	36701-36707	social	_	
175-406	36708-36715	ecology	_	
175-407	36716-36718	of	_	
175-408	36719-36728	childhood	_	
175-409	36729-36732	for	_	
175-410	36733-36741	children	_	
175-411	36742-36744	of	_	
175-412	36745-36755	alcoholics	_	
175-413	36755-36756	:	_	
175-414	36757-36768	Description	_	
175-415	36769-36771	of	_	
175-416	36772-36773	a	_	
175-417	36774-36779	study	_	
175-418	36780-36783	and	_	
175-419	36784-36796	implications	_	
175-420	36797-36800	for	_	
175-421	36801-36802	a	_	
175-422	36803-36817	differentiated	_	
175-423	36818-36824	social	_	
175-424	36825-36831	policy	_	
175-425	36832-36836	Drug	_	
175-426	36837-36842	usage	_	
175-427	36843-36845	as	_	
175-428	36846-36849	one	_	
175-429	36850-36863	manifestation	_	
175-430	36864-36866	of	_	
175-431	36867-36868	a	_	
175-432	36869-36878	sensation	_	
175-433	36879-36886	seeking	_	
175-434	36887-36892	trait	_	
175-435	36893-36894	A	_	
175-436	36894-36895	)	_	
175-437	36896-36905	Schematic	_	
175-438	36906-36908	of	_	
175-439	36909-36915	reward	_	
175-440	36916-36925	condition	_	
175-441	36926-36928	of	_	
175-442	36929-36932	PET	_	
175-443	36933-36941	paradigm	_	
175-444	36941-36942	:	_	
175-445	36943-36949	Trials	_	
175-446	36950-36958	followed	_	
175-447	36959-36962	the	_	
175-448	36963-36967	same	_	
175-449	36968-36974	timing	_	
175-450	36975-36977	as	_	
175-451	36978-36981	the	_	
175-452	36982-36986	fMRI	_	
175-453	36987-36995	paradigm	_	
175-454	36996-37005	presented	_	
175-455	37006-37008	in	_	
175-456	37009-37010	a	_	
175-457	37011-37017	single	_	
175-458	37018-37021	run	_	
175-459	37022-37024	of	_	
175-460	37025-37027	30	_	
175-461	37028-37035	minutes	_	
175-462	37036-37040	with	_	
175-463	37041-37047	reward	_	
175-464	37048-37051	and	_	
175-465	37052-37056	loss	_	
175-466	37057-37061	cues	_	
175-467	37061-37062	.	_	

#Text=Novel changes to cues and feedback were added over time including color and sound to maintain subject interest.
176-1	37063-37068	Novel	_	
176-2	37069-37076	changes	_	
176-3	37077-37079	to	_	
176-4	37080-37084	cues	_	
176-5	37085-37088	and	_	
176-6	37089-37097	feedback	_	
176-7	37098-37102	were	_	
176-8	37103-37108	added	_	
176-9	37109-37113	over	_	
176-10	37114-37118	time	_	
176-11	37119-37128	including	_	
176-12	37129-37134	color	_	
176-13	37135-37138	and	_	
176-14	37139-37144	sound	_	
176-15	37145-37147	to	_	
176-16	37148-37156	maintain	_	
176-17	37157-37164	subject	_	
176-18	37165-37173	interest	_	
176-19	37173-37174	.	_	

#Text=A control condition presenting a neutral cue and target with no feedback was presented during a separate single 30 minute run.
177-1	37175-37176	A	_	
177-2	37177-37184	control	_	
177-3	37185-37194	condition	_	
177-4	37195-37205	presenting	_	
177-5	37206-37207	a	_	
177-6	37208-37215	neutral	_	
177-7	37216-37219	cue	_	
177-8	37220-37223	and	_	
177-9	37224-37230	target	_	
177-10	37231-37235	with	_	
177-11	37236-37238	no	_	
177-12	37239-37247	feedback	_	
177-13	37248-37251	was	_	
177-14	37252-37261	presented	_	
177-15	37262-37268	during	_	
177-16	37269-37270	a	_	
177-17	37271-37279	separate	_	
177-18	37280-37286	single	_	
177-19	37287-37289	30	_	
177-20	37290-37296	minute	_	
177-21	37297-37300	run	_	
177-22	37300-37301	.	_	

#Text=B) Schematic of fMRI paradigm: A single trial of 6 seconds consisted of 2000 ms each for cue; anticipation; and target plus feedback.
178-1	37302-37303	B	_	
178-2	37303-37304	)	_	
178-3	37305-37314	Schematic	_	
178-4	37315-37317	of	_	
178-5	37318-37322	fMRI	_	
178-6	37323-37331	paradigm	_	
178-7	37331-37332	:	_	
178-8	37333-37334	A	_	
178-9	37335-37341	single	_	
178-10	37342-37347	trial	_	
178-11	37348-37350	of	_	
178-12	37351-37352	6	_	
178-13	37353-37360	seconds	_	
178-14	37361-37370	consisted	_	
178-15	37371-37373	of	_	
178-16	37374-37378	2000	_	
178-17	37379-37381	ms	_	
178-18	37382-37386	each	_	
178-19	37387-37390	for	_	
178-20	37391-37394	cue	_	
178-21	37394-37395	;	_	
178-22	37396-37408	anticipation	_	
178-23	37408-37409	;	_	
178-24	37410-37413	and	_	
178-25	37414-37420	target	_	
178-26	37421-37425	plus	_	
178-27	37426-37434	feedback	_	
178-28	37434-37435	.	_	

#Text=Subjects complete 2 runs of 5 minutes each.
179-1	37436-37444	Subjects	_	
179-2	37445-37453	complete	_	
179-3	37454-37455	2	_	
179-4	37456-37460	runs	_	
179-5	37461-37463	of	_	
179-6	37464-37465	5	_	
179-7	37466-37473	minutes	_	
179-8	37474-37478	each	_	
179-9	37478-37479	.	_	

#Text=Reward, loss, and neutral cues were counterbalanced and presented pseudorandomly throughout each run.
180-1	37480-37486	Reward	_	
180-2	37486-37487	,	_	
180-3	37488-37492	loss	_	
180-4	37492-37493	,	_	
180-5	37494-37497	and	_	
180-6	37498-37505	neutral	_	
180-7	37506-37510	cues	_	
180-8	37511-37515	were	_	
180-9	37516-37531	counterbalanced	_	
180-10	37532-37535	and	_	
180-11	37536-37545	presented	_	
180-12	37546-37560	pseudorandomly	_	
180-13	37561-37571	throughout	_	
180-14	37572-37576	each	_	
180-15	37577-37580	run	_	
180-16	37580-37581	.	_	

#Text=A) Location of NAcc regions of interest.
181-1	37582-37583	A	_	
181-2	37583-37584	)	_	
181-3	37585-37593	Location	_	
181-4	37594-37596	of	_	
181-5	37597-37601	NAcc	_	
181-6	37602-37609	regions	_	
181-7	37610-37612	of	_	
181-8	37613-37621	interest	_	
181-9	37621-37622	.	_	

#Text=Group comparisons of B) dopamine release (Effect of group: *p = 0.004, † p = 0.054), C) neural activation in response to reward anticipation, and D) reward feedback.
182-1	37623-37628	Group	_	
182-2	37629-37640	comparisons	_	
182-3	37641-37643	of	_	
182-4	37644-37645	B	_	
182-5	37645-37646	)	_	
182-6	37647-37655	dopamine	_	
182-7	37656-37663	release	_	
182-8	37664-37665	(	_	
182-9	37665-37671	Effect	_	
182-10	37672-37674	of	_	
182-11	37675-37680	group	_	
182-12	37680-37681	:	_	
182-13	37682-37683	*	_	
182-14	37683-37684	p	_	
182-15	37685-37686	=	_	
182-16	37687-37692	0.004	_	
182-17	37692-37693	,	_	
182-18	37694-37695	†	_	
182-19	37696-37697	p	_	
182-20	37698-37699	=	_	
182-21	37700-37705	0.054	_	
182-22	37705-37706	)	_	
182-23	37706-37707	,	_	
182-24	37708-37709	C	_	
182-25	37709-37710	)	_	
182-26	37711-37717	neural	_	
182-27	37718-37728	activation	_	
182-28	37729-37731	in	_	
182-29	37732-37740	response	_	
182-30	37741-37743	to	_	
182-31	37744-37750	reward	_	
182-32	37751-37763	anticipation	_	
182-33	37763-37764	,	_	
182-34	37765-37768	and	_	
182-35	37769-37770	D	_	
182-36	37770-37771	)	_	
182-37	37772-37778	reward	_	
182-38	37779-37787	feedback	_	
182-39	37787-37788	.	_	

#Text=Scatter plots of MID response captured by PET and fMRI: NAcc BOLD response during reward anticipation and feedback versus dopamine release for the left and right nucleus accumbens by group.
183-1	37789-37796	Scatter	_	
183-2	37797-37802	plots	_	
183-3	37803-37805	of	_	
183-4	37806-37809	MID	_	
183-5	37810-37818	response	_	
183-6	37819-37827	captured	_	
183-7	37828-37830	by	_	
183-8	37831-37834	PET	_	
183-9	37835-37838	and	_	
183-10	37839-37843	fMRI	_	
183-11	37843-37844	:	_	
183-12	37845-37849	NAcc	_	
183-13	37850-37854	BOLD	_	
183-14	37855-37863	response	_	
183-15	37864-37870	during	_	
183-16	37871-37877	reward	_	
183-17	37878-37890	anticipation	_	
183-18	37891-37894	and	_	
183-19	37895-37903	feedback	_	
183-20	37904-37910	versus	_	
183-21	37911-37919	dopamine	_	
183-22	37920-37927	release	_	
183-23	37928-37931	for	_	
183-24	37932-37935	the	_	
183-25	37936-37940	left	_	
183-26	37941-37944	and	_	
183-27	37945-37950	right	_	
183-28	37951-37958	nucleus	_	
183-29	37959-37968	accumbens	_	
183-30	37969-37971	by	_	
183-31	37972-37977	group	_	
183-32	37977-37978	.	_	

#Text=Correlations between dopamine release and BOLD response during reward anticipation were not significant (p's > 0.242) but were for feedback (L/R: p = 0.006/0.010).
184-1	37979-37991	Correlations	_	
184-2	37992-37999	between	_	
184-3	38000-38008	dopamine	_	
184-4	38009-38016	release	_	
184-5	38017-38020	and	_	
184-6	38021-38025	BOLD	_	
184-7	38026-38034	response	_	
184-8	38035-38041	during	_	
184-9	38042-38048	reward	_	
184-10	38049-38061	anticipation	_	
184-11	38062-38066	were	_	
184-12	38067-38070	not	_	
184-13	38071-38082	significant	_	
184-14	38083-38084	(	_	
184-15	38084-38087	p's	_	
184-16	38088-38089	>	_	
184-17	38090-38095	0.242	_	
184-18	38095-38096	)	_	
184-19	38097-38100	but	_	
184-20	38101-38105	were	_	
184-21	38106-38109	for	_	
184-22	38110-38118	feedback	_	
184-23	38119-38120	(	_	
184-24	38120-38121	L	_	
184-25	38121-38122	/	_	
184-26	38122-38123	R	_	
184-27	38123-38124	:	_	
184-28	38125-38126	p	_	
184-29	38127-38128	=	_	
184-30	38129-38134	0.006	_	
184-31	38134-38135	/	_	
184-32	38135-38140	0.010	_	
184-33	38140-38141	)	_	
184-34	38141-38142	.	_	

#Text=Scatter plots of NAcc dopamine release versus age of first drunkenness by group.
185-1	38143-38150	Scatter	_	
185-2	38151-38156	plots	_	
185-3	38157-38159	of	_	
185-4	38160-38164	NAcc	_	
185-5	38165-38173	dopamine	_	
185-6	38174-38181	release	_	
185-7	38182-38188	versus	_	
185-8	38189-38192	age	_	
185-9	38193-38195	of	_	
185-10	38196-38201	first	_	
185-11	38202-38213	drunkenness	_	
185-12	38214-38216	by	_	
185-13	38217-38222	group	_	
185-14	38222-38223	.	_	

#Text=Subject Characteristics
#Text=\t\t\tFH+ Low versus High Risk\t \t\t \tMeasure\tFH- Control\tFH+ Low Risk\tFH+ High Risk\tt\tSig\t \tN\t11\t24\t9\t\t\t \tAge – At Scan (years)\t20.6 (2.7)\t22.0 (2.8)\t24.2 (2.9)\t-1.92\t0.064\t \tFamily Expression AUD\t0.02 (.03)\t0.68 (0.37)\t0.56 (0.42)\t0.62\t0.543\t \tIQa\t108\t106 (12)\t112 (12)\t-1.23\t0.228\t \tPast Month Substance Use\t\t\t\t\t\t \t Alcohol (standard drinks)\t12.4 (18.4)\t5.7 (9.3)\t50.9 (97.0)\t-2.32\t0.027\t \t Cigarettes (#)\t23.1 (76.6)\t15.7 (44.4)\t42.8 (122.4)\t-0.95\t0.350\t \t Marijuana (# of joints)\t2.90 (7.00)\t1.46 (6.11)\t21.11 (48.85)\t-1.98\t0.056\t \tCumulative Substance Use\t\t\t\t\t\t \t Cumulative Drink Volume\t713 (1103)\t882 (1403)\t3967 (3721)\t-3.52\t0.001\t \t # Binge Drinking Days\t61 (134)\t82 (160)\t304 (233)\t-3.13\t0.004\t \t # Days of Cigarette Smoking\t203 (329)\t209 (423)\t631 (977)\t-1.76\t0.089\t \t # Days of Marijuana Use\t174 (556)\t34 (112)\t520 (589)\t-3.95\t<0.001\t \t # Alcohol Related Problems\t2.8 (4.3)\t3.0 (3.8)\t9.8 (5.2)\t-4.16\t<0.000\t \t # Drug Related Problems\t0.18 (0.60)\t0.13 (0.45)\t1.22 (1.72)\t-2.94\t0.006\t \tImpulsivityb\t1.72 (1.42)\t2.58 (2.48)\t2.56 (2.50)\t0.03\t0.977\t \tSensation Seekingb\t6.09 (2.12)\t6.13 (2.97)\t8.67 (2.18)\t-2.33\t0.026\t \tResiliencyc\t6.41 (1.02)\t6.42 (0.96)\t6.28 (0.92)\t0.37\t0.714\t \tReactive Controlc\t5.28 (0.86)\t5.06 (0.91)\t4.64 (1.05)\t1.15\t0.260\t \tNegative Emotionalityc\t3.62 (1.17)\t3.54 (0.97)\t3.72 (1.04)\t-0.48\t0.636\t \tAge of Initial\t\t\t\t\t\t \t First Drink\t16.2 (1.5)\t15.8 (3.4)\t11.9 (1.8)\t3.23\t0.003\t \t First Drunk\t17.8 (1.1)\t18.1 (2.0)\t13.9 (1.2)\t5.50\t<0.001\t \t First Marijuana Use\t15.7 (1.1)\t17.0 (3.3)\t15.4 (3.5)\t0.99\t0.339\t \t First Cigarette Use\t16.6 (0.7)\t16.6 (1.3)\t17.2 (3.0)\t-0.53\t0.607\t \t First Illicit Drug Use Other Than Marijuana\t18.7 (4.1)\t16.6 (3.8)\t17.1 (2.6)\t-0.22\t0.833\t \tDiagnosesd\t\t\t\t\t\t \tAlcohol Abuse\t0\t1\t2\t\tns\t \tAlcohol Dependence\t0\t0\t0\t\tns\t \tMarijuana Abuse\t1\t0\t1\t\tns\t \tMarijuana Dependence\t0\t0\t1\t\tns\t \tNicotine Dependence\t0\t0\t0\t\tns\t \tOther Substance Abusee\t0\t0\t0\t\tns\t \tOther Substance Dependencee\t0\t0\t0\t\tns\t \tMajor Depression Disorder\t0\t2\t3\t\tns\t \tAnxiety Disorder\t0\t0\t0\t\tns\t \tExternalizing Behavior\t4\t7\t4\t\tns\t \tAttention Deficit Disorder\t2\t5\t2\t\tns\t \tConduct Disorder\t1\t1\t0\t\tns\t \t
#Text=Data Presented as Mean (Standard Deviation) where applicable.
186-1	38224-38231	Subject	_	
186-2	38232-38247	Characteristics	_	
186-3	38251-38253	FH	_	
186-4	38253-38254	+	_	
186-5	38255-38258	Low	_	
186-6	38259-38265	versus	_	
186-7	38266-38270	High	_	
186-8	38271-38275	Risk	_	
186-9	38281-38288	Measure	_	
186-10	38289-38291	FH	_	
186-11	38291-38292	-	_	
186-12	38293-38300	Control	_	
186-13	38301-38303	FH	_	
186-14	38303-38304	+	_	
186-15	38305-38308	Low	_	
186-16	38309-38313	Risk	_	
186-17	38314-38316	FH	_	
186-18	38316-38317	+	_	
186-19	38318-38322	High	_	
186-20	38323-38327	Risk	_	
186-21	38328-38329	t	_	
186-22	38330-38333	Sig	_	
186-23	38336-38337	N	_	
186-24	38338-38340	11	_	
186-25	38341-38343	24	_	
186-26	38344-38345	9	_	
186-27	38350-38353	Age	_	
186-28	38354-38355	–	_	
186-29	38356-38358	At	_	
186-30	38359-38363	Scan	_	
186-31	38364-38365	(	_	
186-32	38365-38370	years	_	
186-33	38370-38371	)	_	
186-34	38372-38376	20.6	_	
186-35	38377-38378	(	_	
186-36	38378-38381	2.7	_	
186-37	38381-38382	)	_	
186-38	38383-38387	22.0	_	
186-39	38388-38389	(	_	
186-40	38389-38392	2.8	_	
186-41	38392-38393	)	_	
186-42	38394-38398	24.2	_	
186-43	38399-38400	(	_	
186-44	38400-38403	2.9	_	
186-45	38403-38404	)	_	
186-46	38405-38406	-	_	
186-47	38406-38410	1.92	_	
186-48	38411-38416	0.064	_	
186-49	38419-38425	Family	_	
186-50	38426-38436	Expression	_	
186-51	38437-38440	AUD	_	
186-52	38441-38445	0.02	_	
186-53	38446-38447	(	_	
186-54	38447-38450	.03	_	
186-55	38450-38451	)	_	
186-56	38452-38456	0.68	_	
186-57	38457-38458	(	_	
186-58	38458-38462	0.37	_	
186-59	38462-38463	)	_	
186-60	38464-38468	0.56	_	
186-61	38469-38470	(	_	
186-62	38470-38474	0.42	_	
186-63	38474-38475	)	_	
186-64	38476-38480	0.62	_	
186-65	38481-38486	0.543	_	
186-66	38489-38492	IQa	_	
186-67	38493-38496	108	_	
186-68	38497-38500	106	_	
186-69	38501-38502	(	_	
186-70	38502-38504	12	_	
186-71	38504-38505	)	_	
186-72	38506-38509	112	_	
186-73	38510-38511	(	_	
186-74	38511-38513	12	_	
186-75	38513-38514	)	_	
186-76	38515-38516	-	_	
186-77	38516-38520	1.23	_	
186-78	38521-38526	0.228	_	
186-79	38529-38533	Past	_	
186-80	38534-38539	Month	_	
186-81	38540-38549	Substance	_	
186-82	38550-38553	Use	_	
186-83	38562-38569	Alcohol	_	
186-84	38570-38571	(	_	
186-85	38571-38579	standard	_	
186-86	38580-38586	drinks	_	
186-87	38586-38587	)	_	
186-88	38588-38592	12.4	_	
186-89	38593-38594	(	_	
186-90	38594-38598	18.4	_	
186-91	38598-38599	)	_	
186-92	38600-38603	5.7	_	
186-93	38604-38605	(	_	
186-94	38605-38608	9.3	_	
186-95	38608-38609	)	_	
186-96	38610-38614	50.9	_	
186-97	38615-38616	(	_	
186-98	38616-38620	97.0	_	
186-99	38620-38621	)	_	
186-100	38622-38623	-	_	
186-101	38623-38627	2.32	_	
186-102	38628-38633	0.027	_	
186-103	38637-38647	Cigarettes	_	
186-104	38648-38649	(	_	
186-105	38649-38650	#	_	
186-106	38650-38651	)	_	
186-107	38652-38656	23.1	_	
186-108	38657-38658	(	_	
186-109	38658-38662	76.6	_	
186-110	38662-38663	)	_	
186-111	38664-38668	15.7	_	
186-112	38669-38670	(	_	
186-113	38670-38674	44.4	_	
186-114	38674-38675	)	_	
186-115	38676-38680	42.8	_	
186-116	38681-38682	(	_	
186-117	38682-38687	122.4	_	
186-118	38687-38688	)	_	
186-119	38689-38690	-	_	
186-120	38690-38694	0.95	_	
186-121	38695-38700	0.350	_	
186-122	38704-38713	Marijuana	_	
186-123	38714-38715	(	_	
186-124	38715-38716	#	_	
186-125	38717-38719	of	_	
186-126	38720-38726	joints	_	
186-127	38726-38727	)	_	
186-128	38728-38732	2.90	_	
186-129	38733-38734	(	_	
186-130	38734-38738	7.00	_	
186-131	38738-38739	)	_	
186-132	38740-38744	1.46	_	
186-133	38745-38746	(	_	
186-134	38746-38750	6.11	_	
186-135	38750-38751	)	_	
186-136	38752-38757	21.11	_	
186-137	38758-38759	(	_	
186-138	38759-38764	48.85	_	
186-139	38764-38765	)	_	
186-140	38766-38767	-	_	
186-141	38767-38771	1.98	_	
186-142	38772-38777	0.056	_	
186-143	38780-38790	Cumulative	_	
186-144	38791-38800	Substance	_	
186-145	38801-38804	Use	_	
186-146	38813-38823	Cumulative	_	
186-147	38824-38829	Drink	_	
186-148	38830-38836	Volume	_	
186-149	38837-38840	713	_	
186-150	38841-38842	(	_	
186-151	38842-38846	1103	_	
186-152	38846-38847	)	_	
186-153	38848-38851	882	_	
186-154	38852-38853	(	_	
186-155	38853-38857	1403	_	
186-156	38857-38858	)	_	
186-157	38859-38863	3967	_	
186-158	38864-38865	(	_	
186-159	38865-38869	3721	_	
186-160	38869-38870	)	_	
186-161	38871-38872	-	_	
186-162	38872-38876	3.52	_	
186-163	38877-38882	0.001	_	
186-164	38886-38887	#	_	
186-165	38888-38893	Binge	_	
186-166	38894-38902	Drinking	_	
186-167	38903-38907	Days	_	
186-168	38908-38910	61	_	
186-169	38911-38912	(	_	
186-170	38912-38915	134	_	
186-171	38915-38916	)	_	
186-172	38917-38919	82	_	
186-173	38920-38921	(	_	
186-174	38921-38924	160	_	
186-175	38924-38925	)	_	
186-176	38926-38929	304	_	
186-177	38930-38931	(	_	
186-178	38931-38934	233	_	
186-179	38934-38935	)	_	
186-180	38936-38937	-	_	
186-181	38937-38941	3.13	_	
186-182	38942-38947	0.004	_	
186-183	38951-38952	#	_	
186-184	38953-38957	Days	_	
186-185	38958-38960	of	_	
186-186	38961-38970	Cigarette	_	
186-187	38971-38978	Smoking	_	
186-188	38979-38982	203	_	
186-189	38983-38984	(	_	
186-190	38984-38987	329	_	
186-191	38987-38988	)	_	
186-192	38989-38992	209	_	
186-193	38993-38994	(	_	
186-194	38994-38997	423	_	
186-195	38997-38998	)	_	
186-196	38999-39002	631	_	
186-197	39003-39004	(	_	
186-198	39004-39007	977	_	
186-199	39007-39008	)	_	
186-200	39009-39010	-	_	
186-201	39010-39014	1.76	_	
186-202	39015-39020	0.089	_	
186-203	39024-39025	#	_	
186-204	39026-39030	Days	_	
186-205	39031-39033	of	_	
186-206	39034-39043	Marijuana	_	
186-207	39044-39047	Use	_	
186-208	39048-39051	174	_	
186-209	39052-39053	(	_	
186-210	39053-39056	556	_	
186-211	39056-39057	)	_	
186-212	39058-39060	34	_	
186-213	39061-39062	(	_	
186-214	39062-39065	112	_	
186-215	39065-39066	)	_	
186-216	39067-39070	520	_	
186-217	39071-39072	(	_	
186-218	39072-39075	589	_	
186-219	39075-39076	)	_	
186-220	39077-39078	-	_	
186-221	39078-39082	3.95	_	
186-222	39083-39084	<	_	
186-223	39084-39089	0.001	_	
186-224	39093-39094	#	_	
186-225	39095-39102	Alcohol	_	
186-226	39103-39110	Related	_	
186-227	39111-39119	Problems	_	
186-228	39120-39123	2.8	_	
186-229	39124-39125	(	_	
186-230	39125-39128	4.3	_	
186-231	39128-39129	)	_	
186-232	39130-39133	3.0	_	
186-233	39134-39135	(	_	
186-234	39135-39138	3.8	_	
186-235	39138-39139	)	_	
186-236	39140-39143	9.8	_	
186-237	39144-39145	(	_	
186-238	39145-39148	5.2	_	
186-239	39148-39149	)	_	
186-240	39150-39151	-	_	
186-241	39151-39155	4.16	_	
186-242	39156-39157	<	_	
186-243	39157-39162	0.000	_	
186-244	39166-39167	#	_	
186-245	39168-39172	Drug	_	
186-246	39173-39180	Related	_	
186-247	39181-39189	Problems	_	
186-248	39190-39194	0.18	_	
186-249	39195-39196	(	_	
186-250	39196-39200	0.60	_	
186-251	39200-39201	)	_	
186-252	39202-39206	0.13	_	
186-253	39207-39208	(	_	
186-254	39208-39212	0.45	_	
186-255	39212-39213	)	_	
186-256	39214-39218	1.22	_	
186-257	39219-39220	(	_	
186-258	39220-39224	1.72	_	
186-259	39224-39225	)	_	
186-260	39226-39227	-	_	
186-261	39227-39231	2.94	_	
186-262	39232-39237	0.006	_	
186-263	39240-39252	Impulsivityb	_	
186-264	39253-39257	1.72	_	
186-265	39258-39259	(	_	
186-266	39259-39263	1.42	_	
186-267	39263-39264	)	_	
186-268	39265-39269	2.58	_	
186-269	39270-39271	(	_	
186-270	39271-39275	2.48	_	
186-271	39275-39276	)	_	
186-272	39277-39281	2.56	_	
186-273	39282-39283	(	_	
186-274	39283-39287	2.50	_	
186-275	39287-39288	)	_	
186-276	39289-39293	0.03	_	
186-277	39294-39299	0.977	_	
186-278	39302-39311	Sensation	_	
186-279	39312-39320	Seekingb	_	
186-280	39321-39325	6.09	_	
186-281	39326-39327	(	_	
186-282	39327-39331	2.12	_	
186-283	39331-39332	)	_	
186-284	39333-39337	6.13	_	
186-285	39338-39339	(	_	
186-286	39339-39343	2.97	_	
186-287	39343-39344	)	_	
186-288	39345-39349	8.67	_	
186-289	39350-39351	(	_	
186-290	39351-39355	2.18	_	
186-291	39355-39356	)	_	
186-292	39357-39358	-	_	
186-293	39358-39362	2.33	_	
186-294	39363-39368	0.026	_	
186-295	39371-39382	Resiliencyc	_	
186-296	39383-39387	6.41	_	
186-297	39388-39389	(	_	
186-298	39389-39393	1.02	_	
186-299	39393-39394	)	_	
186-300	39395-39399	6.42	_	
186-301	39400-39401	(	_	
186-302	39401-39405	0.96	_	
186-303	39405-39406	)	_	
186-304	39407-39411	6.28	_	
186-305	39412-39413	(	_	
186-306	39413-39417	0.92	_	
186-307	39417-39418	)	_	
186-308	39419-39423	0.37	_	
186-309	39424-39429	0.714	_	
186-310	39432-39440	Reactive	_	
186-311	39441-39449	Controlc	_	
186-312	39450-39454	5.28	_	
186-313	39455-39456	(	_	
186-314	39456-39460	0.86	_	
186-315	39460-39461	)	_	
186-316	39462-39466	5.06	_	
186-317	39467-39468	(	_	
186-318	39468-39472	0.91	_	
186-319	39472-39473	)	_	
186-320	39474-39478	4.64	_	
186-321	39479-39480	(	_	
186-322	39480-39484	1.05	_	
186-323	39484-39485	)	_	
186-324	39486-39490	1.15	_	
186-325	39491-39496	0.260	_	
186-326	39499-39507	Negative	_	
186-327	39508-39521	Emotionalityc	_	
186-328	39522-39526	3.62	_	
186-329	39527-39528	(	_	
186-330	39528-39532	1.17	_	
186-331	39532-39533	)	_	
186-332	39534-39538	3.54	_	
186-333	39539-39540	(	_	
186-334	39540-39544	0.97	_	
186-335	39544-39545	)	_	
186-336	39546-39550	3.72	_	
186-337	39551-39552	(	_	
186-338	39552-39556	1.04	_	
186-339	39556-39557	)	_	
186-340	39558-39559	-	_	
186-341	39559-39563	0.48	_	
186-342	39564-39569	0.636	_	
186-343	39572-39575	Age	_	
186-344	39576-39578	of	_	
186-345	39579-39586	Initial	_	
186-346	39595-39600	First	_	
186-347	39601-39606	Drink	_	
186-348	39607-39611	16.2	_	
186-349	39612-39613	(	_	
186-350	39613-39616	1.5	_	
186-351	39616-39617	)	_	
186-352	39618-39622	15.8	_	
186-353	39623-39624	(	_	
186-354	39624-39627	3.4	_	
186-355	39627-39628	)	_	
186-356	39629-39633	11.9	_	
186-357	39634-39635	(	_	
186-358	39635-39638	1.8	_	
186-359	39638-39639	)	_	
186-360	39640-39644	3.23	_	
186-361	39645-39650	0.003	_	
186-362	39654-39659	First	_	
186-363	39660-39665	Drunk	_	
186-364	39666-39670	17.8	_	
186-365	39671-39672	(	_	
186-366	39672-39675	1.1	_	
186-367	39675-39676	)	_	
186-368	39677-39681	18.1	_	
186-369	39682-39683	(	_	
186-370	39683-39686	2.0	_	
186-371	39686-39687	)	_	
186-372	39688-39692	13.9	_	
186-373	39693-39694	(	_	
186-374	39694-39697	1.2	_	
186-375	39697-39698	)	_	
186-376	39699-39703	5.50	_	
186-377	39704-39705	<	_	
186-378	39705-39710	0.001	_	
186-379	39714-39719	First	_	
186-380	39720-39729	Marijuana	_	
186-381	39730-39733	Use	_	
186-382	39734-39738	15.7	_	
186-383	39739-39740	(	_	
186-384	39740-39743	1.1	_	
186-385	39743-39744	)	_	
186-386	39745-39749	17.0	_	
186-387	39750-39751	(	_	
186-388	39751-39754	3.3	_	
186-389	39754-39755	)	_	
186-390	39756-39760	15.4	_	
186-391	39761-39762	(	_	
186-392	39762-39765	3.5	_	
186-393	39765-39766	)	_	
186-394	39767-39771	0.99	_	
186-395	39772-39777	0.339	_	
186-396	39781-39786	First	_	
186-397	39787-39796	Cigarette	_	
186-398	39797-39800	Use	_	
186-399	39801-39805	16.6	_	
186-400	39806-39807	(	_	
186-401	39807-39810	0.7	_	
186-402	39810-39811	)	_	
186-403	39812-39816	16.6	_	
186-404	39817-39818	(	_	
186-405	39818-39821	1.3	_	
186-406	39821-39822	)	_	
186-407	39823-39827	17.2	_	
186-408	39828-39829	(	_	
186-409	39829-39832	3.0	_	
186-410	39832-39833	)	_	
186-411	39834-39835	-	_	
186-412	39835-39839	0.53	_	
186-413	39840-39845	0.607	_	
186-414	39849-39854	First	_	
186-415	39855-39862	Illicit	_	
186-416	39863-39867	Drug	_	
186-417	39868-39871	Use	_	
186-418	39872-39877	Other	_	
186-419	39878-39882	Than	_	
186-420	39883-39892	Marijuana	_	
186-421	39893-39897	18.7	_	
186-422	39898-39899	(	_	
186-423	39899-39902	4.1	_	
186-424	39902-39903	)	_	
186-425	39904-39908	16.6	_	
186-426	39909-39910	(	_	
186-427	39910-39913	3.8	_	
186-428	39913-39914	)	_	
186-429	39915-39919	17.1	_	
186-430	39920-39921	(	_	
186-431	39921-39924	2.6	_	
186-432	39924-39925	)	_	
186-433	39926-39927	-	_	
186-434	39927-39931	0.22	_	
186-435	39932-39937	0.833	_	
186-436	39940-39950	Diagnosesd	_	
186-437	39958-39965	Alcohol	_	
186-438	39966-39971	Abuse	_	
186-439	39972-39973	0	_	
186-440	39974-39975	1	_	
186-441	39976-39977	2	_	
186-442	39979-39981	ns	_	
186-443	39984-39991	Alcohol	_	
186-444	39992-40002	Dependence	_	
186-445	40003-40004	0	_	
186-446	40005-40006	0	_	
186-447	40007-40008	0	_	
186-448	40010-40012	ns	_	
186-449	40015-40024	Marijuana	_	
186-450	40025-40030	Abuse	_	
186-451	40031-40032	1	_	
186-452	40033-40034	0	_	
186-453	40035-40036	1	_	
186-454	40038-40040	ns	_	
186-455	40043-40052	Marijuana	_	
186-456	40053-40063	Dependence	_	
186-457	40064-40065	0	_	
186-458	40066-40067	0	_	
186-459	40068-40069	1	_	
186-460	40071-40073	ns	_	
186-461	40076-40084	Nicotine	_	
186-462	40085-40095	Dependence	_	
186-463	40096-40097	0	_	
186-464	40098-40099	0	_	
186-465	40100-40101	0	_	
186-466	40103-40105	ns	_	
186-467	40108-40113	Other	_	
186-468	40114-40123	Substance	_	
186-469	40124-40130	Abusee	_	
186-470	40131-40132	0	_	
186-471	40133-40134	0	_	
186-472	40135-40136	0	_	
186-473	40138-40140	ns	_	
186-474	40143-40148	Other	_	
186-475	40149-40158	Substance	_	
186-476	40159-40170	Dependencee	_	
186-477	40171-40172	0	_	
186-478	40173-40174	0	_	
186-479	40175-40176	0	_	
186-480	40178-40180	ns	_	
186-481	40183-40188	Major	_	
186-482	40189-40199	Depression	_	
186-483	40200-40208	Disorder	_	
186-484	40209-40210	0	_	
186-485	40211-40212	2	_	
186-486	40213-40214	3	_	
186-487	40216-40218	ns	_	
186-488	40221-40228	Anxiety	_	
186-489	40229-40237	Disorder	_	
186-490	40238-40239	0	_	
186-491	40240-40241	0	_	
186-492	40242-40243	0	_	
186-493	40245-40247	ns	_	
186-494	40250-40263	Externalizing	_	
186-495	40264-40272	Behavior	_	
186-496	40273-40274	4	_	
186-497	40275-40276	7	_	
186-498	40277-40278	4	_	
186-499	40280-40282	ns	_	
186-500	40285-40294	Attention	_	
186-501	40295-40302	Deficit	_	
186-502	40303-40311	Disorder	_	
186-503	40312-40313	2	_	
186-504	40314-40315	5	_	
186-505	40316-40317	2	_	
186-506	40319-40321	ns	_	
186-507	40324-40331	Conduct	_	
186-508	40332-40340	Disorder	_	
186-509	40341-40342	1	_	
186-510	40343-40344	1	_	
186-511	40345-40346	0	_	
186-512	40348-40350	ns	_	
186-513	40354-40358	Data	_	
186-514	40359-40368	Presented	_	
186-515	40369-40371	as	_	
186-516	40372-40376	Mean	_	
186-517	40377-40378	(	_	
186-518	40378-40386	Standard	_	
186-519	40387-40396	Deviation	_	
186-520	40396-40397	)	_	
186-521	40398-40403	where	_	
186-522	40404-40414	applicable	_	
186-523	40414-40415	.	_	

#Text=Significant values in bold at α = 0.05.
187-1	40416-40427	Significant	_	
187-2	40428-40434	values	_	
187-3	40435-40437	in	_	
187-4	40438-40442	bold	_	
187-5	40443-40445	at	_	
187-6	40446-40447	α	_	
187-7	40448-40449	=	_	
187-8	40450-40454	0.05	_	
187-9	40454-40455	.	_	

#Text=Wechsler Intelligence Scale for Children – 3rd edition or Revised WISC.
188-1	40456-40464	Wechsler	_	
188-2	40465-40477	Intelligence	_	
188-3	40478-40483	Scale	_	
188-4	40484-40487	for	_	
188-5	40488-40496	Children	_	
188-6	40497-40498	–	_	
188-7	40499-40502	3rd	_	
188-8	40503-40510	edition	_	
188-9	40511-40513	or	_	
188-10	40514-40521	Revised	_	
188-11	40522-40526	WISC	_	
188-12	40526-40527	.	_	

#Text=These data were collected when participants were between the ages of 12 and 14 years as part of the ongoing Michigan Longitudinal Study.
189-1	40528-40533	These	_	
189-2	40534-40538	data	_	
189-3	40539-40543	were	_	
189-4	40544-40553	collected	_	
189-5	40554-40558	when	_	
189-6	40559-40571	participants	_	
189-7	40572-40576	were	_	
189-8	40577-40584	between	_	
189-9	40585-40588	the	_	
189-10	40589-40593	ages	_	
189-11	40594-40596	of	_	
189-12	40597-40599	12	_	
189-13	40600-40603	and	_	
189-14	40604-40606	14	_	
189-15	40607-40612	years	_	
189-16	40613-40615	as	_	
189-17	40616-40620	part	_	
189-18	40621-40623	of	_	
189-19	40624-40627	the	_	
189-20	40628-40635	ongoing	_	
189-21	40636-40644	Michigan	_	
189-22	40645-40657	Longitudinal	_	
189-23	40658-40663	Study	_	
189-24	40663-40664	.	_	

#Text=Zuckerman Impulsivity and Sensation Seeking Scale 
#Text=Q-Sort Eisenberg temperament scale 
#Text=Annual assessments using Drinking and Drug History Form (DDHx) since age 11 through scan age; abuse and dependence diagnoses based on Diagnostic Interview Schedule for DSM-IV Child Version, assessed for five years prior to scan ;data presented as number of individuals per group meeting diagnoses.
190-1	40665-40674	Zuckerman	_	
190-2	40675-40686	Impulsivity	_	
190-3	40687-40690	and	_	
190-4	40691-40700	Sensation	_	
190-5	40701-40708	Seeking	_	
190-6	40709-40714	Scale	_	
190-7	40716-40722	Q-Sort	_	
190-8	40723-40732	Eisenberg	_	
190-9	40733-40744	temperament	_	
190-10	40745-40750	scale	_	
190-11	40752-40758	Annual	_	
190-12	40759-40770	assessments	_	
190-13	40771-40776	using	_	
190-14	40777-40785	Drinking	_	
190-15	40786-40789	and	_	
190-16	40790-40794	Drug	_	
190-17	40795-40802	History	_	
190-18	40803-40807	Form	_	
190-19	40808-40809	(	_	
190-20	40809-40813	DDHx	_	
190-21	40813-40814	)	_	
190-22	40815-40820	since	_	
190-23	40821-40824	age	_	
190-24	40825-40827	11	_	
190-25	40828-40835	through	_	
190-26	40836-40840	scan	_	
190-27	40841-40844	age	_	
190-28	40844-40845	;	_	
190-29	40846-40851	abuse	_	
190-30	40852-40855	and	_	
190-31	40856-40866	dependence	_	
190-32	40867-40876	diagnoses	_	
190-33	40877-40882	based	_	
190-34	40883-40885	on	_	
190-35	40886-40896	Diagnostic	_	
190-36	40897-40906	Interview	_	
190-37	40907-40915	Schedule	_	
190-38	40916-40919	for	_	
190-39	40920-40926	DSM-IV	_	
190-40	40927-40932	Child	_	
190-41	40933-40940	Version	_	
190-42	40940-40941	,	_	
190-43	40942-40950	assessed	_	
190-44	40951-40954	for	_	
190-45	40955-40959	five	_	
190-46	40960-40965	years	_	
190-47	40966-40971	prior	_	
190-48	40972-40974	to	_	
190-49	40975-40979	scan	_	
190-50	40980-40981	;	_	
190-51	40981-40985	data	_	
190-52	40986-40995	presented	_	
190-53	40996-40998	as	_	
190-54	40999-41005	number	_	
190-55	41006-41008	of	_	
190-56	41009-41020	individuals	_	
190-57	41021-41024	per	_	
190-58	41025-41030	group	_	
190-59	41031-41038	meeting	_	
190-60	41039-41048	diagnoses	_	
190-61	41048-41049	.	_	

#Text=Includes any of the following: amphetamines, cocaine, sedatives/hypnotics, or opiates.
191-1	41050-41058	Includes	_	
191-2	41059-41062	any	_	
191-3	41063-41065	of	_	
191-4	41066-41069	the	_	
191-5	41070-41079	following	_	
191-6	41079-41080	:	_	
191-7	41081-41093	amphetamines	_	
191-8	41093-41094	,	_	
191-9	41095-41102	cocaine	_	
191-10	41102-41103	,	_	
191-11	41104-41113	sedatives	_	
191-12	41113-41114	/	_	
191-13	41114-41123	hypnotics	_	
191-14	41123-41124	,	_	
191-15	41125-41127	or	_	
191-16	41128-41135	opiates	_	
191-17	41135-41136	.	_	
